

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

Date: 04th September, 2023

Online filing at: www.listing.bseindia.com

To,
The Secretary (DCS/Compliance),
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Subject: Submission of Integrated Annual Report for the Financial Year 2022-23 along with Notice convening the 40th Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: MEDI-CAPS LIMITED (BSE Scrip Code: 523144; ISIN: INE442D01010)

This is to inform that the 40th Annual General Meeting ('AGM') of the Company is scheduled to be held on Friday, 29th September, 2023 at 12:30 P.M. (IST) through Video Conference (VC) /Other Audio Visual means (OAVM), in compliance with relevant circulars issued by the Ministry of Corporate Affairs ('MCA') and the Securities and Exchange Board of India ('SEBI') as amended from time to time. In accordance with the aforesaid circulars issued by the MCA and SEBI, the Integrated Annual Report of the Company for the financial year 2022-23 along with the Notice convening 40th AGM is being sent to those members of the Company whose email addresses are registered with the Company and/or Depository Participant(s).

Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of an Integrated Annual Report of the Company for the financial year 2022-23 containing the Notice convening 40th AGM of the Company. The Integrated Annual Report for the financial year 2022-23 along with Notice convening the 40th AGM is also uploaded on the Company's website at www.medicaps.com and the website of Central Depository Services (India) Limited at www.evotingindia.com.

Kindly take the same on your record and acknowledge.

Thanking You,

Yours Faithfully,

FOR MEDI-CAPS LIMITED

ABHISHEK JAIN
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.N. A36699

Enclosed: as above

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231



**Infrastructure as big as Pithampur needs,
extensive support system,
Enters MEDI-CAPS BUSINESS PARK**

The most crucial part of business building is that it meets, and goes beyond, the needs of the
infrastructure. At Medi-Caps Business Park, we are creating the most advanced and well-
equipped facilities with a modern design. Our focus is on creating a business park that
superbly supports the needs of our clients. Our focus is on creating a business park that
provides a high-quality environment for all modern businesses. The focus is on creating a
business park that provides a high-quality environment for all modern businesses. The
focus is on creating a business park that provides a high-quality environment for all
modern businesses. The focus is on creating a business park that provides a high-quality
environment for all modern businesses. The focus is on creating a business park that
provides a high-quality environment for all modern businesses. The focus is on creating
a business park that provides a high-quality environment for all modern businesses.

40TH ANNUAL REPORT 2022-23

CORPORATE INFORMATION

1. BOARD OF DIRECTORS		
S.N.	NAME	DESIGNATION
1	MR. RAMESH CHANDRA MITTAL	CHAIRMAN & NON-EXECUTIVE DIRECTOR
2	MR. ALOK K. GARG	MANAGING DIRECTOR
3	MRS. KUSUM MITTAL	NON-EXECUTIVE WOMAN DIRECTOR
4	MR. ASHOK OMPRAKASH AGRAWAL	NON-EXECUTIVE INDEPENDENT DIRECTOR
5	MR. PRAMOD FATEHPURIA	NON-EXECUTIVE INDEPENDENT DIRECTOR
6	MR. DHARMENDRA SOLANKI	NON-EXECUTIVE INDEPENDENT DIRECTOR
7	MR. AKSHIT GARG *	NON-EXECUTIVE DIRECTOR
8	MR. SOURABH KUMAR SHRIVAS *	NON-EXECUTIVE INDEPENDENT DIRECTOR
9	MR. GAJENDRA SINGH*	NON-EXECUTIVE INDEPENDENT DIRECTOR

*MR. AKSHIT GARG RESIGNED W.E.F. 21.07.2023
 *MR. SOURABH KUMAR SHRIVAS RESIGNED W.E.F. 21.07.2023.
 *MR. GAJENDRA SINGH WAS APPOINTED AS AN ADDITIONAL DIRECTOR IN THE CATEGORY OF NON-EXECUTIVE INDEPENDENT DIRECTOR W.E.F.11.08.2023.

2. COMMITTEES	
<u>AUDIT COMMITTEE</u> MR. ASHOK OMPRAKASH AGRAWAL- CHAIRMAN MR. PRAMOD FATEHPURIA- MEMBER MR. DHARMENDRA SOLANKI- MEMBER	<u>STAKEHOLDERS' RELATIONSHIP COMMITTEE</u> MR. ASHOK OMPRAKASH AGRAWAL- CHAIRMAN MR. PRAMOD FATEHPURIA- MEMBER MR. DHARMENDRA SOLANKI- MEMBER
<u>NOMINATION AND REMUNERATION COMMITTEE</u> MR. ASHOK OMPRAKASH AGRAWAL- CHAIRMAN MR. PRAMOD FATEHPURIA- MEMBER MR. DHARMENDRA SOLANKI- MEMBER	

3. KMPs	
<u>COMPANY SECRETARY & COMPLIANCE OFFICER</u> MR. ABHISHEK JAIN	<u>CHIEF FINANCIAL OFFICER</u> MR. HEMANT SETHI

4. AUDITORS	
<u>STATUTORY AUDITOR</u> RAWKA & ASSOCIATES CHARTERED ACCOUNTANTS, INDORE	<u>SECRETARIAL AUDITOR</u> L. N. JOSHI & CO. COMPANY SECRETARIES, INDORE
<u>INTERNAL AUDITOR</u> PRAVEEN SHRIVASTAVA & CO. CHARTERED ACCOUNTANTS, INDORE	

5. ADDRESSES	
<u>REGISTERED OFFICE</u> MHOW - NEEMUCH ROAD, SECTOR-1 PITHAMPUR, DHAR (M.P.) 454775 PHONE: 07292-256205 EMAIL: INVESTORS@MEDICAPS.COM WEBSITE: WWW.MEDICAPS.COM	<u>CORPORATE OFFICE</u> 201, PUSHPRATNA PARADISE 9/5, NEW PALASIA, INDORE (M.P.) 452001 PHONE: 0731-4046321, 4028148 EMAIL: INVESTORS@MEDICAPS.COM

6. STOCK EXCHANGE <i>(Where the Company's Securities are Listed)</i>
BSE LIMITED

7. SHARE TRANSFER AGENT
ANKIT CONSULTANCY PRIVATE LIMITED PLOT NO. 60, ELECTRONIC COMPLEX, PARDESHIPURA, INDORE (M.P.) 452010 PHONE: 0731-2551745 EMAIL: INVESTOR@ANKITONLINE.COM

NOTICE OF 40TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the 40th Annual General Meeting (AGM) of the Members of **MEDI-CAPS LIMITED** will be held on Friday, 29th day of September, 2023 at 12.30 P.M. (IST) through Video Conferencing (“VC”) or Other Audio Visual Means (“OAVM”) for which purpose the Registered Office of the company shall be deemed as the venue for the Meeting and the proceedings of the Annual General Meeting shall be deemed to be made thereat, to transact the following businesses:

ORDINARY BUSINESSES:-

1. To consider and adopt the Audited Standalone Financial Statement of the Company together with the Report of the Board of Directors and the Auditors thereon for the financial year ended March 31, 2023.
2. To consider and adopt the Audited Consolidated Financial Statement of the Company together with the Report of the Auditors thereon for the financial year ended March 31, 2023.
3. To appoint a Director in place of Mr. Ramesh Chandra Mittal (DIN: 00035272), who retires by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment.

SPECIAL BUSINESSES:

Item No. 4: Appointment of Mr. Gajendra Singh (DIN: 10253991) as a Non Executive Independent Director of the Company.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT Mr. Gajendra Singh (DIN: 10253991), who was appointed as an Additional Director of the Company with effect from 11th August, 2023, by the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, and who holds office as such up to this Annual General Meeting of the Company under Section 161(1) of the Companies Act, 2013 (“the Act”) and in respect of whom the Company has received a notice in writing under Section 160(1) of the Act from a member proposing his candidature for the office of Director, be and is hereby appointed as a Director of the Company.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 150, 152 and other applicable provisions if any of the Companies Act, 2013 (“the Act”), read with Schedule IV to the Act and Companies (Appointment and Qualifications of Directors) Rules, 2014 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [including any statutory modification(s) or amendment(s) thereto or re-enactment(s) thereof for the time being in force] the appointment of Mr. Gajendra Singh (DIN: 10253991), who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Act and Regulation 16(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, who is eligible for appointment, as a Non Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a term of 5 (five) consecutive years commencing from 11th August, 2023 to 10th August, 2028 (both days inclusive) be and is hereby approved.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as “the Board”, which term shall include any committee(s) constituted or to be constituted by the Board to exercise the powers conferred on the Board by this Resolution) be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be considered necessary, desirable or expedient to give effect to this resolution.”

Item No. 5: Adoption of new set of Articles of Association of the Company containing regulation in conformity with the Companies Act, 2013.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 14, 15 and all other applicable provisions, of the Companies Act, 2013 read with the Companies (Incorporation) Rules, 2014 (including any statutory modification(s) thereto or re-enactment thereof, for the time being in force) and subject to the requisite approvals, consents, permissions and/or sanctions as may be required, if any, the draft regulations contained in the Articles of Association submitted to this meeting and duly initialed by the chairman be and are hereby approved and adopted in substitution and to the entire exclusion, of the regulation contained in the existing Articles of Association of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorised to perform and execute all such acts, deeds, matters and things, as may be necessary, proper or expedient to give effect to this Resolution and for the matters connected therewith or incidental thereto.”

DATE: 11th AUGUST, 2023

PLACE: INDORE

BY ORDER OF THE BOARD OF DIRECTORS

ABHISHEK JAIN

COMPANY SECRETARY

ACS-36699

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Registered Office: Mhow, Neemuch Road,

Sector 1, Pithampur, Dhar (M.P.)-454775

Website: www.medicaps.com

Email: investors@medicaps.com

Phone: 07292-256205

NOTES:-

- In view of the Ministry of Corporate Affairs (MCA) General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020, General Circular no. 02/2021 dated January 13, 2021, General Circular no. 19/2021 dated December 08, 2021, General Circular no. 21/2021 dated December 14, 2021, Circular No. 02/2022 dated 5th May, 2022 followed by Circular No. 10/2022 dated 28th December, 2022 (collectively "MCA Circulars") and Securities and Exchange Board of India ("SEBI") vide its circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, circular no. SEBI/HO/CFD/CMD2/ CIR/P/2021/11 dated January 15, 2021, SEBI circular no. SEBI/HO/CFD/ CMD2/CIR/P/2022/62 dated 13th May, 2022 followed by SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated 5th January, 2023 (collectively "SEBI Circulars"), have permitted companies to conduct AGM through Video Conferencing (VC) or other audio-visual means (OAVM), subject to compliance of various conditions mentioned therein. In compliance with the aforesaid MCA Circulars and SEBI Circulars and the applicable provisions of Companies Act, 2013 and rules made there under, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the 40th AGM of the Company is being convened and conducted through VC/OAVM Facility, which does not require physical presence of Members at a common venue. The Company has availed the facility of Central Depository Services (India) Limited (CDSL) for convening the 40th AGM through VC/OAVM, a detailed process in which the members can attend the AGM through VC/OAVM has been enumerated in Note number 32 of this Notice.
- The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013 (the Act).
- ELECTRONIC DISPATCH OF NOTICE AND ANNUAL REPORT:** In compliance with the aforesaid MCA and SEBI circulars physical copies of the financial statements (including Board's Report, Auditor's Report or other documents required to be attached therewith) for the Financial Year ended 31st March, 2023 pursuant to Section 136 of the Act and Notice calling the AGM pursuant to Section 101 of the Act read with the Rules framed thereunder are being sent only in electronic mode to those Members whose e-mail addresses are registered with the Company/R&STA or the Depositories. The Company will not be dispatching physical copies of such statements and Notice of AGM to any Member.
To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with the Company/R&STA in case the shares are held by them in physical form after complying due procedure.
- Members who have not registered their e-mail address and those members who have become the member of the Company after Friday 18th August, 2023 being the cut-off date for sending soft copy of the Notice of 40th AGM and Annual Report for the financial year 2022-23, may access the same from Company's website at www.medicaps.com, websites of the Stock Exchange i.e. BSE Limited at www.bseindia.com and on the website of CDSL www.evotingindia.com.
- A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY/ PROXIES TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF. SUCH A PROXY/ PROXIES NEED NOT BE A MEMBER OF THE COMPANY.**
Since the 40th AGM of the Company will be convened through VC/OAVM, where there will be no physical attendance of members, the requirement of appointment of proxies pursuant to the provisions of Section 105 of the Act has been dispensed with. Accordingly, attendance slip and proxy form will not be annexed to this Notice.
- Pursuant to the provisions of Sections 112 and 113 of the Act, corporate/ Institutional member can authorize their representatives to attend the AGM through VC/OAVM and cast their votes through e-voting. Provided a scan copy (PDF) of the Board Resolution authorizing such representative to attend the AGM of the Company through VC/OAVM on its behalf and to vote through remote e-voting shall be sent to the Scrutinizer through the registered email address of the member(s) at lnjoshics@gmail.com with a copy marked to the Company at investors@medicaps.com.
- Pursuant to Provision of Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Book of the Company will remain closed during the period from Saturday, 23rd September, 2023 to Friday, 29th September, 2023 (both days inclusive) for the purpose of 40th Annual General Meeting.
- The Statement as required under Section 102 of the Act setting out material facts concerning the businesses with respect to Item Nos. 4 & 5 forms part of this Notice is annexed hereto.
As per the provisions of Clause 3.A.II of the General Circular No. 20/ 2020 dated May 5, 2020, the matters of Special Businesses as appearing at Item Nos. 4 & 5 of the accompanying Notice, are considered to be unavoidable by the Board and hence, forming part of this Notice.

9. The relevant details, pursuant to Regulations 36(3) of the SEBI Listing Regulations and Secretarial Standards-2 on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking appointment/re-appointment/retire by rotation at the AGM are provided as an annexure to the Notice forms integral part of this notice.
10. **IEPF:** Members whose unclaimed dividends/shares are transferred to the IEPF Authority can claim the same by making an online application to the IEPF Authority in the prescribed Form No. IEPF-5 by following the refund procedure as detailed on the website of IEPF Authority <http://www.iepf.gov.in/IEPF/refund.html>.
11. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their demat accounts. Further, as per SEBI Circular dated April 20, 2018 all securities holders holding securities in physical form should submit their PAN and Bank account details to the RTA.
12. Members who hold shares in dematerialized form and want to provide/change/correct the bank account details should send the same immediately to their concerned Depository Participant(s) and not to the Company. Members are also requested to give the MICR Code of their bank to their Depository Participant(s). The Company will not entertain any direct request from such Members for change of address, transposition of names, deletion of name of deceased joint holder and change in the bank account details.
13. Members who are holding shares in physical form are advised to submit particulars of their PAN details, e-mail address, Mobile Number, bank account, viz. name and address of the branch of the bank, MICR code of the branch, type of account and account number etc. to our Registrar and Share Transfer Agent in prescribed Form ISR-1 quoting their folio number and enclosing the self-attested supporting document and other forms pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655 dated November 3, 2021 read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023. Members holding shares in electronic form are requested to submit the details to their respective DP only and not to the Company or RTA.
14. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the listed companies to issue securities in dematerialized form only while processing service requests viz. Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/ exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR-4, the format of which is available on the Company's website investors@medicaps.com and on the website of the Company's Registrar and Transfer Agents <http://ankitonline.com>. It may be noted that any service request can be processed only after the folio is KYC Compliant.
15. SEBI vide its notification dated January 24, 2022 has mandated that all requests for transfer of securities including transmission and transposition requests shall be processed only in dematerialized form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company or RTA, for assistance in this regard.

Further, SEBI vide its circular dated 16th March, 2023 in supersession of earlier circular dated 3rd November, 2021, read with clarification dated 14th December, 2021 introduced common and simplified norms for processing investor's service request by Registrar and Transfer Agent(s) (RTAs) and norms for furnishing PAN, KYC details and Nomination. Accordingly, the RTA cannot process any service requests or complaints received from the holder(s) / claimant(s), till PAN, KYC and Nomination documents / details are updated. Moreover, on or after 1st October, 2023, in case any of the above cited documents / details are not available in the folios, RTA shall be constrained to freeze such folios. The Company has sent individual letters to all the Members holding shares of the Company in physical form for furnishing the aforesaid details. This communication was also intimated to the Stock Exchange and available on the website of the Company. In view of this requirement and to eliminate all risks associated with physical shares and for ease of portfolio management, Members holding shares in physical form are once again requested to update their KYC details (through Form ISR-1, Form ISR-2 and Form ISR-3, as applicable) and consider converting their holdings to dematerialized form. Members can download Forms to make their service request with RTA from link https://medicaps.com/?page_id=22802 or contact the Company's Registrar and Transfer Agent for assistance in this regard.
16. As per the provisions of Section 72 of the Act, the facility for making a nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nominations are requested to register the same by submitting Form No. SH-13. If a Member desires to cancel the earlier nomination and record a fresh nomination, he may submit the same in Form SH-14. Members who are either not desiring to register Nomination or would want to opt out, are requested to fill and submit Form No. ISR-3. The said forms can be downloaded from the RTA website at <http://ankitonline.com>. Members are requested to submit the said form to their DP in case the shares are held in electronic form and to the RTA in case the shares are held in physical form, quoting their folio no./DP-Id/Client id.
17. Members holding shares in physical form, in identical order of names, in more than one folio are requested to send to the Company or RTA, the details of such folios together with the share certificates along with the requisite KYC Documents for consolidating their holdings in one folio. Requests for consolidation of share certificates shall be processed in dematerialized form.
18. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any Member as soon as possible. Members are also advised to not leave their Demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant and holdings should be verified from time to time.

19. In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
20. Members desirous of obtaining any information concerning to the accounts and operations of the Company are requested to send their queries to the Company Secretary at least 7 (seven days) before the date of the meeting so that the required information can be made available at the meeting.
21. The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and Register of Contracts or arrangements in which directors are interested maintained under Section 189 of the Act and relevant documents referred to in this Notice of AGM and explanatory statement, will be available electronically for inspection by the Members during the AGM. All documents referred to in the Notice will also be available for electronic inspection without any fee by the Members from the date of circulation of this Notice up to the date of AGM, i.e. Friday, 29th September, 2023. Members seeking to inspect such documents can send an email to investors@medicaps.com.
22. Members are requested to contact the Registrar and Share Transfer Agent for all matters connected with Company's shares at Ankit Consultancy Private Limited, 60 Pardeshipura, Electronic Complex, Indore (M.P.)
23. **Investor Grievance Redressal:** The Company has designated an exclusive e-mail ID i.e. investors@medicaps.com to enable the investors to register their complaints/ send correspondence, if any.
24. **Webcast:** Members who are entitled to participate in the AGM can view the proceedings of AGM by logging in the website of CDSL at www.evotingindia.com using the login credentials.
25. The Company has appointed Mr. L.N. Joshi, Practicing Company Secretary (Membership No. FCS-5201; CP No.4216) to act as the scrutiner for conducting the remote e-voting process as well as the e-voting during AGM, in a fair and transparent manner.
26. The voting rights of Shareholders shall be in proportion of shares held by them to the total paid up equity shares of the company as on Friday 22nd September, 2023, being the cut-off date.
27. A person, who is not a Member as on Friday 22nd September, 2023 should treat this Notice for information purposes only.
28. A person who has acquired the shares and has become a member of the Company after dispatch of notice of AGM and prior to the Cut-off date i.e. Friday 22nd September, 2023, shall be entitled to exercise his/her vote either electronically i.e. remote e-voting or e-voting during AGM following the procedure mentioned in this Notice.
29. The recorded transcript of the forthcoming AGM shall also be made available on the website of the Company - www.medicaps.com as soon as possible after the Meeting is over.
30. The procedure for joining the AGM through VC/OAVM is mentioned in this Notice. Since the AGM will be held through VC/OAVM, the route map is not annexed in this Notice.
31. In compliance with the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and any amendments thereto, Secretarial Standard on General Meetings ("SS-2"), Regulation 44 of the SEBI Listing Regulations and MCA Circulars, the facility for remote e-voting and e-voting in respect of the businesses to be transacted at the AGM is being provided by the Company through Central Depository Services (India) Limited ("CDSL"). Necessary arrangements have been made by the Company with CDSL to facilitate remote e-voting and e-voting during the AGM.
32. **THE INSTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING AND EVOTING DURING AGM AND JOINING MEETING THROUGH VC/OAVM ARE AS UNDER:**
 - (i) The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
 - (ii) The voting period begins on Tuesday 26th September, 2023 from 9.00 A.M. and ends on Thursday, 28th September, 2023 at 5.00 P.M. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Friday 22nd September, 2023, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
 - (iii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
 - (iv) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (v) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode CDSL/ NSDL is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<p>1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on Login icon and select New System Myeasi Tab.</p> <p>2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</p> <p>3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.</p> <p>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
Individual Shareholders holding securities in demat mode with NSDL Depository	<p>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com. Select "Register Online for IDeAS" "Portal or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsd.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting</p>
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(vi) Login method for e-Voting and joining virtual meeting for physical shareholders and shareholders other than individual holding in Demat form.

- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> • If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

(vii) After entering these details appropriately, click on “SUBMIT” tab.

(viii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

(ix) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

(x) Click on the EVSN for the relevant company i.e. Medi-Caps Limited on which you choose to vote.

(xi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

(xii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.

(xiii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.

(xiv) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.

(xv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.

(xvi) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xvii) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.

(xviii) Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting only

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.

- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; investors@medicaps.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

33. INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

- The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
- The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
- Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
- Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
- Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast seven days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at investors@medicaps.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance seven days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at investors@medicaps.com. These queries will be replied to by the company suitably by email.
- Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
- Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
- If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.
- When a pre-registered speaker is invited to speak at the meeting but he / she does not respond, the next speaker will be invited to speak. Accordingly, all speakers are requested to get connected to a device with a video/ camera along with good Internet speed.
- The Company reserves the right to restrict the number of questions and number of speakers, as appropriate, for smooth conduct of the AGM.

34. PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

- For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to **Company/RTA email id**.
- For Demat shareholders-, Please update your email id & mobile no. with your respective **Depository Participant (DP)**
- **For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.**

35. DECLARATION OF RESULTS:

- The scrutinizer shall, immediately after the conclusion of voting during the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favor or against, if any, to the Chairperson of the Company or the person authorized by him, who shall countersign the same.
- Based on the scrutinizer's report, the Company will submit within 2 (two) working days of the conclusion of the AGM to the Stock Exchange, details of the voting results as required under Regulation 44(3) of the SEBI Listing Regulations.
- The results declared along with the scrutinizer's report, will be hosted on the website of the Company at www.medicaps.com and on the website of CDSL, i.e. www.evotingindia.com, immediately after the

declaration of the result by the Chairperson or a person authorized by him in writing and communicated to the Stock Exchange.

- The Resolutions shall be deemed to be passed on the date of the Meeting, i.e. Friday 29th September, 2023 subject to receipt of the requisite number of votes in favour of the Resolutions.
- 36.** If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33.
- 37.** All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 22 55 33.

DATE: 11th AUGUST, 2023

PLACE: INDORE

BY ORDER OF THE BOARD OF DIRECTORS

ABHISHEK JAIN
COMPANY SECRETARY
ACS-36699

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Registered Office: Mhow, Neemuch Road,

Sector 1, Pithampur, Dhar (M.P.)-454775

Website: www.medicaps.com

Email: investors@medicaps.com

Phone: 07292-256205

STATEMENT AS REQUIRED UNDER SECTION 102 OF THE COMPANIES ACT, 2013

Pursuant to Section 102 of the Companies Act, 2013 ('the Act'), the following Statement sets out all material facts relating to the businesses is mentioned under Item Nos. 4 & 5 of the accompanying Notice dated August 11, 2023:

Item No. 4: Appointment of Mr. Gajendra Singh (DIN: 10253991) as a Non Executive Independent Director of the Company.

Based on the recommendation of the Nomination and Remuneration Committee (NRC), the Board of Directors at its meeting held on 11th August, 2023, appointed Mr. Gajendra Singh (DIN: 10253991) as an Additional Director under the category of Non Executive Independent Director of the Company, not liable to retire by rotation, for a term of five years i.e. from 11th August, 2023, up to 10th August, 2028, subject to the approval of the Members in ensuing Annual General Meeting. According to the provision of Section 161(1) of the Companies Act, 2013 ('the Act'), Mr. Gajendra Singh (DIN: 10253991) shall hold office as an Additional Director up to the date of this Annual General Meeting and is eligible to be appointed as a Non Executive Independent Director.

The Company has, in terms of Section 160(1) of the Act, received in writing a notice from Member, proposing his candidature for the office of Director. Mr. Gajendra Singh (DIN: 10253991) has given his declaration to the Board that he is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has given his consent to act as a Independent Director, he meets the criteria of independence as provided under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations and is not restrained from acting as a Non Executive Independent Director under any order passed by the Securities and Exchange Board of India or any such authority and is eligible to be appointed as a Non Executive Independent Director in terms of Section 164 of the Act. In the opinion of the Board, Mr. Gajendra Singh (DIN: 10253991) is a person of integrity, possesses the relevant expertise/experience, and fulfills the conditions specified in the Act and the SEBI Listing Regulations for appointment as a Non Executive Independent Director and he is independent of the management. In terms of Regulation 25(8) of SEBI Listing Regulations, he has confirmed that he is not aware of any circumstance or situation that exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties.

Mr. Gajendra Singh (DIN: 10253991) has confirmed that he is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, with respect to his registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs. Further he has confirmed that, he had not been a partner of a firm that had transactions during last three financial years with Company amounting to ten percent or more of its gross turnover.

In compliance with the provisions of Section 149 read with Schedule IV to the Act, a copy of the draft appointment letter in relation to appointment of Mr. Gajendra Singh (DIN: 10253991) as a Non-executive Independent Director setting out the terms and conditions of the appointment would be available for inspection by the Members, by writing an email to the Company at investors@medicaps.com.

Further, with effect from 1st January 2022, as per Regulation 25(2A) of the SEBI Listing Regulations, appointment or the re-appointment of an independent director shall be subject to approval of shareholders by way of a special resolution. Mr. Gajendra Singh (DIN: 10253991) fulfils the requirement of an independent director as laid down under Section 149(6) of the Act and Regulation 16 and 25 of the SEBI Listing Regulations.

Given his experience, the Board considers it desirable and in the interest of the Company to have Mr. Gajendra Singh (DIN: 10253991) on the Board of the Company and accordingly the Board recommends the appointment of Mr. Gajendra Singh (DIN: 10253991) as a Non Executive Independent Director in compliance with the provisions of Section 149 read with Schedule IV to the Act and Regulation 17 of the SEBI Listing Regulations and the approval of the Members is

sought for the appointment of Mr. Gajendra Singh (DIN: 10253991) as Independent Director of the Company, as proposed in the Resolution no. 4 for approval by the Members as a Special Resolution.

The disclosure under Regulation 36 of the SEBI Listing Regulations is provided as notes to this notice separately.

Except proposed appointee, none of the Directors, Key Managerial Personnel of the Company and their relatives is, in any way, concerned or interested, financially or otherwise, in the Special Resolution as set out at Item No. 4 of the Notice.

Item No. 5: Adoption of new set of Articles of Association of the Company containing regulation in conformity with the Companies Act, 2013.

The Articles of Association of the Company as currently in force was originally adopted when the Company was incorporated under the Companies Act, 1956 and further amendments were adopted from time to time, over the past several years. The references to specific Sections of the Companies Act, 1956 in the existing Articles of Association may no longer be in conformity with the Companies Act, 2013.

With the introduction of the Companies Act, 2013, it is proposed to amend the existing Articles of Association to make it consistent with the provisions of the Companies Act, 2013 including Rules framed there under. In terms of Section 14 of the Companies Act, 2013, the consent of the Members by way of Special Resolution is required for adoption of new set of Articles of Association of the Company.

A copy of the proposed set of new Articles of Association of the Company would be available for inspection at the Registered Office of the Company during the business hours on any working day, up to the date of the Annual General Meeting and during the Annual General Meeting. In addition, the proposed draft Articles of Association is also available on the Company's website www.medicaps.com for perusal by the Members.

The Board recommends the Special Resolution as set out at Item No.5 of the Notice for approval by the Members.

None of the Directors, Key Managerial Personnel of the Company and their relatives is, in any way, concerned or interested, financially or otherwise, in the Special Resolution as set out at Item No. 5 of the Notice.

DATE: 11th AUGUST, 2023

PLACE: INDORE

BY ORDER OF THE BOARD OF DIRECTORS

ABHISHEK JAIN

COMPANY SECRETARY

ACS-36699

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Registered Office: Mhow, Neemuch Road,

Sector 1, Pithampur, Dhar (M.P.)-454775

Website: www.medicaps.com

Email: investors@medicaps.com

Phone: 07292-256205

Additional Information of Director seeking appointment/re-appointment at this Annual General Meeting pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and Secretarial Standard of General Meeting:

Name of Director	Mr. Ramesh Chandra Mittal (Chairman and Non-Executive Non Independent Director)	Mr. Gajendra Singh (Non-Executive Independent Director)
DIN	00035272	10253991
Date of Birth	16 th June, 1947	02 nd February, 1985
Date of Appointment	06 th August, 1983	11 th August, 2023
Expertise / Experience in specific functional areas	Having wide experience of more than 4 decades in the field of pharma industry and real estates	He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.
Qualification	B. Pharma	B.Com, Masters of Social work (MSW)
No. & % of Equity Shares held in the Company including shareholding as a beneficial owner	10000 (0.08%)	NIL
List of outside Company's directorship held	1. Crystal Devcon Private Limited 2. North Rajasthan Holdings Private Limited 3. Geet Dwellers Private Limited 4. Medgel Private Limited.	Nil
List of Companies in which resigned in the past three years	Nil	Nil

Chairman / Member of the Committees of the Board of Directors of the Company	Nil	Nil
Salary or Sitting fees paid	Nil	Nil
Chairman / Member of the Committees of the Board Directors of other Companies in which he is director	Nil	Nil
Chairman / Member of the Committees of the Board of Directors of other Companies in which he resigned in the past three years	Nil	Nil
Relationship between directors inter-se	Relative of 1) Director Mrs. Kusum Mittal (Wife), 2)-Managing Director Mr. Alok K Garg (son in law)	None
Attendance at Board Meetings	During the year, 1st April, 2022 to 31st March, 2023, 4 Board Meetings of the Company were held, and he had attended all Meetings.	Not applicable since he was appointed during the current financial year 2023-24.
In case of independent directors, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements	NA	The role and capabilities as required in the case of an independent director are well defined in the Policy on Nomination, Appointment, and Removal of Directors. Further, the Board has a defined list of core skills / expertise / competencies, in the context of its business and sector for it to function effectively. The Nomination and Remuneration Committee of the Board has evaluated the profile of Mr. Gajendra Singh and concluded that he possess the relevant skill and capabilities to discharge the role of Independent Director.

DATE: 11th AUGUST, 2023

PLACE: INDORE

BY ORDER OF THE BOARD OF DIRECTORS

ABHISHEK JAIN
COMPANY SECRETARY
ACS-36699

MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

Registered Office: Mhow, Neemuch Road,
Sector 1, Pithampur, Dhar (M.P.)-454775

Website: www.medicaps.com

Email: investors@medicaps.com

Phone: 07292-256205

BOARD'S REPORT

To,
The Members,
MEDI-CAPS LIMITED

Your Board of Directors has pleasure to presenting the 40th Annual Report on the business and operations of Medi-Caps Limited together with the Standalone and Consolidated Audited Financial Statements for the year ended 31st March, 2023.

1. STATE OF AFFAIRS AND FINANCIAL PERFORMANCE: FINANCIAL HIGHLIGHTS AND SUMMARY OF STANDALONE AND CONSOLIDATED FINANCIAL STATEMENTS:

The standalone and consolidated financial statements of the Company for the financial year ended 31st March, 2023, have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs and as amended from time to time.

The following table shows the operational results of the Company for the Financial Year 2022-23 as compared to that of previous year:

(Amount in Lakhs except EPS)

Particulars	Standalone		Consolidated	
	31.03.2023	31.03.2022	31.03.2023	31.03.2022
Total Income	74.60	60.74	5097.42	7178.53
Total Expenditure before Interest and Depreciation	39.79	57.59	4430.86	5991.43
Profit/Loss before Interest, Depreciation & Tax (EBIDTA)	34.81	3.15	666.56	1187.10
Less: Interest	0.00	0.00	0.16	0.02
Less: Depreciation	9.23	9.23	174.32	181.32
Profit/Loss before Tax	25.58	(6.08)	492.08	1005.77
Less:(a) Current Tax	0.00	0.00	122.00	0.00
(b) Earlier year (excess)/short provision for tax written back	0.00	0.00	183.58	0.00
(c) Deferred Tax	(0.14)	1.44	(0.14)	1.44
Profit/ Loss for the period from continuing operations	25.72	(7.52)	186.64	1004.33
Profit/Loss from discontinued operations	(11.07)	3.72	(11.07)	3.72
Profit/Loss for the period	14.65	(3.80)	175.57	1008.05
Other Comprehensive Income	(32.70)	35.69	55.95	146.32
Total Comprehensive Income for the period comprising Profit/(Loss)	(18.05)	31.89	231.52	1154.37
EPS (Equity Shares of Rs. 10/- each) (in Rs.) Basic and Diluted (for continuing and discontinued operations)	0.12	(0.03)	1.41	8.08

STATE OF COMPANY'S AFFAIRS AND REVIEW OF OPERATIONS

The Members are aware that the Company had entered into Real Estate sector and started its first project 'Medicaps Business Park' with M/s. Tirupati Reality & Developers. The Developer has started marketing of the project after receiving the approval under Real Estate Regulatory Authority and the project is getting huge response in the market; impact of the same in terms of revenue will be reflected in the financial years 2023-24.

In financial year 2022-23, on standalone basis, the Company has earned total income of Rs. 74.60 Lakhs and incurred a loss of (after comprehensive income) of Rs. 18.05 Lakhs as compared to previous year where the Company had earned total income of Rs. 60.74 lakhs which consists mainly of Capital Gain on Mutual Fund and earned net profit (after comprehensive income) amounting to Rs. 31.89 Lakhs.

Further on a consolidated basis, the Company has earned total income of Rs. 5097.42 Lakhs as against Rs. 7178.53 Lakhs in the previous year and earned net profit (after comprehensive income) of Rs. 231.52 Lakhs as compared to the previous financial year in which Company earned net profit (after comprehensive income) amounting to Rs. 1154.37 Lakhs. The consolidated financials reflect the cumulative performances of Medi-Caps Limited along with its wholly owned subsidiary (Medgel Private Limited).

Detailed description about the business carried out is contained in the Management Discussion and Analysis report.

2. ANNUAL RETURN

Pursuant to Section 134(3)(a) of the Companies Act, 2013, the draft annual return as on 31st March, 2023 prepared in accordance with Section 92(3) of the Act is made available on the website of your Company and can be assessed using the web link <https://medicaps.com/wp-content/uploads/2023/08/MGT-7%20List.pdf>

3. NUMBER OF MEETINGS OF THE BOARD, ITS COMMITTEE AND AGM

The Board meets at regular intervals to discuss and decide on business policy and strategy apart from other Board business. The notice of Board Meeting is given well in advance to all the Directors. The agenda of the Board/Committee meetings are circulated at least 7 days prior to the date of the meeting. The agenda for the Board and Committee meetings include detailed notes on the items to be discussed at the meeting to enable the Directors to take an informed decision.

The details of the number of meetings of the Board and its Committees held during the Financial Year 2022-23 forms part of the Corporate Governance Report. Further, Annual General Meeting of the Company for Financial year 2021-2022 was held on Wednesday 28th September, 2022.

4. DIVIDEND

Due to inadequate profit, the Board of Directors has not recommended any dividend for the year 2022-23.

5. AMOUNT TRANSFER TO RESERVES

During the year under review, no amount was transferred to any of the reserves by the Company.

6. DEPOSITS

Your Company has not accepted deposit from the public falling within the ambit of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014 and there were no remaining unclaimed deposits as on 31st March, 2023. Further, the Company has not accepted any deposit or loans in contravention of the provisions of the Chapter V of the Companies Act, 2013 and the Rules made there under.

DISCLOSURE OF UNSECURED LOAN RECEIVED FROM DIRECTORS

Pursuant to Section 2(31) Read with Rule 2(1)(c)(viii) of Companies (Acceptance of Deposits) Rules, 2014, (including any statutory modification or re-enactment thereof for the time being in force), the Company had not received any unsecured loan from directors during the financial year.

7. SUBSIDIARIES, ASSOCIATE AND JOINT VENTURES OF THE COMPANY

The Company is continuing having one Wholly Owned Subsidiary i.e. Medgel Private Limited. Further, the Company does not have any associate or joint venture company at the beginning or closing or any time during the year 2022-2023. There are no companies which become/ceased to be subsidiaries during the year of your Company.

A separate statement containing salient features of the Financial Statement of the Subsidiary in the prescribed Form AOC-1 are annexed to this Report as ANNEXURE-A and hence is not repeated here for sake of brevity.

In accordance with fourth proviso of Section 136(1) of the Companies Act, 2013, the Annual Report of the Company, containing therein its standalone and the consolidated financial statements has been placed on the website of the Company, www.medicaps.com. Further, as per fifth proviso of the said section, audited annual accounts of the subsidiary company have also been placed on the website of the Company, https://medicaps.com/?page_id=7256. There has been no material change in the nature of the business of the subsidiary company.

In terms of Section 136 of the Companies Act, 2013 ('the Act'), Financial Statement of the subsidiary company is not required to be sent to the members of the Company. The Company shall provide a copy of the annual accounts of its subsidiary company to the members of the Company on their request. The annual accounts of its subsidiary company will also be kept open for inspection at the registered office of the Company during business hours.

MATERIAL SUBSIDIARY

Medgel Private Limited is material wholly owned subsidiary of the Company as per the thresholds laid down under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred as 'SEBI Listing Regulations'). The Board of Directors of the Company has approved a Policy for determining material subsidiaries which is in line with the SEBI Listing Regulations as amended from time to time. The Policy has been uploaded on the Company's website at: <https://medicaps.com/wp-content/uploads/2022/08/Policy-for-determining-Material-Subsidiary-f.pdf>

8. CONSOLIDATED FINANCIAL STATEMENTS

Your Directors have pleasure in enclosing the Consolidated Financial Statements pursuant to the requirement of Section 129 of the Companies Act, 2013 and Regulation 33 and Regulation 34 of the SEBI Listing Regulations, read with other applicable provisions and prepared in accordance with applicable IND AS, for financial year ended March 31, 2023. The Consolidated Financial Statements form part of this Annual Report.

A Report on the performance and financial position of the subsidiary company included in the Consolidated Financial Statements and their contribution to the overall performance of the Company is provided in Form AOC-1 and forms integral part of this Annual Report.

9. DETAILS OF BOARD OF DIRECTORS AND KMPs

The composition of the Board of Directors of the Company is in accordance with the provision of Section 149 of the Companies Act, 2013 and Regulation 17 of the SEBI Listing Regulations, with an appropriate combination of Executive, Non-Executive and Independent Directors.

a) Constitution of the Board

As on 31st March, 2023, Board of Directors comprises of total 8 (**Eight**) Directors namely:

- (i) Mr. Ramesh Chandra Mittal (DIN: 00035272), Chairman and Non Executive Non Independent Director
- (ii) Mr. Alok K Garg (DIN: 00274321), Managing Director
- (iii) Mrs. Kusum Mittal (DIN: 00035356), Non Executive Non Independent Women Director
- (iv) Mr. Akshit Garg (DIN: 08576807), Non Executive Non Independent Director
- (v) Mr. Pramod Fatehpuria (DIN: 00972389), Independent Director
- (vi) Mr. Ashok Agrawal Omprakash (DIN: 07870578), Independent Director
- (vii) Mr. Dharmendra Solanki (DIN: 09055239), Independent Director
- (viii) Mr. Sourabh Kumar Shrinivas (DIN: 09692160), Independent Director

The Board members are highly qualified with the strong varied experience in the relevant field of the business activities of the Company which plays significant roles for the business policy and decision making process and provide guidance to the executive management to discharge their functions effectively.

b) Change in Directors

During the financial year 2022-23, on the recommendation of Nomination and Remuneration Committee, Mr. Sourabh Kumar Shrivias (DIN: 09692160) was appointed additional director and Non-executive Independent Director and Mr. Akshit Garg (DIN: 08576807) was appointed as additional director and promoter Non-Executive Director by the Board of Directors w. e. f. 04th August, 2022 at its meeting held on 4th August, 2022 which were subsequently confirmed by the members in their 39th Annual General Meeting held on 28th September, 2022.

However, during the Current Financial Year 2023-2024, Mr. Sourabh Kumar Shrivias (DIN: 09692160) and Mr. Akshit Garg (DIN: 08576807) were resigned from the post of directorship of the Company w. e. f. 21st July, 2023.

Further during the Current Financial Year 2023-2024, on the recommendation of Nomination and Remuneration Committee, the Board at its Meeting held on 11th August, 2023 approved appointment of Mr. Gajendra Singh (DIN: 10253991) as an Additional director under the category of Non-Executive Independent Director on the Board of Directors of the Company with effect from 11th August, 2023 to hold office up to the date of ensuing Annual General Meeting of the Company to be held thereafter and subject to the approval of the Members at the said Annual General Meeting, to hold office as an Independent Director for a term of 5 (five) consecutive years commencing from 11th August, 2023 to 10th August, 2028 (both days inclusive). The Company has received the requisite Notice from a Member in writing proposing their appointment as a Non-Executive Independent Director of the Company.

c) Board Independence

Our definition of 'Independent Director' is derived from Regulation 16(1)(b) of SEBI Listing Regulations and Section 149(6) of the Companies Act, 2013. As on 31st March, 2023, the Company is having following 4 (Four) Independent Directors:

1. Mr. Ashok Omprakash Agrawal (DIN: 07870578)
2. Mr. Pramod Fatehpuria (DIN: 00972389)
3. Mr. Dharmendra Solanki (DIN: 09055239)
4. Mr. Sourabh Kumar Shrivias (DIN: 09692160) {Resigned w. e. f. 21st July, 2023}

d) Directors liable to retire by rotation seeking re-appointment

Mr. Ramesh Chandra Mittal (DIN: 00035272) is liable to retire by rotation at the ensuing 40th Annual General Meeting and being eligible offers himself for re-appointment. Your directors recommend passing necessary resolution as proposed in the Item No. 3 of the Notice of the Annual General Meeting.

e) Key Managerial Personnel

Mr. Alok K Garg (DIN: 00274321), Managing Director; Mr. Hemant Sethi, Chief Financial Officer and Mr. Abhishek Jain, Company Secretary and Compliance Officer; have been categorized as the Key Managerial Personnel within the meaning of Section 203 of the Companies Act, 2013.

f) Change in the Key Managerial Personnel

During the year under review, there was no change in the Key Managerial Personnel of the Company.

g) Disqualifications of Directors

During the year declarations were received from the Directors of the Company pursuant to Section 164 of the Companies Act, 2013. Board apprised the same and found that none of the director is disqualified for holding office as director.

10. DECLARATION BY INDEPENDENT DIRECTORS

All Independent Directors have given their declarations as required under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of SEBI Listing Regulations that they meet the criteria of independence as laid down under section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of SEBI Listing Regulations as amended from time to time.

Further in terms of Regulation 25(8) of the SEBI Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence and that they are independent of the Management. The Board of Directors of the Company have taken on record the declaration and confirmation submitted by the Independent Directors after undertaking due assessment of the veracity of the same.

The Board is of the opinion that the Independent Directors of the Company hold highest standards of integrity and possess requisite expertise and experience required to fulfill their duties as Independent Directors.

In terms of Section 150 of the Companies Act, 2013 read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, Independent Directors of the Company have confirmed that they have registered themselves with the databank maintained by The Indian Institute of Corporate Affairs (“IICA”). The Independent Directors, except who is exempt, have also cleared online proficiency self-assessment test conducted by the IICA within a period of 2 (two) years from the date of inclusion of their names in the data bank.

Mr. Pramod Fatehpuria (DIN: 00972389) Independent Director of the Company is exempted from the requirement to undertake online proficiency self-assessment test and Mr. Ashok Omprakash Agrawal (DIN: 07870578) & Mr. Dharmendra Solanki (DIN: 09055239) Independent Directors of the Company have passed online proficiency self-assessment test.

Further director appointed during the current financial year 2023-24, Mr. Gajendra Singh (DIN: 10253991), Non-Executive Independent Director of the Company is required to clear the online proficiency self-assessment test in prescribed time.

11. DIRECTORS’ RESPONSIBILITY STATEMENT

Based on the framework and testing of internal financial controls and compliance systems established and maintained by the Company, work performed by the internal, statutory, and secretarial auditors and external agencies, including audit of internal financial controls over financial reporting by the Statutory Auditors and the reviews performed by Management and the relevant Board Committees, including the Audit Committee, the Board is of the opinion that the Company’s internal financial controls were adequate and effective during the financial year 2022-23.

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that-

- in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the loss of the Company for that year;
- The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- the Directors have prepared the annual accounts on a going concern basis;
- the Directors have laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and operating effectively;
- the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

12. COMMITTEES OF THE BOARD OF DIRECTORS

The Company has various Committees which have been constituted as a part of the good corporate governance practices and the same are in compliance with the requirements of the relevant provisions of applicable laws and statutes. Your Company has an adequately qualified and experienced Audit Committee consisting of Mr. Ashok Omprakash Agrawal (DIN: 07870578) as Chairman, Mr. Pramod Fatehpuria (DIN: 00972389) and Mr. Dharmendra Solanki (DIN: 09055239) as members of the Committee. The recommendations of the Audit Committee were duly approved and accepted by the Board during the year under review. The other Committees of the Board are:

- (i) Nomination and Remuneration Committee
- (ii) Stakeholders' Relationship Committee

The details with respect to the composition, powers, roles, terms of reference, meetings held and attendance of the Directors at such Meetings of the relevant Committees are given in the Report on Corporate Governance of the Company which forms part of this Annual Report.

13. MEETING OF INDEPENDENT DIRECTORS

The Independent Directors met once during the year under review. The meeting was conducted on 10th November, 2022 in an informal manner without the presence of the Chairman, Managing Director and Non-Executive Non-Independent Directors of the Company.

14. COMPANY'S POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

The Board has on the recommendation of the Nomination and Remuneration Committee framed a Nomination and Remuneration Policy which lays down the criteria for identifying the persons who are qualified to be appointed as directors and or senior management personnel of the company, along with the criteria for determination of remuneration of directors, KMP's and other employees and their evaluation and includes other matters, as prescribed under the provisions of Section 178 of Companies Act, 2013 and Regulation 19 of SEBI Listing Regulations. Policy of the Company has been given at the website of the Company at <https://medicaps.com/wp-content/uploads/2016/06/Remuneration-Policy.pdf>. The details of the same are also covered in Corporate Governance Report forming part of this Annual Report.

A) FORMAL ANNUAL BOARD EVALUATION

The Board of Directors has carried out an annual evaluation of its own performance, Board Committees and individual directors pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations. The performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The Company has devised a policy for performance evaluation of the Board, Committees and other individual Directors (including Independent Directors) which include criteria for performance evaluation of Non-Executive Directors and Executive Directors. The evaluation process inter alia considers attendance of Directors at Board and committee meetings, acquaintance with business, communicating inter se board members, effective participation and domain knowledge, compliance with code of conduct, vision and strategy.

The Board carried out an annual performance evaluation of the Board, Committees, Individual Directors and the Chairman. The Chairman of the respective Committees shared the report on evaluation with the respective Committee members. The performance of each Committee was evaluated by the Board, based on report on evaluation received from respective Committees.

The report on performance evaluation of the Individual Directors was reviewed by the Chairman of the Board and feedback was given to Directors.

Performance Evaluation Criteria for Independent Directors:

Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated. The performance evaluation criteria for independent directors are determined by the Nomination and Remuneration Committee. An indicative list of factors that may be evaluated include participation and contribution by a director, commitment, effective deployment of knowledge and expertise, effective management of relationship with stakeholders, integrity and maintenance of confidentiality and independence of behavior and judgments. Further details are reported in the Corporate Governance Report.

Statement with regard to integrity, expertise and experience of the Independent Director appointed during the year

During the year under review, Mr. Sourabh Kumar Shrivastava (DIN: 09692160) was appointed as an Independent Director in the Company. At the time of appointment of Mr. Sourabh Kumar Shrivastava (DIN: 09692160), the Nomination and Remuneration Committee of the Board considered that he had a vast post qualification experience and a good exposure in Administration. He is well known for his Strategic thinking skills and abilities to deal with management issues. Mr. Sourabh Kumar Shrivastava possess humble confidence with leadership qualities and Business acumen and it was believed that he would exercise objective independent judgment on corporate affairs and maintains high ethical standards and shall take into account the interests of stakeholders. However, Mr. Sourabh Kumar Shrivastava (DIN: 09692160) resigned from the post of Independent Director of the Company with effect from 21st July, 2023.

Further, in the opinion of the Board, all Independent Directors possess requisite qualifications, experience, expertise and hold high standards of integrity for the purpose of Rule 8(5) (iiia) of the Companies (Accounts) Rules, 2014. List of key skills, expertise and core competencies of the Board, including the Independent Directors, is provided in Corporate Governance Report.

B) FAMILIARIZATION PROGRAMME OF INDEPENDENT DIRECTORS

The details of program for familiarization of Independent Directors of the Company is available on Company's website at <https://medicaps.com/wp-content/uploads/2023/02/Familiarization-policy-updation-2022-23.pdf>

15. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

Pursuant to the requirement of Regulation 34(3) read with Schedule V SEBI Listing Regulations disclosure on particulars relating to Investment are stated in Note No. 3 & 6 of Standalone Financial Statement. Further your company has not given any loan or advances in nature of loan to any other Body Corporate or person. Details of investments and guarantee given are disclosed as under:

(Amount in Lakhs)

Name of the Company	Nature of Transactions	Investment made/ Guarantee/ Loans Provided	Closing value as on 31 st March, 2023
Medgel Private Limited (Wholly Owned Subsidiary)	Non-Current	Investment	4282.35
Natural Capsules Limited	Non-Current	Investment	0.39
Mutual Funds & SIP	Current and Non-Current	Investment	806.90

*The investments are reported as per relevant Ind-As.

The above stated investments are within the limits as specified under Section 186 of the Companies Act, 2013.

Further during the financial year 2022-23, the Company had withdrawn its corporate guarantee given in favour of wholly owned material subsidiary i.e. Medgel Private Limited; towards a cash credit limit of Rs. 2 crore availed by wholly owned material subsidiary from IDBI Bank Limited, Indore.

16. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTY

In line of the requirements of the Companies Act, 2013 and the SEBI Listing Regulations, the Company has developed a Policy on dealing with related party transactions, Standard Operating Procedures for purpose of identification and monitoring of such transactions.

The policy of RPT is available on the Company's website <https://medicaps.com/wp-content/uploads/2017/03/RPT-Policy-W.E.F-25.07.2018-Final-Updated.pdf>

During the year under review, all related party transactions entered into by the Company, were approved by the Audit Committee and were at arm's length and in the ordinary course of business. Prior omnibus approval is obtained for related party transactions which are of repetitive nature and entered in the ordinary course of business and on an arm's length basis. There were no material related party contracts entered into by the Company during the year under review. Accordingly, the disclosure of related party transactions as required under Section 134(3)(h) of the Act in Form AOC-2 is not applicable to the Company for FY 2022-23 and hence does not form part of this report.

Details of related party transactions entered into by the Company, in terms of Companies Act, 2013 and IndAS-24 have been disclosed in the notes to the standalone financial statement forming part of this Annual Report 2022-23.

17. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars in respect of conservation of energy, technology absorption and foreign exchange earnings and outgo, as required under sub-section (3)(m) of Section 134 of the Companies Act, 2013 read with Rule (8)(3) of the Companies (Accounts) Rules, 2014 are given as under :

S. No.	Particulars	Details
(A)	Conservation of Energy	
(i)	The steps taken or impact on conservation of energy	Not applicable as there was no such business operation
(ii)	The steps taken by the company for utilizing alternate sources of energy	Not applicable as there was no such business operation
(iii)	The capital investment on energy conservation equipments	Nil
(B)	Technology Absorption	
(i)	The efforts made towards technology absorption	Not Applicable
(ii)	The benefits derived like product improvement, cost reduction, product development or import substitution	Not Applicable
(iii)	In case of imported technology (imported during the last three years reckoned from the beginning of the Financial Year)	The Company has neither purchased within India nor imported any technology.

(iv)	The expenditure incurred on Research and Development	The Company has not incurred any expenditure on Research and Development during the year under review.	
(c)	Foreign Exchange Earnings and Outgo		
Particulars		2022-23	2021-22
Foreign Exchange Earnings: (Amount in lacs)		Nil	Nil
Foreign Exchange Outgo: (Amount in lacs)		Nil	Nil

18. ADEQUACY OF INTERNAL FINANCIAL CONTROL AND ITS EFFECTIVENESS

The Board is expected to play an important role in establishing the control environment, including clarity of expectations regarding integrity and ethics and adherence to codes of conduct and creating clear accountability for performance of internal control responsibilities. The Company's Board of Directors has devised systems, policies and procedures/frameworks, which are currently operational within the Company for ensuring the orderly and efficient conduct of its business, which includes adherence to Company's policies, safeguarding assets of the Company, prevention and detection of frauds and errors, accuracy and completeness of the accounting records and timely preparation of reliable financial information. In line with best practices, the Audit Committee and the Board reviews these internal control systems to ensure they remain effective and are achieving their intended purpose. Where weaknesses, if any, are identified as a result of the reviews, new procedures are put in place to strengthen controls. These controls are in turn reviewed at regular intervals. The company has laid down adequate systems and well drawn procedures for ensuring internal financial controls. It has appointed an external audit firm as internal auditors for periodically checking and monitoring the internal control measures.

Nothing has come to the attention of the Directors to indicate that any material breakdown in the function of these controls, procedures or systems occurred during the year under review. There have been no significant changes in the Company's internal financial controls during the year that have materially affected or are reasonably likely to materially affect its internal financial controls. There are inherent limitations to the effectiveness of any system of disclosure, controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.

19. CORPORATE SOCIAL RESPONSIBILITY

In view of the net worth, profits and turnover, the Company does not fall under the provisions of the Section 135 of the Companies Act, 2013 and the rules made there under. Hence the obligations under Section 135 of the Companies Act, 2013 are not applicable to the Company.

20. RATIO OF THE REMUNERATION OF EACH DIRECTOR TO THE MEDIAN EMPLOYEE'S REMUNERATION AND PARTICULARS OF EMPLOYEES

Pursuant to provision of Section 197(12) of Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended up to date, given in the "ANNEXURE-B" and forms an integral part of Board Report.

During the year, none of the employees received remuneration in excess of Rs. 102.00 Lakhs or more per annum or Rs. 8.50 Lakhs per month for the part of the year. In accordance with the provisions of Section 197 of the Companies Act, 2013 read with rule 5(2) and rule (3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Therefore, there is no information to disclose in terms of the provisions of the Companies Act, 2013.

Further the statement containing details of Top Ten Employees in terms of remuneration of employees as required under Section 197(12) of the Act, read with Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended up to the date, is available at Corporate Office of the Company. In terms of Section 136(1) of the Act, the Annual Report is being sent to the Members excluding the aforesaid details. Any Member desirous of obtaining above said details may write to the Company Secretary or email at investors@medicaps.com.

Pursuant to Section 197(14) of the Companies Act, 2013, Mr. Alok K Garg (DIN: 00274321), Managing Director of the Company has drawn remuneration of Rs. 74.10 Lacs from wholly owned subsidiary company in capacity of Managing Director of Medgel Private Limited and Mr. Akshit Garg (DIN: 08576807), Non Executive Non Independent Director of the Company has drawn remuneration of Rs. 36.65 Lacs from wholly owned subsidiary company in capacity of Whole Time Director of Medgel Private Limited. Apart from this none of the Director of the Company received any remuneration or commission from the wholly owned subsidiary company.

21. REPORT ON CORPORATE GOVERNANCE

As per Regulation 34(3) read with Schedule V of the SEBI Listing Regulations, a separate section on "Corporate Governance Practices" followed by the Company together with a certificate from the Statutory Auditors of the

Company confirming compliance with the conditions of the Corporate Governance, forms part of the Annual Report.

22. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis Report for the year under review, as stipulated under SEBI Listing Regulations is presented in a separate section forming part of the Annual Report.

23. VIGIL MECHANISM/WHISTLE BLOWER POLICY

The Company has a robust vigil mechanism through its Whistle Blower Policy approved and adopted by Board of Directors of the Company in compliance with the provisions of Section 177(9) and (10) of the Companies Act, 2013 and Regulation 22 of the SEBI Listing Regulations. The Policy also provides adequate protection to the Directors and employees who report unethical practices and irregularities from any victimization on raising of concerns of any violations of legal or regulatory requirements, incorrect or misrepresentation of any financial statements and reports, etc. The Vigil Mechanism/Whistle Blower Policy of the Company can be accessed on the Company's website at the <http://medicaps.com/wp-content/uploads/2021/07/whistle-blower-policy.pdf>

During the year under review no protected disclosure from any Whistle Blower was received by the designated officer under the Vigil Mechanism.

24. STATUTORY AUDITORS

Rawka & Associates, Chartered Accountants (FRN: 021606C), were re-appointed as Statutory Auditors of your Company in the 39th Annual General Meeting held on 28th September, 2022, for another term of five consecutive years from the conclusion of 39th Annual General Meeting up to the conclusion of the 44th Annual General Meeting to be held for the financial year 2026-27.

The Auditor's Report and the notes on financial statement for the year 2022-23 referred to in the Auditor's Report are self-explanatory and do not call for any further comments.

DISCLOSURE FOR FRAUDS AGAINST THE COMPANY

There were no instances for other than reportable fraud to the Central Government covered under Section 134(3)(ca) of the Companies Act, 2013. Further, the Auditors have not found any fraud as required to be reported by them under Section 143(12) to the Central Government during the year 2022-23.

25. SECRETARIAL AUDIT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company had appointed **L. N. Joshi & Co., Practising Company Secretaries, Indore** to undertake the Secretarial Audit of the Company for the Financial Year 2022-2023. The Report of the Secretarial Auditor for the year 2022-23 is annexed herewith as "ANNEXURE-C".

There is no qualification, reservation or adverse remark or disclaimer in Secretarial Audit report except the following:

Secretarial Auditor Observations	Management comments
<i>There are 3 (Three) charges which were satisfied long back but no evidence for the satisfaction were produced before me and these charges are showing in the Index of Charges at the portal of MCA.</i>	<i>The matter is very old and the company is in continuous follow up with the ROC for deletion of the charge ID, however, in absence of the adequate evidence for filing of the Form-17 (under the Companies Act, 1956), these charges could not be removed from MCA Portal.</i>
<i>Pursuant to Para 5 of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/70 dated May 25, 2022, the Company has not taken any contingency insurance policy to meet out the risk arising out of issuance of duplicate securities.</i>	<i>The Company is in process to obtain referred policy but till date no insurance company is agreed to provide the same.</i>

26. INTERNAL AUDITOR

The Board of Directors in their meeting held on 23rd May, 2023 on the recommendation of Audit Committee approved the appointment of **Praveen Shrivastava & Company, Chartered Accountant, as an Internal Auditor** of the Company for the financial year 2023-24.

Further during the financial year 2022-23, the Company took their suggestions and recommendations to improve and strengthen the internal control systems. Their scope of work includes review of operational efficiency, effectiveness of systems and processes, compliances and assessing the internal control strengths in all areas.

The Audit Committee reviews adequacy and effectiveness of the Company's internal control environment and monitors the implementation of audit recommendations including those relating to strengthening of the Company's risk management policies and systems

27. COST AUDITOR AND RECORDS

Pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, amended time to time, the provision regarding Cost Audit and Records was not applicable to the Company during the year 2022-23.

28. SECRETARIAL AUDIT OF MATERIAL UNLISTED WHOLLY OWNED SUBSIDIARY COMPANY

Medgel Private Limited, a material wholly owned subsidiary of the Company undertakes Secretarial Audit under Section 204 of the Companies Act, 2013. The Secretarial Audit of Medgel Private Limited for the Financial Year 2022-23 was carried out pursuant to Section 204 of the Companies Act, 2013 read with Regulation 24A of the SEBI Listing Regulations. The Secretarial Audit Report of Medgel Private Limited submitted by L.N. Joshi & Company, Practicing Company Secretaries is annexed as **ANNEXURE-D** and forms an integral part of this Report.

29. ANNUAL SECRETARIAL COMPLIANCE REPORT

The Company has undertaken an audit for the financial year 2022-23 for all applicable compliances as per SEBI Regulations and Circulars/ Guidelines issued there under. Pursuant to provision of Regulation 24A, the Annual Secretarial Compliance Report has been submitted to the stock exchange within 60 days of the end of the financial year.

30. MD/CFO CERTIFICATE

The Managing Director and CFO of your Company have issued necessary certificate pursuant to the provisions of Regulation 17(8) of the SEBI Listing Regulations and the same forms part of this Annual Report.

31. CODE OF CONDUCT

Pursuant to Regulation 17(5) of the SEBI Listing Regulations requires listed companies to lay down a Code of Conduct for its Directors and senior management, incorporating duties of Directors as laid down in the Companies Act, 2013. The Company has adopted Code of Conduct for all Directors and Senior Management of the Company and the same has been hosted on the website of the Company at <https://medicaps.com/wp-content/uploads/2021/08/Code-of-Conduct-for-Board-Senior-Management-Personnel.pdf>. All Directors and Senior Management personnel have affirmed compliance with the Code for 2022-23. Declaration on adherence to the code of conduct is forming part of the Corporate Governance Report.

32. STATEMENT FOR RISK MANAGEMENT POLICY AND INTERNAL ADEQUACY

The Company has its Risk Management Policy which is reviewed by the Board of Directors of the Company and the Audit Committee of Company from time to time so that management controls the risk through a structured network. The main objective of this policy is to ensure sustainable business growth with stability and to promote a proactive approach in reporting, evaluating and resolving risks associated with the business. In order to achieve the key objectives, the policy establishes a structured and methodical approach to risk management, in order to guide decisions on risk related issues. The Audit Committee has additional oversight in the area of financial risks and controls. The major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. The Board is entrusted with the task of monitoring and reviewing the Risk Management Plan and procedures of the Company. This acts as a supplement to the Internal Control Mechanism and Audit function of the Company.

33. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRING AFTER BALANCE SHEET DATE

There are no material changes and commitments affecting the financial position of the company which have occurred between the end of the financial year to which the financial statements relate and the date of this Board's report.

34. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company recognizes its responsibility and continues to provide a safe working environment for women, free from sexual harassment and discrimination. In compliance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has put in place a Policy on prevention of Sexual Harassment of Women at workplace and has duly constituted an Internal Compliant under the same.

There was no case of sexual harassment reported during the year under review. Further, the Company has complied with the provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

35. LISTING WITH STOCK EXCHANGE

The Company's shares are listed on BSE Limited. The Company has paid Annual Listing Fee for Financial Year 2023-24.

36. INSURANCE

The Company's movable assets are adequately insured against the risk, as consider necessary by the Management from time to time.

37. DEPOSITORY SYSTEM

Your Company's shares are tradable compulsorily in electronic form and your Company has connectivity with both the Depositories i.e. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). In view of the numerous advantage offered by the Depository System, members are requested to avail of the facility of Dematerialization of the Company's shares on either of the Depositories mentioned as aforesaid.

38. COMPLIANCE OF SECRETARIAL STANDARDS

Your Company is in compliance of with the applicable Secretarial Standards, issued by the Institute of Company Secretaries of India and approved by the Central Government under Section 118(10) of the Companies Act, 2013.

39. SIGNIFICANT OR MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS WHICH IMPACT THE GOING CONCERN STATUS AND THE COMPANY'S OPERATION IN FUTURE.

There are no significant material orders passed by the Regulators which would impact the going concern status of the Company and its future operations.

40. OTHER DISCLOSURES:

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions/events on these items during the year under review:-

- Company has not issued equity shares with differential rights as to dividend, voting or otherwise.
- As on 31st March 2023, none of the Directors of the company hold instruments convertible into equity shares of the Company.
- Company has not issued any Shares (including Sweat Equity Shares) to employees of the Company under any Scheme and also not made any Stock Option Schemes.
- Voting rights which are not directly exercised by the employees in respect of shares for the subscription/purchase of which loan was given by the Company (as there is no scheme pursuant to which such persons can beneficially hold shares as envisaged under Section 67(3)(c) of the Companies Act, 2013).
- There has been no change in the nature of business of your Company.
- The Business Responsibility and Sustainability Report on the environmental, social and governance disclosures, as required under Regulation 34(2) of the SEBI Listing Regulations, is not applicable to your Company for the financial year ending 31st March, 2023.
- No application was made or any proceeding is pending under the Insolvency and Bankruptcy Code, 2016 during the year in respect of your Company.
- There was no one time settlement of loan obtained from the Banks or Financial Institutions.

41. ACKNOWLEDGEMENT AND APPRECIATION

The Board of Directors of your Company wish to express their deep gratitude towards the valuable co-operation and support received from the various Ministries and Departments of Government of India, various State Governments, the Banks/Financial Institutions and shareholders. Further, the Board places its special appreciation for the cooperation and continued support extended by employees of the Company at all levels.

FOR AND ON BEHALF OF BOARD OF DIRECTORS

DATE: 11TH AUGUST, 2023

PLACE: INDORE

RAMESH CHANDRA MITTAL

CHAIRMAN

DIN: 00035272

ALOK K GARG

MANAGING DIRECTOR

DIN: 00274321

“ANNEXURE – A”

FORM AOC-1*(Pursuant to first proviso to sub-section (3) of Section 129 read with rule 5 of Companies (Accounts) Rules, 2014)*

**Statement containing salient features of the financial statement of
Subsidiaries/Associate Companies/Joint Ventures
Part “A”: Subsidiaries**

(Amount in Lakhs)

S. No.	Particulars	Details
1	Name of the Subsidiary	Medgel Private Limited
2	The date since when subsidiary was acquired	17 th October, 2011
3	Reporting period for the subsidiary concerned, if different from the holding company’s reporting period	Same as of Holding Company (01.04.2022 to 31.03.2023)
4	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries.	NA (there is no foreign subsidiary)
5	Share capital	1468.20
6	Reserves and surplus	5746.38
7	Total assets	7904.30
8	Total Liabilities	689.72
9	Investments	2292.21
10	Turnover	4857.75
11	Profit before taxation	466.51
12	Provision for taxation	305.58
13	Profit after taxation	160.93
14	Proposed Dividend	0
15	Extent of shareholding (in percentage)	100%

Notes:

1. Names of subsidiaries which are yet to commence operations : N.A.
2. Names of subsidiaries which have been liquidated or sold during the year : N.A.

Part “B”: Associates and Joint Ventures

(Not Applicable to the company as company not having any associates and not entered in to any joint venture with any entity)

**As per our report of even date,
RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
FIRM REG. NO.: 021606C**

FOR AND ON BEHALF OF THE BOARD

**VENUS RAWKA
PARTNER
M.N.429040**

**RAMESH CHANDRA MITTAL
CHAIRMAN
DIN: 00035272**

**ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321**

**DATE: 23rd MAY, 2023
PLACE: INDORE**

**HEMANT SETHI
C.F.O**

**ABHISHEK JAIN
COMPANY SECRETARY
M.N: A36699**

“ANNEXURE B”

Particulars of Employees

[Statement as per Section 197(12) of the Companies Act, 2013, read with the Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

A. The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year:

S. No.	Name of Directors	Designation	Ratio Between Directors and Median Employee
1.		Nil	

Note: No remuneration was paid to any Director in the financial year 2022-23.

B. The percentage increase in the remuneration of each Director, CFO, Chief Executive Officer, Company Secretary or Manager in the financial year 2022-23 is as follows:

S. No.	Name of Person	Designation	% increase in remuneration
1.	Mr. Hemant Sethi	Chief Financial Officer	22.22%
2.	Mr. Abhishek Jain	Company Secretary	17.50%

Further, percentage increase in Remuneration of Directors doesn't apply as no remuneration/ sitting fee/commission is paid to them.

C. the percentage increase in the median remuneration of all employees in the financial year: -5.32%

D. The number of permanent employees on the Roll of the Company as on 31st March, 2023: 5 (Five)

It may be noted that the Company has permanently discontinued the manufacturing activities in the Company w.e.f. 21st November, 2019 and consequentially the Company has laid off the employees of the Company after providing full and final unemployment compensation as per law.

E. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

Usually on the basis of Remuneration Policy of the Company, salary of the employees is increased in the range of 18%-20%. Further no remuneration was given to managerial personnel during the financial year; therefore comparison of increase in remuneration of employees with increase in remuneration of managerial personnel's was not applicable.

F. Affirmation that the remuneration is as per the Remuneration Policy of the Company:

The Board affirms that remuneration is as per the remuneration policy of the Company.

FOR AND ON BEHALF OF BOARD

DATE: 11TH AUGUST, 2023

PLACE: INDORE

RAMESH CHANDRA MITTAL

CHAIRMAN

DIN: 00035272

ALOK K GARG

MANAGING DIRECTOR

DIN: 00274321

FORM NO. MR-3
SECRETARIAL AUDIT REPORT
For the Financial Year ended 31st March, 2023

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
MEDI-CAPS LIMITED
CIN: L70100MP1983PLC002231
Registered Office:
Mhow - Neemuch Road Sector 1
Pithampur Dhar (M.P.) 454775

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **MEDI-CAPS LIMITED** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering **1st April 2022 to 31st March, 2023** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **MEDI-CAPS LIMITED** for the financial year ended on **31st March, 2023** according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (*not applicable to the company during the audit period*);
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (*not applicable to the company during the audit period*);
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (*not applicable to the company during the audit period*);
 - (e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (*not applicable to the company during the audit period*);
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (*not applicable to the company during the audit period*);
 - (h) The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 (*not applicable to the company during the audit period*);
 - (i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time;

(vi) I have relied on the representation made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, laws and Regulations to the Company on test check basis. The

management of the Company confirmed that the Company has entered into real estate business and has discontinued the manufacturing activities of Pharmaceuticals business. Therefore, the laws, regulations, directions, orders applicable **specifically** to the Company is Real Estate (Regulation and Development) Act, 2016.

I have also examined compliance with the applicable clauses of Secretarial Standards on Meeting of Board of Directors (SS-1) and Secretarial Standards on General Meetings (SS-2), issued by The Institute of Company Secretaries of India.

I further report that I have not reviewed the applicable financial laws (direct and indirect tax laws), Accounting Standards, since the same have been subject to review and audit by the Statutory Auditors of the Company.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above **subject to following observation:**

1. *There are 3 (Three) Charges which were satisfied long back but no evidence for the satisfaction were produced before me and these charges are still showing in the Index of Charges at the portal of MCA.*
2. *Pursuant to Para 5 of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/70 dated May 25, 2022, the Company has not taken any contingency insurance policy to meet out the risk arising out of issuance of duplicate securities.*

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of Board of Directors that took place during the year under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period, the company has not undertaken event/action having major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, and standards etc. referred to above.

For L.N. Joshi & Company
Company Secretaries

Dated: 11th August, 2023
Place: Indore

L.N. Joshi
Proprietor
FCS: 5201; C.P. No 4216
UDIN: F005201E000746821
Peer Review Certificate No. 1722/2022
Unique Code Number: S2002MP836100

Note: This report is to be read with our letter of even date which is annexed as Annexure herewith and forms integral part of this report.

ANNEXURE to Secretarial Audit Report

To,
The Members,
MEDI-CAPS LIMITED
CIN: L70100MP1983PLC002231
Registered Office:
Mhow - Neemuch Road Sector 1
Pithampur Dhar (M.P.) 454775

My report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the processes and practices, I followed, provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For L.N. Joshi & Company
Company Secretaries

Dated: 11th August, 2023
Place: Indore

L.N. Joshi
Proprietor
FCS: 5201; C.P. No 4216
UDIN: F005201E000746821
Peer Review Certificate No. 1722/2022
Unique Code Number: S2002MP836100

“ANNEXURE – D”

SECRETARIAL AUDIT REPORT**Form No. MR-3**For the Financial Year Ended on 31st March, 2023

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
MEDGEL PRIVATE LIMITED
CIN: U24239MP2007PTC019204
Registered Office:
201, Pushpratna Paradise
9/5 New Palasiya, Opposite Uco bank
Indore (M.P.) 452001

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **MEDGEL PRIVATE LIMITED** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering **1st April, 2022 to 31st March, 2023**, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **MEDGEL PRIVATE LIMITED** for the financial year ended on **31st March, 2023** according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under; (*not applicable to the company during the audit period*)
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under; (*not applicable to the company during the audit period*)
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (*not applicable to the company during the audit period*)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; (*not applicable to the company during the audit period*)
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; (*not applicable to the company during the audit period*)*
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (*not applicable to the company during the audit period*)
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (*not applicable to the company during the audit period*)
 - (e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (*not applicable to the company during the audit period*);
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; (*not applicable to the company during the audit period*)
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (*not applicable to the company during the audit period*);
 - (h) The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 (*not applicable to the company during the audit period*);

(i) The Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 as amended from time to time. **(Applicable to the extent of material wholly owned subsidiary company of Medi-Caps Limited)**

*The Company being a material wholly owned subsidiary of Medi-Caps Limited (Listed Entity), Directors and certain employees of the Company have been categorized as Designated Persons and are covered by the Code of Conduct under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended, of Medi-Caps Limited.

(vi) I have relied on the representation made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, laws and Regulations to the Company on test check basis. The laws, regulations, directions, orders applicable specifically to the Company are as follows:

1. Drugs and Cosmetics Act, 1940
2. Standard Weight and Measurement Act, 1976

I have also examined compliance with the applicable clauses of Secretarial Standards on Meeting of Board of Directors(SS-1) and Secretarial Standards on General Meetings(SS-2) issued by The Institute of Company Secretaries of India.

I further report that I have not reviewed the applicable financial laws (direct and indirect tax laws), Accounting standard, since the same have been subject to review and audit by the Statutory Auditors of the Company.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. During the year there was no change in the composition of Board of Directors.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors of the Company, as the case may be.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period, the company has not undertaken event/action having a major bearing in the company's affair in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred above.

For L.N. Joshi & Company
Company Secretaries

Dated: 5th August, 2023
Place: Indore

L.N. Joshi
Proprietor
FCS: 5201; CP No 4216
UDIN: F005201E000746667
Peer Review Certificate No. 1722/2022
Unique Code Number: S2002MP836100

Note: This report is to be read with our letter of even date which is annexed as Annexure herewith and forms an integral part of this report.

ANNEXURE to Secretarial Audit Report

To,
The Members,
MEDGEL PRIVATE LIMITED
CIN: U24239MP2007PTC019204
Registered Office:
201, Pushpratna Paradise
9/5 New Palasiya, Opposite Uco bank
Indore (M.P.) 452001

My report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the processes and practices, I followed, provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For L.N. Joshi & Company
Company Secretaries

Dated: 5th August, 2023
Place: Indore

L.N. Joshi
Proprietor
FCS: 5201; CP No 4216
UDIN: F005201E000746667
Peer Review Certificate No. 1722/2022
Unique Code Number: S2002MP836100

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

BUSINESS

Medi-Caps Limited is a flagship Company of central India's renowned Medi-Caps group. After serving to the humanity for more than four decades through its quality pharma products, Company entered into the real estate business. The Company started its first project "MEDI-CAPS BUSINESS PARK" with focus on city centric developments well spread-out across central India region. In upcoming era Company's focus will be on Strategic Land acquisition and developing the premium residential and commercial properties. The strength of the Company has been to follow a debt free financial structure to ensure efficient Return on Equity.

INDUSTRY STRUCTURE AND DEVELOPMENTS

The effect of the pandemic was huge on the real estate sector, accordingly after the pandemic; real estate sector witnessed a huge pickup across the major property hubs of the metros, the tier one, and tier two cities. Housing finance companies, banks which are lending to retail loans have increased their amount of lending by also about 12% to 15% on an average; this itself indicates that there is a increase in potential buyer in this sector. As research says the system will change so 2023-2024 is going to see a boom year for real estate as concerned a 15% growth and finance companies are very interested to lend more to retail loans because the NPAs in retail loans have fallen to less than 1.5% of all the banks/housing finance institutions which is the lowest NPA in any sector whatsoever of lending that takes place in the financing sector. So all in all looks like a positive boom in upcoming years.

The Indian real estate market is one of the most quickly evolving and fast-growing sectors in the country's economy. With increasing urbanization and growing incomes, the real estate sector in India has bloomed over the recent past and become a significant contributor to the economy. With the increasing demand for homes, prominent builders have made slight adjustments to pricing, leading to expectations of future house price predictions on an upward trajectory.

As we have already seen, the property market in India is poised to grow immensely in 2023 as well as in the years to come. According to reports, in the period from 2023 to 2028, the sector will register a compound annual growth rate of 9.2%. Since work-from-home and hybrid models have already gained popularity, there is a growing tendency among customers to move away from the city and opt for larger homes in the suburbs. Yet another trend is the integration of living spaces and office spaces. Developers now offer dedicated office spaces in the clubhouse or as a separate space. In addition to this, they also offer provisions for home offices in individual units.

OPPORTUNITIES

Supportive Government policies and initiatives have opened the doors for immense opportunities in the real estate sector in India. Some of the major Government initiatives to encourage development in the real estate sector are as follows:

- The Real Estate Regulatory Authority introduced the Real Estate (Regulation and Development) Act (RERA), which came into existence in March 2016. Intended to provide transparency and accountability in the sector, RERA protects the interest of all the stakeholders involved and ensures speedy resolution in case of disputes. Naturally, buyers are more confident investing their money in the market.
- An amendment to the existing Benami Transactions Act gave teeth to the act, making it more stringent. The act further enhanced India's status as an investment destination by instilling professionalism, accountability, and greater transparency in transactions.
- The Union Budget 2022-23 emphasized the need to develop Mega-Cities as well as a greater emphasis on Tier 2 and Tier 3 cities. These cities are expected to become economic highfliers in the near future. In 25 years, about half of the world's population will most likely be living in cities. To prepare for this, orderly urban growth is essential. The government seeks to assist and collaborate with the states in developing urban capacity.
- The Finance Minister anticipates 9.2 percent GDP growth in the fiscal year 2022-23. With a planned capital investment of Rs 7.5 lakh crore, these indications might increase market cash liquidity, directly influencing the real estate industry.

THREATS

Though property market in India is one of the most booming sectors, it is not devoid of challenges and risks. The major threats borne by the Companies in the real estate sector are:

- One of the biggest challenges faced by the sector is the high dependency on workforce. As per reports, in 2023, there was a 15-25% shortage of workforce in the construction sector.
- Increased price of construction materials.
- With banks setting stringent norms for real estate lending, it is difficult for developers to finance their projects. Yet another concern is liquidity, if the asset is not being sold within the set timeframe, it will result in loss for the developer.
- With growing awareness about the need for sustainability practices to protect the environment, property developers are finding ways to be compliant, resulting in increased cost, and time.

SEGMENT-WISE OR PRODUCT-WISE PERFORMANCE

On standalone basis the Company will perform in one segment only; hence no information is reportable under this head. However on Consolidated basis Company have two reportable segments i.e. real estate in parent company and pharma division in wholly owned subsidiary. Further segment performance is given in note no. 26 of consolidated financial statement.

OUTLOOK

Leading experts in the Indian property market is viewing 2023-24 as a booming year for the industry. According to them, in the next nine months, there will be 10-15% hike in sales collectively in residential, commercial, and retail segments. With the demand for housing on the rise, it's a sure bet to invest in residential real estate. Likewise, both commercial and retail segments are rapidly expanding, thanks to the immense growth in the respective sectors. Obviously, for investors, it is the right time to add real estate in their portfolio.

Ever since India's property market was thrown open for foreign direct investment, the sector has been witnessing a significant inflow of investments. Of late, it has been touching new heights. For instance, in the period from 2017 to 2022 there

has been a three-fold increase in foreign institutional inflows, attracting USD 26.6 billion. This amounts to 81% of the total investments in the sector during the period

RISKS AND CONCERNS

The Company is exposed to a number of risks such as economic, regulatory, taxation and environmental risks as well as sectoral investment outlook. Some risks that may arise in the normal course of business and could impact its ability to address future developments comprise credit risk, liquidity risk, counterparty risk, regulatory risk, commodity inflation risk and market risk.

The Company has implemented robust risk management policies that set-out the tolerance for risk and your Company's general risk management.

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY

In line with the size, scope, and complexity of its operations, the Company has a strong internal financial control system. It has put in place sufficient controls, processes, and policies to ensure the orderly and efficient conduct including adherence to policies, asset protection, fraud detection and prevention, accuracy and completeness of accounting records. Internal controls over financial reporting have been created using the proper frameworks, ensuring the accuracy of the Company's financial statements and lowering the risk of error. Regular internal audits and checks ensure that responsibilities are discharged effectively; that gives business valuable insights to act decisively quickly

These internal control systems ensure compliance with all applicable laws and regulations. The Company has clearly defined policies, and organizational structure for its business functions to ensure a smooth conduct of its business. Also, as mandated by the Companies Act, 2013, the Company has implemented the Internal Financial Control (IFC) framework to ensure proper internal controls over financial reporting. Apart from this, a well-defined system of internal audit is in place so as to independently review and strengthen these internal controls. The Audit Committee of the Company regularly reviews the reports of the internal auditors and recommends actions for further improvement of the internal controls.

FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

As informed earlier the Company is currently operating under real estate sector. Company's first project "MEDI-CAPS BUSINESS PARK" is now ready to be delivered and getting huge response in the market; and management hopes that this will be a great step which will establish the Company as a key player of real estate sector. Company is expecting revenue from this dream project in F.Y. 2023-24 accordingly In F.Y. 2022-23 Company has derived a profit from continuing operations of Rs. 25.72 lakhs only.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES

Our personnel, in our opinion, are our most valuable assets and are essential to attaining both our vision and growth goals. Diversity, inclusivity, equal opportunity, non discrimination, meritocracy, and freedom of expression are the cornerstones of our workplace culture. In order to provide the best possible working conditions for our employees, we regularly review our human resources practices.

DETAILS OF SIGNIFICANT CHANGES IN THE KEY FINANCIAL RATIOS:

Key Ratio	2021-22	2022-23	Change	Variance (in %)	Reason for more than 25% variance.
Interest Coverage Ratio	-	-	-	-	No interest expenses were incurred during the year.
Current Ratio	197.73	194.66	-3.07	-1.55 %	N.A.
Debt Equity Ratio	-	-	-	-	N.A.
Net Profit Margin (%)	-	-	-	-	N.A.
Return on Net worth (any change)	-0.0012	0.0024	0.0036	292.86%	During the year the company earned a profit which resulted into better ROE.
Operating Profit Margin (%)	-	-	-	-	N.A.
Debtors turnover Ratio	-	-	-	-	N.A.
Inventory Turnover Ratio	-	-	-	-	N.A.

CAUTIONARY STATEMENT

Some of the Statements in Management discussion and Analysis describing company's objective may be "forward looking statement" within the meaning of applicable Securities law and Regulations. Actual results may differ substantially or materially from those expressed or implied. Important factors that could influence companies operation include various global and domestic economic factors.

REPORT ON CORPORATE GOVERNANCE

(As per Regulation 34(3) read with Schedule V(c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forming part of the Board's Report

This Corporate Governance Report relating to the year ended on March 31, 2023 has been issued in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015") and amendment thereof and forms a part of the Report of the Board of Directors of the Medi-Caps Limited ("the Company").

To comply with Regulation 34 read with Schedule V of the SEBI Listing Regulations, 2015, the report containing the details of Corporate Governance of the Company is as follows:

I. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

Corporate Governance is about commitment to values and ethical business conduct. Timely and accurate disclosure of information regarding the financial situation, performance, ownership and management of the Company is an important part of Corporate Governance. Corporate Governance philosophy stems from our belief that corporate governance is a key element in improving efficiency, growth enhancing investor confidence and return to the shareholders. The Company has always been committed to the principles of good Corporate Governance. Your Company is not only in compliance with the requirements stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015") as amended from time to time, with regard to Corporate Governance, but is also committed to sound Corporate Governance principles and practice and constantly strives to adopt emerging best Corporate Governance practices being followed worldwide. The details of compliance are as follows:

THE GOVERNANCE STRUCTURE:

Medi-Caps Limited's governance structure is based on the principles of freedom to the executive management within a given framework to ensure that the powers vested in the executive management are exercised with due care and responsibility so as to meet the expectation of all the stakeholders. In line with these principles, the Company has formed three tiers of Corporate Governance structure, viz:

(i) The Board of Directors: The primary role of the Board is to protect the interest and enhance value for all the stakeholders. It conducts overall strategic supervision and control by setting the goals and targets, policies, practices, governance standards, reporting mechanism and accountability and decision making process to be followed.

(ii) Committees of Directors: There are various committees of Directors such as Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee, which are focused on financial reporting, audit and internal controls, compliance issues, appointment and remuneration of Directors, Auditors, investor grievance redress and Senior Management Employees, Risk Management framework and Corporate Governance compliance.

(iii) Executive Management: The entire business including the support services are managed with clearly demarcated responsibilities and authorities at different levels.

Managing Director: The Managing Director is responsible for achieving the Company's vision and mission, business strategies, project execution, mergers and acquisition, significant policy decisions and all the critical issues having significant business and financial implications. He is also responsible for the overall performance and growth of the Company and ensures implementation of the various rules and regulations including the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the decisions of the Board of Directors and its various Committees. He reports to the Board of Directors for any non-compliance.

II. BOARD OF DIRECTORS

A. Board composition and category of directors

The Company is fully compliant with the Corporate Governance norms in the terms of constitution of the Board of Directors ("the Board"). As on 31st March 2023; board of directors of the Company was consisting 8 (eight) directors as given in the table below. The Composition of the Board is in conformity with Regulation 17 of the SEBI Listing Regulations, 2015 read with Section 149 of the Companies Act, 2013.

Independent Directors are non-executive directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations, 2015 read with Section 149(6) of the Companies Act, 2013. The maximum tenure of independent directors is in compliance with the Companies Act, 2013. All the Independent Directors have confirmed that they meet the criteria as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations, 2015 read with Section 149(6) of the Companies Act, 2013.

None of the Director is a Director in more than 10 public limited companies (as specified in Section 165 of the Companies Act, 2013) or acts as an Independent Director in more than 7 listed companies or 3 listed companies in case he/she serves as a Whole-time Director/MD in any listed company (as specified in Regulation 17A of the SEBI Listing Regulations, 2015). Further, none of the Directors on the Board is a member of more than 10 Committees and Chairman of more than 5 Committees (as specified in Regulation 26 of the SEBI Listing Regulations, 2015), across all the Indian public limited companies in which he/she is a Director. The Board does not have any nominee director representing any institution.

The name and categories of Directors, DIN, the number of Directorships, Committee positions held by them in the companies and the list of listed entities where he/she is a Director along with the category of their Directorships and other details are given hereafter:

Name of Directors	DIN	Category	Number of Directorship (including Medi-Caps Limited)		Number of Committee Chairmanship/Membership (including Medi-Caps Limited)	
			Chairman	Member	Chairman	Member
Mr. Ramesh Chandra Mittal	00035272	Promoter and Non-Executive Director (Chairman of the Board and Company)	2	5	0	0
Mr. Alok K Garg	00274321	Promoter and Executive Director (Managing Director)	0	2	0	1
Mrs. Kusum Mittal	00035356	Promoter, Non-Executive Woman Director	0	1	0	0
Mr. Pramod Fatehpuria	00972389	Non-Executive Independent Director	0	3	0	3
Mr. Ashok Omprakash Agrawal	07870578	Non-Executive Independent Director	0	2	3	3
Mr. Dharmendra Solanki	09055239	Non-Executive Independent Director	0	1	0	2
*Mr. Akshit Garg	08576807	Promoter, Non-Executive Director	0	2	0	0
*Mr. Sourabh Kumar Shrivias	09692160	Non-Executive Independent Director	0	1	0	0

* Mr. Akshit Garg was appointed as an Additional Director under the category of Promoter Non Executive Director of the Company w.e.f. 04th August, 2022 which was further confirmed by the members in 39th Annual General Meeting held on 28th September, 2022.

*Mr. Sourabh Kumar Shrivias was appointed as an Additional Director under the category of Non Executive Independent Director of the Company w.e.f. 04th August, 2022 which was further confirmed by the members in 39th Annual General Meeting held on 28th September, 2022.

*Mr. Sourabh Kumar Shrivias (DIN: 09692160), Non-Executive Independent Director and Mr. Akshit Garg (DIN: 08576807) promoter Non-Executive Director were resigned from the post of directorship of the Company w. e. f. 21st July, 2023.

- Committee considered as Audit Committee and Stakeholders Relationship Committee, including that of your Company. Committee membership(s) and Chairmanship(s) are counted separately.

B. The names of other listed entities where the Directors have directorship and their category of directorship in such listed entities:

None of the Director is holding directorship in any other listed Company.

C. Attendance of Directors at the Board Meetings held during 2022-23 and the previous Annual General Meeting held on 28th September, 2022:

The Board Meeting is conducted at least once in every calendar quarter to discuss the performance of the Company and its quarterly Financial Results, along with other matters of the Company. The Board also meets to consider other business(es), whenever required, from time to time. During the financial year 2022-23, four (4) Board Meetings were held. The gap between two meetings did not exceeded 120 days according to provisions laid down in Companies Act, 2013, SEBI Listing Regulations, 2015 and Secretarial Standards prescribed by the Institute of Company Secretaries of India and approved by the Central Government.

The date on which the Board meetings were held:-25th May, 2022, 04th August, 2022, 10th November, 2022 and 09th February, 2023.

Name of Directors	Category	Number of Board Meetings entitled to attend during the year	Number of Board Meetings Attended	Attendance at the 39 th AGM held on 28 th September, 2022
Mr. Ramesh Chandra Mittal (DIN: 00035272)	Promoter and Non-Executive Director (Chairman of the Board and Company)	4	4	Yes
Mr. Alok K Garg (DIN: 00274321)	Promoter and Executive Director (Managing Director)	4	4	Yes
Mrs. Kusum Mittal (DIN: 00035356)	Promoter, Non-Executive Woman Director	4	4	Yes
Mr. Pramod Fatehpuria (DIN: 00972389)	Non-Executive Independent Director	4	4	No

Mr. Ashok Omprakash Agrawal (DIN: 07870578)	Non-Executive Independent Director	4	4	Yes
Mr. Dharmendra Solanki (DIN: 09055239)	Non-Executive Independent Director	4	4	Yes
*Mr. Akshit Garg (DIN: 08576807)	Promoter, Non-Executive Director	2	2	Yes
*Mr. Sourabh Kumar Shrivastava (DIN: 09692160)	Non-Executive Independent Director	2	2	Yes

* Mr. Akshit Garg was appointed as an Additional Director under the category of Promoter Non Executive Director of the Company w.e.f. 04th August, 2022 which was further confirmed by the members in 39th Annual General Meeting held on 28th September, 2022.

*Mr. Sourabh Kumar Shrivastava was appointed as an Additional Director under the category of Non Executive Independent Director of the Company w.e.f. 04th August, 2022 which was further confirmed by the members in 39th Annual General Meeting held on 28th September, 2022.

*Mr. Sourabh Kumar Shrivastava (DIN: 09692160), Non-Executive Independent Director and Mr. Akshit Garg (DIN: 08576807) promoter Non-Executive Director were resigned from the post of directorship of the Company w. e. f. 21st July, 2023.

D. Notice and Agenda:

All the meetings are conducted as per well designed and structured notice and agenda. All the agenda items are backed by necessary supporting information and documents (except for the critical price sensitive information, which is circulated separately or placed at the meeting) to enable the Board to take informed decisions. Agenda also includes minutes of the meetings of all the Board Committees and subsidiaries for the information of the Board. Additional agenda items in the form of "Other Business" are included with the permission of the majority of Directors including one Independent Director. Agenda papers are circulated seven days prior to the Board Meeting. In addition, for any business exigencies, the resolutions are passed by circulation and later placed at the subsequent Board/Committee Meeting for ratification/approval.

E. Invitees and Proceedings:

Apart from the Board members, the Company Secretary, the CFO is invited to attend the Board Meetings. The CFO makes presentation on the quarterly and annual operating and financial performance and on annual operating and capex budget. The Managing Director and other senior executives make presentations on capex proposals and progress, operational health and other business issues. The Chairman of various Board Committees brief the Board on all the important matters discussed and decided at their respective committee meetings, which are generally held prior to the Board meeting.

F. Post Meeting Action:

Post meetings, all important decisions taken at the meeting are communicated to the concerned officials and departments. Action Taken Report is prepared and reviewed periodically by the Managing Director for the action taken / pending to be taken.

G. Support and Role of Company Secretary:

He acts as interface between the Board and the Management and provides required assistance on compliance of the SEBI Listing Regulations, 2015, SEBI (SAST) Regulations, 2011 and Companies Act, 2013.

H. Confirmation that in the opinion in of the Board, the Independent Directors fulfills the condition specified in this regulation and is independent of the Management:

All the Independent Directors of the Company have given their respective declaration/ disclosures under section 149(7) of the Act read with Regulation 25(8) of the SEBI Listing Regulations, 2015 and have confirmed that they fulfill the independence criteria as specified under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, 2015 and have also confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence. Further, the Board after taking these declaration/disclosures on record and acknowledging the veracity of the same concluded that the Independent Directors are persons of integrity and possess the relevant expertise and experience to qualify as Independent Directors of the Company and are Independent of the Management.

On the basis of the declarations made by the Independent Directors, the Board of Directors are of the opinion that the Independent Directors of the Company fulfills conditions specified in Companies Act, 2013 and under SEBI Listing Regulations, 2015 and are Independent of the management of the Company.

I. Disclosure of relationship between Directors inter-se:

Name of Directors	Relationship	Name of other Directors in inter-se relationship
Mr. Ramesh Chandra Mittal (DIN: 00035272)	Husband	Mrs. Kusum Mittal (Promoter and Non Executive Director)
	Father in Law	Mr. Alok K Garg (Promoter and Managing Director)
Mr. Alok K Garg (DIN: 00274321)	Son in law	Mr. Ramesh Chandra Mittal (Chairman, Promoter and Non Executive Director) and Mrs. Kusum Mittal (Promoter and Non Executive Director)
	Father	Mr. Akshit Garg (Promoter and Non Executive Director)
Mrs. Kusum Mittal (DIN: 00035356)	Wife	Mr. Ramesh Chandra Mittal (Chairman, Promoter and Non Executive Director)
	Mother in law	Mr. Alok K Garg (Promoter and Managing Director)

Mr. Akshit Garg (DIN: 08576807)	Son	Mr. Alok K Garg (Promoter and Managing Director)
------------------------------------	-----	--

J. Number of Shares and convertible instruments held by Non-Executive Directors as on 31st March, 2023

	<i>No. of Shares Held</i>	<i>Convertible Instruments</i>
Mr. Ramesh Chandra Mittal (DIN: 00035272)	10,000	0
Mrs. Kusum Mittal (DIN: 00035356)	10,000	0
Mr. Ashok Omprakash Agrawal (DIN: 07870578)	0	0
Mr. Pramod Fatehpuria (DIN: 00972389)	0	0
Mr. Dharmendra Solanki (DIN: 09055239)	0	0
Mr. Akshit Garg (DIN: 08576807)	0	0
Mr. Sourabh Kumar Shrivastava (DIN: 09692160)	0	0

The Company had not issued any convertible instrument till date.

K. The details and web link of Familiarization Programs imparted to Independent Directors:

On appointment, the concerned director is issued a Letter of Appointment setting out in details the terms of appointment, duties, responsibilities and expected time commitments. Each newly appointed Independent Director is taken through an induction and familiarization program including the presentation and interactive session with the Managing Director, Executive Committee members and other Functional Heads on the Company's marketing, finance and other important aspects. The Company Secretary briefs the Director about their legal and regulatory responsibilities as a Director. On the matters of specialized nature, the Company engages outside experts/consultants for presentation and discussion with the Board members. The details of familiarization program can be accessed from the web-link: <https://medicaps.com/wp-content/uploads/2023/02/Familiarization-policy-updation-2022-23.pdf>

L. Meeting of Independent Directors:

Pursuant to the Regulation 25(3) of SEBI Listing Regulations, 2015 and Schedule IV of the Companies Act, 2013, the Independent Directors of the Company shall hold at least one meeting in a year without presence of non-Independent Directors and members of the Management. Accordingly, meeting of the Independent Directors of the Company was held on 10th November, 2022 to consider the following businesses as required under Regulation 25(4) of SEBI Listing Regulations, 2015 and the Companies Act, 2013:

- Review the performance of Non-Independent Directors and the Board of Directors as a whole;
- Review the performance of the Chairman of the Company of the Company and taking into account the views of executive directors and non-executive directors and;
- Assess the quality, quantity and timelines of flow of information between the Company's management and the Board of Directors that is necessary for the Board to effectively and reasonably perform their duties.

Attendance of Independent Directors in Independent Directors' meeting:

Name of Directors	Meetings held during the year	Meetings attended
Mr. Ashok Omprakash Agrawal (DIN: 07870578)	1	1
Mr. Pramod Fatehpuria (DIN: 00972389)	1	1
Mr. Dharmendra Solanki (DIN: 09055239)	1	1
Mr. Sourabh Kumar Shrivastava (DIN: 09692160)	1	1

M. Matrix of skills/expertise/competence of the Board of Directors

The following is the list of core skills/expertise/competencies identified by the Board of Directors as required in the context of the Company's business and that the said skills are already available with the Board members:

- Knowledge on Company's businesses (Real Estate Sector), policies and business culture major risks/threats and potential opportunities and knowledge of the industry in which the Company operates.
- Behavioural skills - attributes and competencies to use their knowledge and skills to contribute effectively to the growth of the Company,
- Business Strategy, Sales and Marketing, Corporate Governance, Forex Management, Administration, Decision Making,
- Financial and Management skills,
- Technical / professional skills and specialized knowledge in relation to Company's business.

These skills/competencies are broad-based, encompassing several areas of expertise/ experience. Each Director may possess varied combinations of skills/experience within the described set of parameters, and it is not necessary that all Directors possess

all skills/experience listed therein. In the table below, the specific areas of focus or expertise of individual board members have been highlighted:

Skills to be possessed by Directors	Mr. Ramesh Chandra Mittal	Mr. Alok K Garg	Mrs. Kusum Mittal	Mr. Pramod Fatehpuria	Mr. Ashok Omprakash Agrawal	Mr. Dharmendra Solanki	Mr. Akshit Garg	Mr. Sourabh Kumar Shrivastava
Knowledge on Company's businesses (Real Estate Sector), policies and business culture major risks/threats and potential opportunities and knowledge of the industry in which the Company operates	Yes	Yes	Yes	Yes	-	Yes	Yes	Yes
Behavioural skills - attributes and competencies to use their knowledge and skills to contribute effectively to the growth of the Company	Yes	Yes	-	Yes	Yes	Yes	Yes	Yes
Business Strategy, Sales and Marketing, Corporate Governance, Forex Management, Administration, Decision Making	-	Yes	Yes	-	Yes	-	Yes	Yes
Financial and Management skills	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Technical / Professional skills and specialized knowledge in relation to Company's business	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

N. Detailed Reason for resignation of Independent Director who resigns before the expiry of his/her tenure along with the confirmation by such director that there are no other material reasons other than those provided:

During the year under review, none of the Independent Directors of the Company had resigned before the expiry of their respective tenure(s).

III. AUDIT COMMITTEE

Pursuant to the provision of Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI Listing Regulations, 2015, the Company has an independent Audit Committee. The composition, procedure, meeting and Role/Function of the Committee comply with the requirements of the Companies Act, 2013 as well as those of SEBI Listing Regulations, 2015. The Audit

Committee reviews all applicable mandatory information under Part C of Schedule II pursuant to Regulation 18 of SEBI Listing Regulations, 2015.

A. The brief terms of reference of the Audit Committee includes the following:

- Oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommendation for the appointment, remuneration and terms of appointment of auditors of the Company;
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- Reviewing with management, the annual financial statement and auditor's report thereon before submission to the Board for approval, with particular reference to:
 - a. Matters required to be included in the Directors Responsibility Statement to be included in the Board's Report as per Section 134(3)(c) of the Companies Act, 2013.
 - b. Changes, if any, in the Accounting policies and practices and the reasons for the same.
 - c. Major accounting entries involving estimates based on the exercise of judgment by management;
 - d. Significant adjustments made in the financial statements arising out of audit findings;
 - e. Compliance with listing and other legal requirements relating to financial statements;
 - f. Disclosure of any related party transactions;
 - g. Modified opinion(s) in the draft audit report.
- Reviewing with the management, the quarterly financial statements before submission to the board for approval;
- Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public issue or rights issue or preferential issue or qualified institutions placement, and making appropriate recommendations to the board to take up steps in this matter;
- Review and monitor the auditor's independence and performance and effectiveness of audit process;
- Approval or any subsequent modification of transactions of the company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Valuation of undertakings or assets of the company, wherever it is necessary;
- Evaluation of internal financial controls and risk management systems;
- Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there on;
- Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- To look into the reasons for substantial defaults in the payment to the depositories, debenture holders, shareholders (in case of non-payment of declared dividend) and creditors;
- To review the functioning of the Whistle Blower mechanism;
- Approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;
- Carrying out any other function as is mentioned in the terms of reference of the audit committee.
- Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- Considering and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the Company and its shareholders.

B. The Audit Committee shall mandatorily reviews the following information:

- 1) Management Discussion and Analysis of financial condition and results of operations;
- 2) Management letters/letters of internal control weaknesses issued by the statutory auditors;
- 3) Internal audit reports relating to internal control weaknesses; and
- 4) The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
- 5) Statement of deviations:
 - (a) Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
 - (b) Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

C. Composition and attendance of members at the meetings of the Audit Committee held during the year 2022-23

During the Financial Year 2022-23 four (4) meetings were held as on 25th May, 2022, 04th August, 2022, 10th November, 2022 and 09th February, 2023.

The composition and attendance of each member of the Committee are as under:

Name of the members of the Committee	Category and designation in the Committee	Total number of meeting held during their tenure	Number of Meeting attended
Mr. Ashok Omprakash Agrawal (DIN: 07870578)	Chairman - Independent Director	4	4
Mr. Pramod Fatehpuria (DIN: 00972389)	Member - Independent Director	4	4
Mr. Dharmendra Solanki (DIN:09055239)	Member - Independent Director	4	4

Company Secretary of the Company acts as the Secretary to the Committee.

Pursuant to Clause 4.1.1 of Secretarial Standards on General Meeting, the Chairman of the Audit Committee or, in his absence, any other Member of the Committee authorised by him on his behalf shall attend the General Meeting of the Company. Mr. Ashok Omprakash Agrawal (DIN: 07870578) was virtually present at the last Annual General Meeting of the Company held on 28th September, 2022 through Video Conferencing (“VC”)/Other Audio Visual Means (“OAVM”) to answer the shareholder’s queries. All the members of the Committee are financial literate and possess accounting and related financial management expertise.

IV. NOMINATION AND REMUNERATION COMMITTEE

Pursuant to the provision of Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI Listing Regulations, 2015, the Company has constituted a Nomination and Remuneration Committee. The Nomination and Remuneration Committee (NRC), comprising three independent directors as its members, inter-alia oversees the Company’s nomination process for the Directors, senior management and coordinates the annual self-evaluation of the performance of the Board, Committees and of individual Directors.

The composition, procedure, role/function of the Committee complies with the requirements of the Companies Act, 2013 as well as SEBI Listing Regulations, 2015 are given below:

(A) Brief terms of reference of the Nomination and Remuneration Committee includes the following:

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy relating to the remuneration of the directors, key managerial personnel and other employees;
- For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - i. use the services of an external agencies, if required;
 - ii. Consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - iii. Consider the time commitments of the candidates.
- Formulation of criteria for evaluation of performance of independent directors and the board of directors
- Devising a policy on diversity of Board of Directors;
- Identifying persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal.
- Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- Recommend to the Board, all remuneration, in whatever form, payable to senior management.

(B) Composition and attendance of members of Nomination and Remuneration Committee held during the financial year 2022-23

During the financial year 2022-23, the Committee met on one occasion i.e., 04th August, 2022.

The composition and attendance of each member of the Nomination and Remuneration Committee of the Company is as under:

Name of the Directors	Category and designation in the Committee	Number of Meeting held during their tenure	No. of Meeting attended
Mr. Ashok Omprakash Agrawal (DIN: 07870578)	Chairman - Independent Director	1	1
Mr. Pramod Fatehpuria (DIN: 00972389)	Member - Independent Director	1	1
Mr. Dharmendra Solanki (DIN: 09055239)	Member - Independent Director	1	1

As per Section 178(7) of the Companies Act, 2013, SEBI Listing Regulations, 2015 and Secretarial Standards, the Chairman of the Committee or, in his absence, any other member of the Committee authorized by him in this behalf shall attend the General Meeting of the Company. The Chairman of the Committee, Mr. Ashok Omprakash Agrawal (DIN: 07870578) was virtually present at the 39th Annual General Meeting of the Company held through Video Conferencing (“VC”)/Other Audio Visual Means (“OAVM”) on 28th September, 2022 to answer shareholders’ queries.

(C) Performance evaluation criteria for Independent Directors:

The performance evaluation criterion for Independent Directors is determined by the Nomination and Remuneration Committee. An indicative list of factors that may be evaluated include participation and contribution by a director, commitment, effective deployment of knowledge and expertise, effective management of relationship with stakeholders, integrity and maintenance of confidentiality and independence of behavior and judgment.

The evaluation of independent directors is done by the entire board of directors which includes:

- (a) Performance of the directors; and
- (b) Fulfillment of the independence criteria as specified in these regulations and their independence from the management.

Provided that in the above evaluation, the directors who are subject to evaluation shall not participate.

(D) Remuneration Policy and Policy on selection of Directors:

Pursuant to Regulation 19 read with Part D of Schedule II of SEBI Listing Regulations, 2015 and Section 178 of the Companies Act, 2013, the Nomination and Remuneration Committee has adopted a Nomination and Remuneration policy for selection and appointment, re-appointment, removal and appraisals of Directors and Senior Management and the policy has been uploaded on the Company's website at the web link: <https://medicaps.com/wp-content/uploads/2016/06/Remuneration-Policy.pdf>

V. STAKEHOLDERS' RELATIONSHIP COMMITTEE

As required under Section 178(5) of the Companies Act, 2013 ("the Act") read with the provisions of Regulation 20 of SEBI Listing Regulations, 2015, the Board has in place Stakeholders Relationship Committee. This Committee deals with stakeholder relations and grievances raised by the investors in a timely and effective manner and to the satisfaction of investors. The Committee oversees performance of the Registrar and Share Transfer Agents of the Company relating to investor services and recommends measures for improvement.

(A) The brief terms of reference of Stakeholder Relationship Committee includes the following

The role of the Committee shall inter-alia include the following:

- Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.
- Review of measures taken for effective exercise of voting rights by shareholders.
- Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent.
- Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company.

(B) Composition and attendance of members of Stakeholders' Relationship Committee held during the financial year 2022-23.

During the financial year 2022-23, Committee met once on 09th February, 2023.

The composition and attendance of each member of the committee are as under:

Name of the Director/Member	Category and Designation in the Committee	Number of Meeting held during their tenure	No. of Meetings Attended
Mr. Ashok Omprakash Agrawal (DIN: 07870578)	Chairman - Independent Director	1	1
Mr. Pramod Fatehpuria (DIN: 00972389)	Member - Independent Director	1	1
Mr. Dharmendra Solanki (DIN: 09055239)	Member - Independent Director	1	1

As per Section 178(7) of the Companies Act, 2013, SEBI Listing Regulations, 2015 and Secretarial Standards, the Chairman of the Committee or, in his absence, any other member of the Committee authorized by him in this behalf shall attend the General Meeting of the Company. The Chairman of the Committee, Mr. Ashok Omprakash Agrawal (DIN: 07870578) was virtually present at the 39th Annual General Meeting of the Company held through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") on 28th September, 2022.

(C) Name, designation and address of Compliance Officer of the Company:

CS ABHISHEK JAIN, Company Secretary and Compliance Officer

MEDI-CAPS LIMITED

C.O.-201, Pushpratna Paradise, 9/5 New Palasiya,

Opposite, UCO Bank Indore (M.P.)-452001 INDIA

Tel. No.: 0731- 4046321, 0731- 4028148

Fax No.: 0731- 4041435

Email: investors@medicaps.com

(D) Status report of investor queries and complaints for the period from April 1, 2022 to March 31, 2023 is given below:

Status Report of investor queries and complaints for the period from April 1, 2022 to March 31, 2023 is given below:

S. No.	Particulars	Number of Complaints
--------	-------------	----------------------

01	Investor complaints pending at the beginning of the year	Nil
02	Investor complaints received during the year	2
03	Investor complaints disposed off during the year	2
04	Investor complaints remaining unresolved at the end of the year	Nil

SEBI COMPLAINTS REDRESS SYSTEM (SCORES)

The Securities and Exchange Board of India (“SEBI”) administers a centralized web based complaints redress system (“SCORES”). It enables investors to lodge and follow up complaints and track the status of redressal online on the website at www.scores.gov.in. It also enables the market intermediaries and listed companies to receive the complaints from investors against them, redress such complaints and report redressal of such complaints. All the activities starting from lodging of a complaint till its disposal are carried online in an automated environment and the status of every complaint can be viewed online at any time. The Company has registered itself on SCORES and endeavors to resolve all investor complaints received through SCORES.

VI. RISK MANAGEMENT:

The Company is not required to constitute Risk Management Committee. However, the Company has a well defined risk management framework in place. The risk management framework is at various levels across the Company.

VII. REMUNERATION OF DIRECTORS:

- All pecuniary relationship or transactions of the non-executive directors vis-à-vis the listed entity: Non Executive Directors does not have any pecuniary relationship or transactions with the Company.
- Criteria of making payments to Non-Executive Directors: During the year no remuneration and payment made to any non Executive Director of the Company.
- During the year no remuneration and payments made to the Executive Director of the Company.
- No sitting Fees was paid to any Director of the Company during the financial year.
- The Company has not granted any bonuses/stock options/pension etc. to any of its directors.
- Details of fixed component and performance linked incentives along with the performance criteria: Nil.
- The Company does not have service contract with any of its directors. Notice period of minimum 30 days has been fixed for directors. Further, the Company does not pay any severance fee.

VIII. GENERAL BODY MEETINGS

A. Location and time for last three Annual General Meetings held

The last three Annual General Meetings of the Company were held as detailed below:

Financial Year	Date of AGM	Time of AGM	Venue
37 th AGM 2019-20*	30 th September, 2020	12.30 P.M.	Mhow - Neemuch Road, Sector -1, Pithampur, District Dhar, (M.P.) 454775
38 th AGM 2020-21*	28 th September, 2021	11.00 A.M.	Mhow - Neemuch Road, Sector -1, Pithampur, District Dhar, (M.P.) 454775
39 th AGM 2021-22*	28 th September, 2022	12:00 P.M.	Mhow - Neemuch Road, Sector -1, Pithampur, District Dhar, (M.P.) 454775

*Meetings conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM) for which purpose the registered office of the Company shall be deemed as the venue for the meeting.

B. Special Resolutions passed in last three Annual General Meeting:

- No Special Resolution was passed by the Company in 37th AGM held on 30th September, 2020.
- In 38th AGM held on 28th September, 2021, the Company has passed the following special resolution(s):
 - Continuation of directorship of Mr. Ramesh Chandra Mittal (DIN: 00035272) as the Non-Executive Director and Chairman of the Company on attaining the age of 75 (seventy five) years.
 - Re-appointment of Mr. Ashok Omprakash Agrawal (DIN: 07870578) as a Non-Executive Independent Director of the Company for a second term of 5 years.
- In 39th AGM held on 28th September, 2022, the Company has passed the following special resolution(s):
 - Appointment of Mr. Sourabh Kumar Shrivastava (DIN: 09692160) as a Non Executive Independent Director of the Company.

C. Special Resolution(s) passed through Postal Ballot:

- No resolution was passed by postal ballot during the last financial year.
- None of the business proposed to be transacted in the ensuing Annual General Meeting require passing of a resolution through Postal Ballot.

IX. CODE FOR PREVENTION OF INSIDER TRADING PRACTICES:

The Company has formulated and adopted the ‘Code of Practices and Procedures for Fair disclosure of unpublished price sensitive information’ which, inter alia, includes Policy for determination of “Legitimate Purpose” and ‘code of Conduct for Prevention of Insider Trading in Securities of Medi-Caps Limited in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“the Regulations”). The Code is also available on the Company’s website <https://medicaps.com/wp-content/uploads/2017/03/COC-25.08.2020.pdf>

The Company’s code of conduct has been formulated to regulate, monitor and ensure reporting of trading by the Designated Persons and their immediate relatives towards achieving compliance with the Regulations and is designed to maintain the highest ethical standards of trading in Securities of the Company by persons to whom it is applicable. The Code lays down Guidelines, which advises them on procedures to be followed and disclosures to be made, while dealing with securities of the Company and

cautions them of the consequences of violations. During the year under review, the Company's Code of Conduct was amended in line with the amendments brought in the Regulations by SEBI.

X. MANAGEMENT DISCUSSION AND ANALYSIS:

The Management Discussion and Analysis is a part of the Annual report and annexed separately.

XI. DISCLOSURE REGARDING DIRECTOR SEEKING APPOINTMENT/RE-APPOINTMENT AT THE ENSUING ANNUAL GENERAL MEETING:

Brief resume(s) of the Director proposed to be appointed/re-appointed/retire by rotation and eligible for re-appointment is given in the Notice convening the Annual General Meeting in separate annexure.

XII. MEANS OF COMMUNICATION

The Company recognizes the importance of two way communication with Shareholders and of giving a balanced reporting of results and progress. Full and timely disclosure of information regarding the Company's financial position and performance is an important part of your Company's corporate governance ethos.

Your Company follows a robust process of communicating with its stakeholders, security holders and investors through multiple channels of communications such as dissemination of information on the website of the Stock Exchange, the Annual Report and uploading relevant information on its website.

The extract of quarterly, Half-yearly and Annual Financial results are published in widely circulated newspapers such as Free Press Journal (English) and Choutha Sansar (Hindi) in compliance with Regulation 47 of the SEBI Listing Regulations, 2015. These are not sent individually to the shareholders.

Financial Results:

The unaudited quarterly results are announced within forty- five days of the close of each quarter, other than the last quarter. The audited annual results are announced within sixty days from the end of the financial year as required under the SEBI Listing Regulations 2015. The aforesaid financial results are announced to the Stock Exchange within the statutory time period from the conclusion of the Board Meeting(s) at which these are considered and approved.

Other Information:

Your Company discloses to the Stock Exchange, all information required to be disclosed under Regulation 30 read with Part 'A' and Part 'B' of Schedule III of the SEBI Listing Regulations, 2015 including material information having a bearing on the performance/ operations of the Company and other price sensitive information. All information is filed electronically on the online portal of BSE Limited – Corporate Compliance & Listing Centre (BSE Listing Centre).

The Company's website: www.medicaps.com contains a separate dedicated section "Investor Relations" where information for shareholders is available. The Quarterly/Annual Financial Results, annual reports, investor forms, stock exchange information, shareholding pattern, corporate benefits, policies, investors' contact details, etc., are posted on the website in addition to the information stipulated under Regulation 46 of the SEBI Listing Regulations, 2015. The Company has not made any official releases and presentation to any institution.

XIII.GENERAL SHAREHOLDER INFORMATION.


Date, Time and Venue of Annual General Meeting	Friday, 29 th September, 2023 at 12:30 P.M. (IST) through Video Conferencing or Other Audio Video Means (OAVM) for which purposes the Registered Office shall be deemed to be venue of the Meeting
Financial Year	The financial year covers the period from 1 st April, to 31 st March.
Financial Year Reporting for 2023-2024	
1 st Quarter ending 30 th June, 2023	On or Before 14 th August, 2023
2 nd Quarter ending 30 th Sept, 2023	On or Before 14 th November, 2023
3 rd Quarter ending 31 st Dec, 2023	On or Before 14 th February, 2024
4 th Quarter ending 31 st March, 2024	On or Before 30 th May, 2024
Dividend Payment Date	No Dividend was recommended by the Board of Directors for Financial Year ended 31 st March, 2023
Date of Annual Book Closure (both days inclusive)	From Saturday, 23 rd September, 2023, to Friday 29 th September, 2023 (both days inclusive)
Listing on Stock Exchange	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 (M.H.)
Listing Fees	Board of Directors of the Company confirmed that Annual Listing Fees for the financial year 2023-24 has been paid to BSE Limited, Mumbai
Stock Code	523144
ISIN No.	INE442D01010
CIN	L70100MP1983PLC002231
Market Price Data: High/Low during each month in the last Financial Year.	As per attached Table-1
Relative Performance of Share Price V/S BSE Sensex	As per attached Table-2

Suspension of Securities	Not applicable
Registrars and Share Transfer Agents (For physical and Demat shares)	ANKIT CONSULTANCY PRIVATE LIMITED CIN : U74140MP1985PTC003074 SEBI REG. No. INR000000767 Plot No. 60, Electronics Complex, Pardeshipura, Indore - 452010 (M.P) Tel.:0731-4065797, 4065799, Fax: 0731-4065798 E-mail: investor@ankitonline.com Web Address: www.ankitonline.com
Share Transfer System	Share transfers and related operations for the Company are processed by the Company's RTA. Shareholders may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the Listed Companies to issue securities in demat form only while processing service requests viz. Issue of duplicate securities certificate, claim from Unclaimed Suspense Account; Renewal/ Exchange of securities certificate; Sub-division/ Splitting of securities certificate; Consolidation of securities certificates/folios; Transmission and Transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR-4, the format of which is available on the Company's website www.medicaps.com and on the website of the Company's Registrar and Transfer Agents http://ankitonline.com . Shareholders holding equity shares of the Company in physical form are requested to kindly get their equity shares converted into demat/ electronic form to get inherent benefits of dematerialisation and also considering that physical transfer of equity shares/ issuance of equity shares in physical form have been disallowed by SEBI.
Distribution of shareholding as on 31.03.2023	As per attached Table-3
Dematerialization of shares and liquidity	1,20,26,824 shares are dematerialized (as on 31.03.2023) i.e. 96.45% of total shares viz.; 1,24,69,956 equity shares
Outstanding GDRs/ ADRs/ Warrants or any convertible instruments, conversion date and likely impact on equity	The Company has not issued any GDRs/ADRs/ Warrants or any convertible instruments.
Commodity price risk or foreign exchange risk and hedging activity	Your Company does not deal in any commodity and hence is not directly exposed to any commodity price risk. Further, the Company has no foreign exchange exposure; hence hedging is not required.
Plant Location	The company has closed its manufacturing activity thus does not have any manufacturing plants. Company's first real estate project 'Medicaps Business Park' is situated at Mhow - Neemuch Road, Sector-1, Pithampur, Dhar (M.P.) - 454775
Address for Shareholders' correspondence:	Corporate Office:- 201, Pushpratna Paradise, 9/5 New Palasia, Indore (M.P.)-452001 INDIA Tel. No.: 0731- 4046321, 0731- 4028148 Fax No.: 0731- 4041435 Email: investors@medicaps.com
List of Credit Ratings	During the year under review your Company has not obtained any Credit Rating as the same was not applicable to the company

Table-1: Market Price Data (in Rs.)

The monthly high and low price of shares of the Company traded at the BSE Limited, for the period start from April, 2022 to March, 2023 are given below:

Month	April 22	May 22	June 22	July 22	Aug 22	Sep 22	Oct 22	Nov 22	Dec 22	Jan 23	Feb 23	Mar 23
High	59.00	58.45	53.80	53.30	57.70	49.70	49.80	49.50	53.00	46.45	44.50	41.50
Low	47.50	48.90	41.15	43.15	38.65	43.00	43.45	41.25	39.00	42.00	36.25	30.62

Table-2: Relative performance of share price v/s. BSE Sensex:**Table-3: Distribution of Shareholding according to size class as on March 31, 2023**

Category (Shares)	Number of Share holders	% age of total Share holder	Shares	% age of Total Shares
Up to 100	11320	73.94	303299	2.43
101-200	1105	7.22	177503	1.43
201-300	686	4.48	191163	1.54
301-400	555	3.63	214833	1.72
401-500	309	2.02	148099	1.19
501-1000	680	4.44	531506	4.26
1001-2000	344	2.25	531694	4.26
2001-3000	91	0.59	230663	1.85
3001-4000	52	0.34	185965	1.49
4001-5000	34	0.22	159528	1.28
5001-10000	67	0.44	490522	3.93
10000-Above	65	0.43	9305181	74.62
TOTAL	15308	100.00	12469956	100.00

INFORMATION FOR PHYSICAL SHAREHOLDERS**Common and Simplified Norms for updation of PAN and Know Your Customer (KYC) details**

SEBI had vide circular dated March 16, 2023 introduced Common and Simplified Norms for furnishing PAN, KYC details and Nomination by the Shareholders in supersession of circulars dated November 3, 2021 and December 14, 2021 according to which, all shareholders holding shares in physical form are mandatorily required to furnish PAN (compulsorily linked with Aadhaar), nomination, contact details, bank account details and specimen signature to RTA. Further, it is mandated that the RTA shall not process any service request or complaint of shareholder still PAN, KYC and nomination document/details are received. In case any one of aforesaid documents is not available on or after October 1, 2023, the folios shall be frozen by the RTA. Necessary communication through letters has been sent to all the physical shareholders in this regard.

Members are requested to update the above details by submitting the forms available on the Company's website www.medicaps.com or the Company's RTA website i.e. <http://ankitonline.com>. For further queries, you can approach our Registrar and Share Transfer Agent (RTA).

XIV. SUBSIDIARY COMPANIES

Regulation 16(1)(c) of the SEBI Listing Regulations, 2015 defines a "material subsidiary" mean a subsidiary, whose income or net worth exceeds ten percent of the consolidated income or net worth respectively, of the listed entity and its subsidiaries in the immediately preceding accounting year. Under this definition the Company have one unlisted material wholly owned subsidiaries viz; Medgel Private Limited.

The subsidiary of the Company functions independently, with an adequately empowered Board of Directors and adequate resources. The minutes of the Board Meetings of the subsidiary company are placed before the Board of Directors on a quarterly basis. The financial statements of the subsidiary company are presented to the Audit Committee at every quarterly meeting. The Company has also complied with other requirement of Regulation 24 of the SEBI Listing Regulations, 2015 with regard to Corporate Governance requirements for Subsidiary Company. Further as per provision of Regulation 24A of SEBI Listing Regulations, 2015, secretarial audit report for material subsidiary has also been undertaken and annexed with this Annual Report.

The SEBI Listing Regulations, 2015 mandates the appointment of at least one independent director of the listed parent company on the Board of unlisted material subsidiary companies in India. In compliance with the aforesaid provision, Mr. Pramod Fatehpuria (DIN: 00972389) and Mr. Ashok Omprakash Agrawal (DIN: 07870578), Independent Directors have been appointed in Medgel Private Limited (Unlisted Material wholly owned subsidiary Company).

Disclosure requirements with respect to Material Subsidiaries of the Company

The Company have one unlisted material wholly owned subsidiary Company viz; Medgel Private Limited, incorporated in India as on 10th January, 2007. Further Rawka & Associates, Chartered Accountant (Firm Registration No. 021606C) is statutory auditor of the Company who was re-appointed in Annual General Meeting held on 27th September, 2022 as the Statutory Auditor of the Company for a second term of five consecutive years to hold office from conclusion of 15th Annual General Meeting up to the conclusion of 20th Annual General Meeting (AGM to be held for financial year ended 2026-27).

XV. OTHER DISCLOSURES

A. Disclosures on materially significant related party transactions that may have potential conflict with the interests of listed entity at large & web link where policy on dealing with related party transactions.

All transactions entered into with related parties under Regulation 23 of the SEBI Listing Regulations 2015, during the year under review were on arm's length basis and in the ordinary course of business. There are no materially significant related party transactions of the Company which have potential conflict with the interest of the Company at large. Further, the particulars of transactions between the Company and its related parties in accordance with the Indian Accounting Standards (IND AS) are set out in Note No. 29 of Standalone Financial Statements forming part of the annual report. Your Company has formulated a Policy on Materiality of and Dealing with Related Party Transactions which specify the manner of entering into related party transactions. This Policy has also been posted on the website of the Company and can be accessed through web link: <https://medicaps.com/wp-content/uploads/2017/03/RPT-Policy-W.E.F-25.07.2018-Final-Updated.pdf>

As per the Regulation 23(9) of SEBI Listing Regulations, Company has filed disclosure of Related Party Transaction with BSE Limited within prescribed time limit in the format as specified by the Board from time to time.

B. Policy for determining 'material' subsidiaries:-

Your Company has formulated a Policy for Determining 'Material' Subsidiaries as defined in Regulation 16(1)(c) of the SEBI Listing Regulations 2015. This Policy has also been posted on the website of the Company and can be accessed through web-link: <https://medicaps.com/wp-content/uploads/2022/08/Policy-for-determining-Material-Subsidiary-f.pdf>

C. Disclosure of Accounting Treatment in preparation of Financial Statements

The Company adopted Indian Accounting Standards ("Ind AS") from 1st April, 2017. Accordingly, the financial statements have been prepared in accordance with Ind AS as per the Companies (Indian Accounting Standards) Rules, 2015 as amended and notified under Section 133 of the Act and other relevant provisions of the Act.

D. Details of non-compliance by the Company, fine, and strictures imposed on the Company by Stock Exchange or SEBI, or any statutory authority, on any matter related to capital markets, during the last three years:

There were no such non-compliance by the Company and no fine, penalty and strictures imposed by the stock exchange or the SEBI or any statutory authority on any matter related to capital market during the last three years.

E. Vigil Mechanism/Whistle Blower Policy

In accordance with Regulation 22 of the SEBI Listing Regulations 2015, the Company has formulated a Whistle Blower policy and has established a Vigil Mechanism for directors and employees to enable the Directors, employees and all stakeholders of the Company to report genuine concerns, to provide for adequate safeguards against victimization of persons who use such mechanism and make provision for direct access to the Chairman of the Audit Committee. The Company affirms that no personnel have been denied access to the Audit Committee under Vigil Mechanism. Details of Whistle Blower Policy are provided in the Board's Report section of this Annual Report and which is also available on the Company's website and can be accessed at the web link: <http://medicaps.com/wp-content/uploads/2021/07/whistle-blower-policy.pdf>

F. Commodity Price Risk or Foreign Exchange Risk and Hedging activities:

Your Company does not deal in any commodity and hence is not directly exposed to any commodity price risk. Further, the Company has no foreign exchange exposure; hence hedging is not required.

G. Funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32(7A) of SEBI Listing Regulations, 2015

During the year under review, the Company has not raised funds through preferential allotment or qualified institutions placement as specified under Regulation 32(7A) of SEBI Listing Regulations.

H. Details of compliance with mandatory requirement and adoption of non-mandatory requirement:

Your Company has complied with all the mandatory corporate governance requirements under the SEBI Listing Regulations, 2015. Specifically, your Company confirms compliance with Corporate Governance requirements specified in Regulations 17 to 27 and clauses (b) to (i) and (t) of sub regulation (2) of regulation 46 of the SEBI Listing Regulations, 2015. The Company has fulfilled the following non-mandatory requirements as prescribed in Regulation 27(1) read with PART E of Schedule II of SEBI Listing Regulations, 2015:

- **The Board:** Mr. Ramesh Chandra Mittal (Promoter/Non Executive Director) was appointed as Chairman of the Board and Company.
- **Shareholder's Rights:** As the extract of quarterly, half yearly, financial performance are published in the newspapers and are also posted on the Company's website, the same are not mailed to the shareholders
- **Modified opinion(s) in audit report:** During the year under review, the Auditors have provided an unmodified audit opinion on the financial statements of the Company.

- **Reporting of Internal Auditor:** In accordance with the provisions of Section 138 of the Companies Act, 2013, the Company has appointed an Internal Auditor who reports to the Audit Committee. Quarterly internal audit reports are submitted to the Audit Committee which reviews the audit reports and suggests necessary action.
- **Separate posts of Chairperson and the Managing Director or the Chief Executive Officer:** Not applicable, since company has appointed Mr. Ramesh Chandra Mittal Promoter & Non Executive Director of the company as Chairman of the Board and Company. Further he is also related to the Managing Director of the Company.

The Company has submitted quarterly compliance report on Corporate Governance with the Stock Exchange, in accordance with the requirements of Regulation 27(2)(a) of the SEBI Listing Regulations 2015.

I. Certificate from Practicing Company Secretary for Non- Disqualification of directors:

As required under Part C of Schedule V of the SEBI Listing Regulations, 2015, the Company has obtained a certificate from CS L. N. Joshi (FCS 5201 C.P. No. 4216), proprietor of LN Joshi & Co., Practicing Company Secretaries, certifying that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of the Company by the Securities and Exchange Board of India/ Ministry of Corporate Affairs or any such statutory authority.

J. Disclosure in relation to Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In compliance with Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 the Board has constituted an Internal Committee and Mrs. Kusum Mittal is the Chairperson of the Committee. As there was no reference to the Committee, no meeting was required to be held during the year 2022-23.

The Company has formulated a Policy for Prevention of Sexual Harassment at Workplace to ensure prevention, prohibition and protection against sexual harassment. The policy provides the guidelines for reporting of such harassment and the procedure for resolution & redressal of the complaints of such nature.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:-

S. No.	Particulars	No. of Complaints
i)	Number of Complaints filed during the financial year	Nil
ii)	Number of Complaints disposed off during the financial year	Nil
iii)	Number of Complaints pending as at the end of financial year	Nil

K. Disclosure on Acceptance of Recommendations made by the Committees to the Board

During the financial year under review, various recommendations were made by the Committees to the Board of Directors, which were all accepted by the Board, after necessary deliberations.

L. Total Fees for all Services Paid by the Company and its subsidiaries, on a Consolidated Basis, to the Statutory Auditor and all the entities in the network firm/network entity of which the statutory auditor is a part:

The details of total fees for all services paid by the Company and its subsidiaries, on a consolidated basis, to the statutory auditor and all the entities in the network firm/network entity of which the statutory auditor is a part, are as follows:

(Amount in Lacs)

Particulars	Medi-Caps Limited	Medgel Private Limited (Wholly Owned Subsidiary of the Medi-caps Limited)	Total
Audit Fees	0.30	2.50	2.80
Tax Audit Fees	0.00	0.20	0.20
Others	0.00	0.30	0.30
Total	0.30	3.00	3.30

M. Disclosure by company and its subsidiary for loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount:-

The Company and its subsidiary have not made any Loans and advances in the nature of loans to firms/companies in which directors are interested during the FY 2022-23.

XVI. TRANSFER OF AMOUNTS/SHARES TO INVESTOR EDUCATION AND PROTECTION FUND:

Pursuant to the provisions of Sections 124 and 125 of the Companies Act, 2013 read with the IEPF (Accounting, Audit, Transfer and Refund) Rules, 2016, dividend / interest / refund of applications which remains unclaimed/unpaid for a period of 7 years is required to be transferred to IEPF. Further, the IEPF Rules mandate the companies to transfer all shares on which dividend remains unclaimed/unpaid for a period of 7 consecutive years to the demat account of the IEPF Authority.

Please note that the Company has transferred unpaid/unclaimed dividend pertaining to the financial year 2008-09, 2009-10, 2010-11 and 2011-12 and corresponding shares thereon to the IEPF. Further there are no remaining unpaid/unclaimed dividend and shares pending which are due for transfer to the IEPF.

The Members/claimants whose shares or unclaimed dividends get transferred to IEPF may claim the shares or apply for refund from the IEPF Authority by following the refund procedure as detailed on the website of IEPF Authority at www.iepf.gov.in/IEPF/refund.html.

XVII. DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/UNCLAIMED SUSPENSE ACCOUNT

The Company does not have any shares in the demat suspense account/unclaimed suspense account.

XVIII. CODE OF CONDUCT

The Board of Directors has laid down the Code of Conduct for all the Board Members and members of the senior management. The Code is also placed on the Company's website at the below mentioned web-link – <http://medicaps.com/wp-content/uploads/2021/08/Code-of-Conduct-for-Board-Senior-Management-Personnel.pdf>

A certificate from the Managing Director, affirming compliance of the said Code by all the Board Members and members of the senior management to whom the Code is applicable, is annexed separately to this report. Further, the Directors and the Senior Management of the Company has submitted disclosure to the Board that they do not have any material financial and commercial transactions that may have a potential conflict with the interest of the Company at large.

XIX. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT OF SUB-PARAS (2) TO (10) OF PART C OF SCHEDULE V, WITH REASONS THEREOF:-

Not, applicable, Company has complied all the requirements of Corporate Governance Report of sub-para (2) to (10) of Part C of Schedule V of SEBI Listing Regulations 2015.

XX. MD/ CFO CERTIFICATION

The Managing Director and the Chief Financial Officer of the Company have provided annual certification on financial reporting and internal controls to the Board in terms of Regulation 17(8) read with Part B of Schedule II of the SEBI Listing Regulations 2015. Copy of such certificate is annexed with this report.

The Managing Director and the Chief Financial Officer also provided quarterly certification on financial results to the Board in terms of Regulation 33(2)(a) of the SEBI Listing Regulations 2015.

XXI. CERTIFICATE ON CORPORATE GOVERNANCE

The Company has obtained a certificate from the Statutory Auditors of the Company regarding compliance with the conditions of Corporate Governance as stipulated in terms of Regulation 34(3) read with Schedule V of the SEBI Listing Regulations, 2015 and the same is annexed with this report.

XXII. OTHERS INFORMATION

- Proceeds from public issues, right issues, preferential issues, etc. :- Not applicable
- The Company has adopted a policy on dissemination of information on the material events to stock exchanges in accordance with the Regulation 30 of the SEBI Listing Regulations 2015. The said policy is available on the website of the Company at following web link: <https://medicaps.com/wp-content/uploads/2023/08/Policy-for-determination-of-materiality-of-events-or-information.pdf>
- The Company has adopted the policy on preservation of documents in accordance with the Regulation 9 of the SEBI Listing Regulations 2015. The documents preservation policy is available on the website of the company at following web link: <http://medicaps.com/wp-content/uploads/2016/06/Policy-for-preservation-of-Documents.pdf>

XXIII. DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT**Compliance with the Code of Business Conduct and Ethics**

I, Alok K Garg, Managing Director of Medi-Caps Limited declare that all the members of Board of Directors and Senior Management Personnel have affirmed compliance with the Code of Conduct for the financial year ended on 31st March, 2023.

FOR, MEDI-CAPS LIMITED

DATE: 11TH AUGUST, 2023

PLACE: INDORE

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

{ Pursuant to Regulation 34(3) read with Schedule V Para C sub clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 }

To,
The Members of
MEDI-CAPS LIMITED

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Medi-Caps Limited** having CIN: L70100MP1983PLC002231 and having registered office at Mhow - Neemuch Road, Sector 1 Pithampur, Dhar-454775 (M.P.) (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company and its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2023 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India (SEBI), Ministry of Corporate Affairs, or any such other Statutory Authority.

Details of Directors:

S. No.	Name of Directors	DIN	Date of appointment in Company
1	Mr. Ramesh Chandra Mittal	00035272	06/08/1983
2	Mr. Alok K Garg*	00274321	01/04/1999
3	Mrs. Kusum Mittal	00035356	04/05/1991
4	Mr. Pramod Fatehpuria	00972389	29/05/2014
5	Mr. Ashok Omprakash Agrawal	07870578	25/07/2017
6	Mr. Dharmendra Solanki	09055239	05/02/2021
7	Mr. Akshit Garg	08576807	04/08/2022
8	Mr. Sourabh Kumar Shrivastava	09692160	04/08/2022

Note: Date of Appointment Mr. Alok K Garg showing on MCA portal is 01/04/2007.

**Mr. Sourabh Kumar Shrivastava (DIN: 09692160, Non-Executive Independent Director and Mr. Akshit Garg (DIN: 08576807) Promoter Non-Executive Director were resigned from the post of directorship of the Company w. e. f. 21st July, 2023.*

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on these based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

FOR L.N. JOSHI & COMPANY
COMPANY SECRETARIES

DATED: 11TH AUGUST, 2023
PLACE: INDORE

L. N. JOSHI
PROPRIETOR
FCS: 5201; C.P. NO 4216
UDIN: F005201E000746832
PEER REVIEW CERTIFICATE NO. 1722/2022
UNIQUE CODE NUMBER: S2002MP836100

MD AND CFO COMPLIANCE CERTIFICATE

{ COMPLIANCE CERTIFICATE PURSUANT TO REGULATION 17(8) READ WITH PART B OF SCHEDULE II OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 }

To,
The Board of Directors
MEDI-CAPS LIMITED

We hereby certify to the Board of Directors of **MEDI-CAPS LIMITED** that:

- A. We have reviewed the financial statements and the Cash Flow Statement prepared based on the Indian Accounting Standards for the year ended on March 31, 2023 and that to the best of our knowledge and belief, we state that:
- 1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - 2) These statements together present a true and fair view of the Company's affairs and are in compliance with applicable Indian Accounting Standards and laws and regulations.
- B. There are, to the best of our knowledge and belief no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- D. We have indicated to the auditors and the Audit Committee about:
- 1) significant changes in internal control over financial reporting during the year;
 - 2) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - 3) that there were no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

FOR AND ON BEHALF OF THE BOARD

DATE: 23RD MAY, 2023
PLACE: INDORE

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

HEMANT SETHI
CHIEF FINANCIAL OFFICER

COMPLIANCE CERTIFICATE FROM AUDITORS' REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE REQUIREMENTS UNDER SEBI (LISTING OBLIGATIONS AND DISCLOSURES REQUIREMENTS) REGULATIONS 2015

To,
The Members of
MEDICAPS LIMITED
Mhow-Neemuch Road, Sector 1, Pithampur, Dhar (M.P.) 454775

We have examined the compliance of conditions of Corporate Governance by **Medicaps Limited** ('the Company') for the year ended 31st March, 2023, as stipulated in Regulations 17 to 27, clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and paragraphs C, D and E of Schedule V of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, as amended from time to time ('Listing Regulations').

The compliance of conditions of Corporate Governance as stipulated under the Listing Regulations is the responsibility of the Management. Our examination was limited to procedures and implementations thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations.

We have examined the relevant records of the Company in accordance with the Generally Accepted Auditing Standards in India, to the extent relevant and as per the Guidance Note on Reports or Certificates for Special Purposes and Guidance Note on Certification of Corporate Governance both issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAL.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

DATE: 08TH AUGUST, 2023
PLACE: INDORE
UDIN: 23429040BGXBET5949

FOR, RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 021606C

VENUS RAWKA
PARTNER
M. NO. 429040

INDEPENDENT AUDITORS' REPORT ON STANDALONE FINANCIAL STATEMENTS

**TO,
THE MEMBERS OF
MEDICAPS LIMITED,
PITHAMPUR - M.P.**

Report on Audit of Ind AS Standalone Financial Statements***Opinion***

We have audited the accompanying Ind AS Standalone Financial Statements of **MEDICAPS LIMITED** ('the Company'), which comprise the balance sheet as at 31st March 2023, the statement of profit and loss (including other comprehensive income), the cash flow statement and the statement of changes in equity for the year then ended and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "The Ind AS Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS Standalone Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, the Loss (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Ind AS Standalone Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Ind AS Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Ind AS Standalone Financial Statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS Standalone Financial Statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Other Information – Information other than financial statement and Auditor's Report- thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report, but does not include the consolidated financial statements, standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If based on the work we have performed we conclude that there is a material misstatement of this other information, we are required to communicate the matter to those charged with Governance. We have nothing to report in this regard.

Responsibility of Management for Ind AS Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Ind AS Standalone Financial Statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Ind AS Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or

in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced.

We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the 'Annexure A' statement on the matters specified in paragraphs 3 and 4 of the Order to the extent applicable.
2. As required by section 143(3) of the Act, we report that:
 - a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss Including other comprehensive income, the Cash Flow Statement, and statement of change in equity dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the aforesaid Ind AS Standalone Financial Statements comply with the Indian Accounting Standards specified under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended.
 - e. On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164(2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended in our opinion and to the best of our information and according to the explanations given to us, no remuneration is paid or provided by the company to its directors during the year.

- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules 2014, in our opinion and to the best of our information and according to the explanations given to us:
- I. The Company has disclosed the impact of pending litigations in its financial position in the Ind AS Standalone Financial Statements.
 - II. The Company did not have any long term contracts including derivatives contract for which there were any material foreseeable losses.
 - III. The company was not required to transfer any amount to Investor Education and Protection Fund during the financial year.
 - IV.
 - a. The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entities, including foreign entities ("Intermediaries"), with the understanding whether recorded in writing or not that the intermediary shall whether directly or indirectly lend or invest in other persons or entities identified in any manner by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of ultimate beneficiaries.
 - b. The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the company from any person(s) or entities including foreign entities ("Funding Parties") with the understanding that such company shall whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or provide guarantee, security or the like on behalf of the Ultimate beneficiaries.
 - c. Based on the audit procedures performed, we report that nothing has come to our notice that has caused us to believe that the representations given under sub-clause (i) and (ii) by the management contain any material mis-statement.
 - V. No dividend has been declared or paid by the Company during the year.

PLACE: INDORE
DATE: 23/05/2023
UDIN: 23429040BGXBDZ8972

FOR: RAWKA & ASSOCIATES
 CHARTERED ACCOUNTANTS
 FIRM REG. NO: 021606C

VENUS RAWKA
 (PARTNER)
 M. NO.: 429040

Annexure 'A' to Independent Auditors' Report

(Referred to Para 1 under the heading on "Report on Other Legal and Regulatory Requirements" section of our report of even date to the members of Medi-caps Limited for the year ended 31st March, 2023)

- (i)
 - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipments.
 - (B) The Company does not have any Intangible Assets.
 - (b) As explained to us, the Property, Plant & Equipments have been physically verified by the management of the Company in accordance with phased programme of verification, which in our opinion is reasonable, considering the size and nature of its business. No material discrepancies were noticed during such verification.
 - (c) According to information and explanation given to us and on the basis of records of the Company examined by us, we report that, the title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreement are duly executed in favor of the lessee) disclosed in the Financial Statements are held in the name of the Company.
 - (d) The Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) during the year, therefore clause 3(i)(d) of the Order is not applicable.
 - (e) No proceedings have been initiated during the year or are pending against the Company as at March 31,2023 for holding any benami property under the Benami Transactions (Prohibition) Act,1988 and rules made thereunder.
- (ii)
 - (a) According to the information and explanations given to us, physical verification of the inventories has been conducted by the management at reasonable interval. The Company has maintained proper records of inventory, there was no material discrepancies noticed on physical verification of the inventories as compared to the book.
 - (b) The Company had no working capital limit against the security of the inventories during the year.
- (iii)
 - (a) During the year the Company has not provided loans, advances in the nature of loans during the year. However the Company has provided guarantee in favour of its Wholly Owned Subsidiary, Medgel Private Limited towards a cash credit limit of Rs. 2 Crores availed from IDBI Bank Limited, Indore, which has been withdrawn during the financial year.
 During the year the Company has not provided loans, advances in the nature of loans, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to any a parties other than subsidiaries.
 - (b) During the year the investments made are not prejudicial to the Company's interest. The Company has not granted any loans or advances during the year.
 - (c) The Company has not granted loans during the year. Therefore Clause 3(iii)(c) of the Order is not applicable.

- (d) There are no amounts of loans granted to companies which are overdue for more than ninety days.
- (e) There were no loans which had fallen due during the year, that have been renewed or extended or fresh loans granted to settle the over dues of existing loans given to the same parties.
- (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company.
- (iv) According to the information and explanations given to us, during the year the company has not entered into any eligible transactions as specified in the provisions of section 185 and 186 of the Companies Act, 2013 hence this clause is not applicable to the Company. However, the company has given guarantee of Rs. 2.00 Crores for the Loan taken by Medgel Private Limited (wholly owned subsidiary) from IDBI Bank Ltd which has been withdrawn during the year.
- (v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73 to 76 of the Act and the Rules framed there under to the extent notified.
- (vi) According to the information and explanations given to us, the Company is not covered under Companies (Cost Records and Audit) Rules, 2014 prescribed by the Central Government under Section 148(1) of the Act, hence this clause is not applicable to the Company.
- (vii) (a) According to the information and explanations given to us and on the basis of the records of the Company, the Company is generally regular in depositing undisputed statutory dues including Goods and Service Tax, Provident Fund, Employee's State Insurance, Sales Tax, Service Tax, Custom Duty, Excise Duty, Value Added Tax, Cess and other material statutory dues with the appropriate authorities.
As provided to us by the management, the extent of the arrears of outstanding statutory dues as at the last day of the financial year concerned for a period of more than six months from the date they became payable, are Nil.
- (b) According to the records of the Company, there are no dues outstanding of income tax / Sales Tax/ wealth tax / service tax / custom duty / excise duty / VAT / cess etc. on account of any dispute except the following:

Name of the Statute	Nature of Dues	Forum where dispute is pending	Period to which the amount relates	Amount Involved	Amount Unpaid
Income Tax Act, 1961	Income Tax	CIT(A)	A.Y. 2017-18	Rs. 9,86,409/-	Rs. 7,88,128/-
Income Tax Act, 1961	Income Tax	ITAT	A.Y. 2018-19	Rs. 20,44,810/-	Rs. 20,44,810/-
Income Tax Act, 1961	Income Tax	CIT(A)	A.Y. 2014-15	Rs. 3,77,00,360/-	Rs. 3,77,00,360/-

- (viii) There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- (ix) a) The Company has not defaulted in repayment of loans or other borrowings taken from the banks. The Company has not taken loans from financial institutions and Government.
- b) The Company has not been declared wilful defaulter by any bank or financial institution or government or other lender.
- c) The Company has not taken any term loan during the year and there are no outstanding term loans at the beginning of the year and hence, reporting under clause 3(ix)(c) of the Order is not applicable.
- d) On an overall examination of the financial statements of the Company, no funds were raised on short-term basis and neither they have been, used during the year for long-term purposes by the Company.
- e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiary.
- f) According to the information and explanations given to us and procedures performed by us, we report that the company has not raised loans during the year on the pledge of securities held in its subsidiary.
- (x) (a) In our opinion and according to the information and explanations given to us, the company has not raised moneys by way of any public offer including debt instruments and term Loans during the year and hence the provisions of clause 3 (x)(a) of the Order are not applicable to the Company.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.
- (xi) (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (c) As represented to us by the management, there are no whistle blower complaints received by the company during the year.

- (xii) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Ind AS Standalone Financial Statements as required by the applicable Indian accounting standards.
- (xiv) a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
b) We have considered the internal audit reports for the year under audit, issued to the Company during the year, in determining the nature, timing and extent of our audit procedures.
- (xv) In our opinion and according to the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company.
- (xvi) a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a) of the Order is not applicable.
b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the year.
c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
d) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year. Accordingly Clause 3(xviii) of the Order is not applicable.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- (xx) a) Corporate Social Responsibility (CSR) is not applicable to the company, hence, reporting under clause 3(xx)(a) of the Order is not applicable for the year.
b) The Company does not have ongoing projects relating to CSR. Hence reporting under clause 3(xx)(b) of the Order is not applicable.

PLACE: INDORE

DATE: 23/05/2023

UDIN: 23429040BGXBDZ8972

FOR: RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
FIRM REG. NO: 021606C

VENUS RAWKA
(PARTNER)
M. NO.: 429040

Annexure 'B' to Independent Auditors' Report

(Referred to Para 2(f) under the heading of "Report on Other Legal and Regulatory Requirements" section of our report of even date to the members of Medi-Caps Limited for the year ended 31st March, 2023)

Report on the Internal Financial Controls Over financial reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **MEDICAPS LIMITED** ("the Company") as of 31st March, 2023 in conjunction with our audit of the Ind AS Standalone Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls over Financial Reporting, both applicable to an audit of the Internal Financial Controls and both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to

obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Standalone Financial Statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Standalone Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on, the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

PLACE: INDORE

DATE: 23/05/2023

UDIN: 23429040BGXBDZ8972

FOR: RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

FIRM REG. NO: 021606C

VENUS RAWKA

(PARTNER)

M. NO.: 429040

MEDI-CAPS LIMITED			
Standalone Balance Sheet as at 31st March, 2023			
CIN: L70100MP1983PLC002231			
		Amount in Lacs.	
Particulars	Note	As at 31st March 2023	As at 31st March 2022
A. Assets			
1 Non-Current Assets			
(a) Property, Plant and Equipment	2	246.49	277.50
(b) Financial Assets			
i. Investments	3	4390.67	4390.74
ii. Other Financial Assets		0.00	0.00
(c) Other non-current assets	4	4.91	5.02
Sub-Total - Non Current Assets		4642.07	4673.26
2 Current assets			
(a) Inventories	5	0.00	0.00
(b) Financial Assets			
i. Investments	6	806.90	976.83
ii. Trade receivables	7	223.82	224.16
iii. Cash and cash equivalents	8	4.05	11.06
iv. Bank Balance other than (iii) above	9	0.00	67.61
(c) Other current assets	10	485.70	227.63
Sub-Total - Current Assets		1520.47	1507.29
Total		6162.54	6180.55
B. EQUITY AND LIABILITIES			
1 EQUITY			
(i) Equity Share Capital	11	1247.00	1247.00
(ii) Other Equity	12	4863.75	4881.80
Sub-Total - Equity		6110.75	6128.80
2 LIABILITIES			
I. Non-Current Liabilities			
(a) Provisions	13	0.00	0.00
(b) Deferred tax liabilities (Net)	14	43.98	44.13
Sub-Total - Non Current Liabilities		43.98	44.13
II. Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		0.00	0.00
(ii) Trade payables due to	15		
(a) Total Outstanding dues of Micro enterprises and Small enterprises: and		0.00	0.00
(b) Total Outstanding dues of creditors other than Micro enterprises and Small Enterprises		0.00	0.05
(b) Other current liabilities	16	7.81	7.57
(c) Current Tax Liabilities (Net)	17	0.00	0.00
Sub-Total -Current Liabilities		7.81	7.62
Total		6162.54	6180.55
The Notes referred to above are integral part of Standalone Financial Statement. Note on Accounts as Note '1 to 36'			
As per our report of even date, Rawka & Associates Chartered Accountants Firm Reg. No.:-021606C		For and on behalf of the board ,	
Venus Rawka Partner Membership No. 429040 Place : Indore Date : 23/05/2023 UDIN: 23429040BGXBDZ8972	Ramesh Chandra Mittal Chairman & Director DIN:00035272	Alok K. Garg Managing Director DIN:00274321	
	Hemant Sethi C.F.O.	Abhishek Jain Company Secretary ACS: 36699	

MEDI-CAPS LIMITED			
Standalone Profit and Loss statement for the year ended 31st March, 2023			
CIN: L70100MP1983PLC002231			
Amount in Lacs.			
Particulars	Note	For the Year Ended 31st March 2023	For the Year Ended 31st March 2022
I. Revenue from operations	18	10.14	0.00
II. Other Income	19	64.46	60.74
III. Total Income (I + II)		74.60	60.74
IV. Expenses:			
Cost of materials consumed	20	0.00	0.00
Purchase of stock in trade		0.00	0.00
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	21	0.00	0.00
Employee benefit expense	22	23.26	45.13
Finance Cost	23	0.00	0.00
Depreciation and amortization expense	2	9.23	9.23
Other expenses	24	16.53	12.46
Total Expenses		49.02	66.82
V. Profit before exceptional and extraordinary items and tax (III - IV)		25.58	-6.08
VI. Exceptional Items		0.00	0.00
VII. Profit before extraordinary items and tax (V - VI)		25.58	-6.08
VIII. Extraordinary Items		0.00	0.00
IX. Profit before tax (VII - VIII)		25.58	-6.08
X. Tax expense:			
(1) Current tax		0.00	0.00
(2) Earlier year excess provision for tax written back		0.00	0.00
(3) Deferred tax	26	-0.14	1.44
XI. Profit/(Loss) for the period From continuing Operations (IX - X)		25.72	-7.52
XII. Profit/(Loss) From Discontinued Operation	27	-11.07	3.72
XIII. Total Profit/(Loss) for the Period (XI+XII)		14.65	-3.80
XIV. Other Comprehensive Income			
A (i) Items that will not be reclassified to Profit and Loss		-32.70	35.69
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss			
B (i) Items that will be reclassified to Profit or Loss			
(ii) Income Tax relating to items that will be reclassified to Profit or Loss			
Total Comprehensive Income for the period comprising Profit(Loss) and other comprehensive income for the period (XIII + XIV)		-18.05	31.89
XVI. Earning per equity share:	31		
For Continuing Operation			
(1) Basic		0.21	-0.06
(2) Diluted		0.21	-0.06
For Discontinued Operation			
(1) Basic		-0.09	0.03
(2) Diluted		-0.09	0.03
For Continuing and Discontinued Operation			
(1) Basic		0.12	-0.03
(2) Diluted		0.12	-0.03

The Notes referred to above are integral part of Standalone Financial Statement.
Note on Accounts as Note '1 to 36'

As per our report of even date,
Rawka & Associates
Chartered Accountants
Firm Reg. No.: -021606C

For and on behalf of the board ,

Venus Rawka
Partner
Membership No. 429040
Place : Indore
Date : 23/05/2023
UDIN: 23429040BGXBDZ8972

Ramesh Chandra Mittal
Chairman & Director
DIN:00035272

Alok K. Garg
Managing Director
DIN:00274321

Hemant Sethi
C.F.O.

Abhishek Jain
Company Secretary
ACS: 36699

MEDI-CAPS LIMITED							
Standalone Statement of Changes in Equity for the period ended 31.03.2023							
CIN: L70100MP1983PLC002231							
Amount in Lacs.							
A. Equity Share Capital							
(1) Current reporting Period							
Equity Share Capital Rs. 10 Each	Balance at the Beginning of the reporting period	Changes in equity share capital due to prior period errors	Restated balance at the beginning of the reporting period	Changes in equity share capital during the year	Balance at the end of the reporting period		
2022-23	1247.00	0	0	0	1247.00		
(2) Previous reporting Period							
Equity Share Capital Rs. 10 Each	Balance at the Beginning of the reporting period	Changes in equity share capital due to prior period errors	Restated balance at the beginning of the reporting period	Changes in equity share capital during the year	Balance at the end of the reporting period		
2021-22	1247.00	0	0	0	1247.00		
B. Other Equity							
(1) Current reporting Period 2022-23							
	Reserves and Surplus						Total
	General Reserves (specify nature)	Share Forfeiture account	Security Premium	Capital Reserve	Retained Earnings	Other Items of Other Comprehensive Income	
Balance at the beginning of the reporting period 01.04.2022	304.57	27.55	0.00	9.90	4314.21	225.57	4881.80
Changes in accounting policy or prior period errors	0.00	0.00	0.00	0.00	0.00		0.00
Restated balance at the beginning of the reporting period	304.57	27.55	0.00	9.90	4314.21	225.57	4881.80
Dividends	0.00	0.00	0.00	0.00	0.00		0.00
Profit For the Year	0.00	0.00	0.00	0.00	14.65	-32.70	-18.05
Balance at the end of the reporting period 31.03.2023	304.57	27.55	0.00	9.90	4328.86	192.87	4863.75
(2) Previous reporting Period 2021-22							
Balance at the beginning of the reporting period 01.04.2021	304.57	27.55	0.00	9.90	4318.01	189.88	4849.91
Changes in accounting policy or prior period errors	0.00	0.00	0.00	0.00	0.00		0.00
Restated balance at the beginning of the reporting period	304.57	27.55	0.00	9.90	4318.01	189.88	4849.91
Dividends	0.00	0.00	0.00	0.00	0.00		0.00
Profit For the Year	0.00	0.00	0.00	0.00	-3.80	35.69	31.89
Balance at the end of the reporting period 31.03.2022	304.57	27.55	0.00	9.90	4314.21	225.57	4881.80
As per our report of even date,							
Rawka & Associates			For and on behalf of the board ,				
Chartered Accountants							
Firm Reg. No.:-021606C							
Venus Rawka			Ramesh Chand Mittal		Alok K. Garg		
Partner			Chairman & Director		Managing Director		
Membership No. 429040			DIN:00035272		DIN:00274321		
Place : Indore							
Date :23/05/2023			Hemant Sethi		Abhishek Jain		
UDIN: 23429040BGXBDZ8972			C.F.O.		Company Secretary		
			ACS: 36699				

MEDI CAPS LIMITED		
Cash Flow Statement for the year ended 31st March 2023		
CIN: L70100MP1983PLC002231		
Amount in Lacs.		
PARTICULARS	31st March 2023	31st March 2022
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	25.58	-6.08
Adjustment For:		
Depreciation	16.01	18.19
Dividend Income	0.00	0.00
Other Comprehensive Income	-32.70	35.69
Profit/(Loss) from Discontinue operation	-11.07	3.72
Operating Profit before Working Capital Change	-2.18	51.52
Ajustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	0.33	16.94
(Increase)/ Decrease in Inventories	0.00	4.94
(Increase)/ Decrease in Loans & Advances	-257.96	-52.05
Increase/ (Decrease) in Current Liabilities & Prov.	0.19	-116.43
Cash Generated from Working Capital	-257.44	-146.61
Cash generated from Operation	-259.62	-95.08
Net Income Tax Paid	0.00	0.00
Net cash Flow from Operating Activity	-259.62	-95.08
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	170.00	71.15
Sale/(Purchase) of Fixed Assets	15.00	29.82
Dividend Received	0.00	0.00
Net Cash used in Investing Activities	185.00	100.97
C. Cash Flow from Financial Activities		
Increase/ (Decrease) in Bank Borrowings	0.00	0.00
Net Cash Used in Financial Activities	0.00	0.00
Net Increase in Cash and Cash Equivalents (A+B+C)	-74.62	5.89
Cash & Cash Equivalents at the Beginning of the year	78.67	72.79
Closing of the year	4.05	78.67
Increase in Cash and Cash Equivalents	-74.62	5.89
Note: This Cash flow statement is belongs to Continuing and Discontinued operation both		
As per our report of even date annexed	For and on behalf of Board	
Rawka & Associates		
Chartered Accountants		
Firm Reg. No.: -021606C		
Venus Rawka	Ramesh Chandra Mittal	Alok K. Garg
Partner	Chairman & Director	Managing Director
Membership No. 429040	DIN:00035272	DIN: 00274321
Place : Indore		
Date : 23/05/2023		
UDIN : 23429040BGXBDZ8972	Hemant Sethi	Abhishek Jain
	C.F.O.	Company Secretary
		ACS: 36699

NOTE -1- BASIC ACCOUNTING POLICIES (STANDALONE)

1. Corporate Information:

Medi-Caps Limited ("the Company") is a Public Limited Company incorporated in India under the Companies Act, 1956 in 1983 as Medi-Caps Pvt. Ltd. The Company has permanently discontinued its manufacturing activities on 21.11.2019 and now operates in Real Estate Sector. The registered office of the Company is located at Mhow - Neemuch Road, Sector- 1, Pithampur, Dhar [MP] -454775. The financial statements were authorised to be issued in accordance with a resolution of the directors on 23rd May, 2023.

The Company's shares are listed for trading on BSE Limited.

2. Basis of preparation:

(i) Compliance with Ind AS

These financial statements have been prepared to comply in all material aspects with the Indian Accounting Standards (hereinafter referred to as the ('Ind AS')) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ('Act') read with of the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act.

(ii) Historical Cost Convention

The financial statements have been prepared and presented under the historical cost convention and on accrual basis of accounting, Indian Accounting Standards prescribed under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014, except where otherwise stated, the accounting principles have been consistently applied.

3. Rounding of amounts:

All amounts disclosed in the financial statement and notes have been rounded off to the nearest Lakhs; except where otherwise indicated.

4. Current versus non-current classification:

The company presents its assets and liabilities in the balance sheet on current/non-current classification. An Asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realised within twelve months after the reporting period; or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is Current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other Liabilities are classified as non-current.

Deferred tax liabilities are classified under non-current Liabilities.

5. Use of Estimates and Assumptions:

The preparation of financial statements in accordance with Ind AS requires subjective and complex judgments to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses at the date of these financial statements.

Estimates and underlying assumptions are reviewed at each balance sheet date. Revisions to accounting estimates are recognised in the period in which the estimate is revised and future periods affected.

In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements are as below:

- Fair value of Financial Assets and Financial liabilities,
- The useful lives of, or expected pattern of consumption of the future economic benefits embodied in, depreciable assets,
- Valuation of Inventories and Inventory obsolescence,
- Provisions and Bad Debts.

6. Revenue Recognition:

Sale of Goods

Revenue from sale of goods is recognized when the significant risks and rewards of ownership of the goods are transferred to the buyer, usually on delivery of the goods and when all the following conditions are satisfied:

- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- The costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns and allowance, trade discounts and volume rebates and does not include Value added tax (VAT), Central Sales tax (CST) and any other taxes.

7. Property, Plant and Equipment:

Property, plant and equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses. The initial cost of an asset comprises of its purchase price or construction cost, any costs directly attributable to bringing the asset into the location and condition necessary for it to be capable of operating in the manner intended by management. The purchase price or construction cost is the aggregate amount, paid and the fair value of any other consideration given to acquire the asset.

When significant parts of plants and equipments are required to be replaced at intervals, the Company depreciates them separately based on their specific useful life. All other repair and maintenance costs are recognised in Statement of Profit or Loss as and when incurred.

The residual values and useful lives of property, plant and equipment are reviewed at each financial year end and changes, if any, are accounted prospectively

Depreciation on Property, Plant & Equipment is provided on straight line method. In accordance with requirements prescribed under Schedule II of the Companies Act, 2013, Company has assessed the estimated useful lives of its property, plant and equipment and has adopted the useful lives and residual value as prescribed in Schedule II. The estimated useful lives of assets are as follows:

ASSETS	USEFUL LIFE OF ASSET
Factory Building	30 years
Office Building	30 years
Plant & Machinery	20 years
Furniture & Fixtures	10 years
Vehicles	8 years

8. Inventories:

Inventories are valued at Lower of cost or net realizable value. Costs incurred in bringing each product to its present location and conditions are accounted for as follows:

Raw materials

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Finished goods and work-in-progress

Cost includes direct materials, labour and a proportion of manufacturing overheads based on the normal operating capacity.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

9. Trade Receivable:

Trade receivables are recognized at fair value, the outstanding balances of sundry debtors, advances etc. are verified by the management periodically and on the basis of such verification management determines whether the said outstanding balance are good, bad or doubtful and accordingly same are written off or provided for.

Receivables that are expected in one year or less, are classified as current assets, if not they are presented as non-current assets.

10. Cash Flow Statement:

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

For the purpose of presentation in the Statement of Cash Flows, cash and cash equivalents includes cash in hand and Balances with Banks.

11. Investments:

The investments are valued at fair market value and are therefore reported as per relevant Ind AS-113 and Comprehensive Income consequent to the effect has been reported in Financial Statements.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value.

12. Cash and cash equivalents:

Cash and cash equivalent in the balance sheet comprise of cash in hand and at banks. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and bank balances, as defined above.

13. Share Capital:

Ordinary shares are classified as equity.

During the year there is no change in the subscribed share capital as issued by the company.

14. Earnings per Share:

Basic earnings per share is calculated by dividing the profit attributable to owners of the Company by average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders is adjusted for after income tax effect of interest and other financing costs associated with dilutive potential equity shares and the number of shares that are outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

15. Provisions:

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

16. Deferred Tax:

Deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases, and unutilized business loss and depreciation carry-forwards and tax credits. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carry-forwards and unused tax credits could be utilized.

Deferred tax assets and liabilities are measured based on the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

17. Borrowings:

Borrowings are initially recognised at fair value, net of transaction costs incurred. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in statement of profit or loss over the period of the borrowings. Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

18. Borrowings Cost:

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur.

The Company ceases capitalising borrowing costs when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete.

19. Trade payables:

These amounts represent liabilities for goods that have been acquired in the ordinary course of business from suppliers. Trade payables are presented as current liabilities unless payment is not due within 12 months after the reporting period.

20. Current Tax:

Tax on income for the current period is determined on the basis of estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments / appeals.

Where current tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

21. Employee Benefits:

Gratuity:

The Employee's Gratuity Fund Scheme, which is defined benefit plan, is managed by Trust maintained with Life Insurance Corporation of India (LIC). The liability with respect to Gratuity is made as per the method stipulated in the payment of gratuity Act, 1972.

22. Financial Instruments and Risk Review:

The Company's principal Financial Assets include investments, trade receivables, cash and cash equivalents, other bank balances and loan. The Company's financial liabilities comprise of borrowings and trade payables.

23. Fair Value Hierarchy:

The Fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of the following three levels:

Level 1- Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities,

Level 2- Inputs are other than quoted prices included within Level-1 that are observable for the assets or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3- Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on the assumptions that are neither supported by prices from observable current market transactions in the instrument nor are they based on available market data. The following table summarises carrying amounts of financial instruments by their categories and their values in fair value hierarchy for each year presented.

For 31st March, 2023

(Amount in Lacs)

Particulars	FVTPL			FVTOCI	Amortized Cost	Total
	Level-1	Level-2	Level-3			
Financial Assets						
Investments	0	0	0	5197.57	0	5197.57
Trade Receivables	0	0	0	0	223.82	223.82
Cash & Cash Equivalents	0	0	0	0	4.05	4.05
Other Bank Balances	0	0	0	0	0	0
Loans	0	0	0	0	0	0
Derivative Assets	0	0	0	0	0	0
Other Financial Assets	0	0	0	0	0	0
Total	0	0	0	5197.57	227.87	5425.44
Financial Liabilities						
Borrowings	0	0	0	0	0	0
Trade Payables	0	0	0	0	0	0
Derivative Liabilities	0	0	0	0	0	0
Other Financial Liabilities	0	0	0	0	0	0
Total	0	0	0	0	0	0

For 31st March, 2022

Particulars	FVTPL			FVTOCI	Amortized Cost	Total
	Level-1	Level-2	Level-3			
Financial Assets						
Investments	0	0	0	5367.57	0	5367.57
Trade Receivables	0	0	0	0	224.16	224.16
Cash & Cash Equivalents	0	0	0	0	11.06	11.06
Other Bank Balances	0	0	0	0	67.61	67.61
Loans	0	0	0	0	0	0
Derivative Assets	0	0	0	0	0	0
Other Financial Assets	0	0	0	0	0	0
Total	0	0	0	5367.57	302.83	5670.40
Financial Liabilities						
Borrowings	0	0	0	0	0	0
Trade Payables	0	0	0	0	0	0
Derivative Liabilities	0	0	0	0	0	0
Other Financial Liabilities	0	0	0	0	0	0
Total	0	0	0	0	0	0

Note-02- Property , Plant and Equipments Amount in Lacs.

S. No	PARTICULAR	GROSS CARRYING AMOUNT				DEPRECIATION				NET BLOCK		Useful Life
		As at 31.03.2022	Additions	Deductions	As at 31.03.2023	Up to 31.03.2022	For the year	Deletions	Upto 31.03.2023	As at 31.03.2023	As at 31.03.2022	
Own Assets:												
1	Free Hold Land	11.78	0.00	0.00	11.78	0.00	0.00	0.00	0.00	11.78	11.78	
2	Factory Building	239.05	0.00	0.00	239.05	209.53	6.78	0.00	216.32	22.73	29.51	30 Years
3	Office Building	191.21	0.00	0.00	191.21	65.91	6.56	0.00	72.48	118.74	125.30	30 Years
4	Plant & Machinery	1313.50	0.00	300.00	1013.50	1247.83	0.00	285.00	962.83	50.68	65.68	20 Years
5	Furniture & Fixtures	70.60	0.00	0.00	70.60	69.42	0.00	0.00	69.42	1.18	1.18	10 Years
6	Vehicles	150.46	0.00	0.00	150.46	106.41	2.67	0.00	109.08	41.38	44.05	8 Years
7	Computers	22.82	0.00	0.00	22.82	22.82	0.00	0.00	22.82	0.00	0.00	3 Years
	TOTAL	1999.42	0.00	300.00	1699.42	1721.92	16.01	285.00	1452.93	246.49	277.50	
	PREVIOUS YEAR	2113.17	0.00	113.75	1999.42	1787.67	18.19	83.93	1721.92	277.50	325.51	

Note :

1 During the year depreciation on computer not charged, Since Computer has depreciated fully earlier but nominal value of Rs. 1- kept in books because computer exist in physical form at the year end.

MEDI-CAPS LIMITED
Notes on Financial Statement for the year ended 31st March, 2023

		Amount in Lacs.	
		As at 31st March 2023	As at 31st March 2022
Note : 03 Non-Current Investments			
a)	Investment in properties	107.93	107.93
b)	Investment in Equity instruments		
i)	Trade Investment (Unquoted) In Subsidiary Company 1,46,81,953 (1,46,81,953) Equity Share of Rs. 10/- each of Medgel Private Limited	4282.35	4282.35
		4282.35	4282.35
ii)	Investment in Equity Instrument (Quoted) 100 (100) Equity Shares of Natural Capsules	0.39	0.46
		0.39	0.46
		4390.67	4390.74
	Aggregate amount of quoted Investments	0.01	0.01
	Aggregate Market value of quoted Investments	0.39	0.46
	Aggregate amount of unquoted Investments	4390.28	4390.28
	Aggregate amount of impairment in value of Investment	0.00	0.00
Note : 04 Other Non Current Assets			
(Unsecured, considered good unless otherwise stated)			
	Security Deposits	4.91	5.02
		4.91	5.02
Note : 05 Inventories			
Value at Cost or Net Realisable Value, Whichever is Lower			
	Raw Materials	0.00	0.00
	Finished Goods	0.00	0.00
	Stores and Spares	0.00	0.00
	Packing Material	0.00	0.00
		0.00	0.00
Note : 06 Current Investment			
Investment in Mutual Funds (Quoted)			
	Axis Focused 25 Fund	8.57	10.13
	IDFC Equity Fund	121.17	124.80
	Reliance Top 200 Equity Fund	139.27	130.73
	HDFC Low Duration Fund	370.05	337.97
	HDFC Banking & PSU	18.08	41.53
	Birla Mutual Fund	0.02	37.55
	Reliance Money Manager Fund- Growth	149.74	294.11
		806.90	976.83
	Aggregate amount of quoted Investments	614.41	751.71
	Aggregate Market value of quoted Investments	806.90	976.83
	Aggregate amount of unquoted Investments	0.00	0.00
	Aggregate amount of impairment in value of Investment	0.00	0.00
		As at 31st March 2023	As at 31st March 2022
Note : 07 Trade Receivables			
(a)	Trade Receivables considered good - Secured		
(b)	Trade Receivables considered good - Unsecured	223.82	224.16
(c)	Trade Receivables which have significant increase in credit risk		
(d)	Trade Receivables- Credit impaired		
		223.82	224.16



As on 31st March 2023

Note : 7A Trade Receivables Ageing Schedule

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(a) Trade Receivables considered good - Secured						
(b) Trade Receivables considered good - Unsecured	0	0	0.00	0.00	223.82	223.82
(c) Trade Receivables which have significant increase in credit risk						
(d) Trade Receivables- Credit impaired						

As on 31st March 2022

Note : 7A Trade Receivables Ageing Schedule

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(a) Trade Receivables considered good - Secured						
(b) Trade Receivables considered good - Unsecured	0.34	0	0.00	157.46	66.36	224.16
(c) Trade Receivables which have significant increase in credit risk						
(d) Trade Receivables- Credit impaired						

	As at 31st March 2023	As at 31st March 2022
Note : 08 Cash & Cash Equivalents		
(a) Balances with banks In Current Accounts	3.95	10.97
(b) Cheques, drafts on hands	0.00	0.00
(c) Cash on Hand	0.09	0.09
Note : 09 Bank Balance other than above	4.05	11.06
Balance with Scheduled Banks : In Fixed Deposit Accounts	0.00	67.61
(a) Earmarked balances With bank	0.00	0.00
(b) Balances held as margin money or security against guarantees and other commitments	0.00	0.00
	0.00	67.61

Note : 10 Other Current Assets		
(Unsecured & Considered Good - Advance recoverable in Cash or in kind or for value to be received)		
(i) Advances other than capital advances Advance to Suppliers & Others	211.22	51.00
(ii) Others		
Balance with Government Authorities	0.00	0.00
Advance Tax & TDS (Net of Provisions)	195.32	169.29
Pre-Operative Exp.	7.34	7.34
Deposit with Banks (FDR)	71.82	0.00
Other Loans & Advances	0.00	0.00
	485.70	227.63

	Amount in Lacs.	
	As at 31st March 2023	As at 31st March 2022
Note : 11 Equity		
Authorised Share Capital : 1,50,00,000 Equity Shares of Rs. 10/- each (Previous Year 1,50,00,000 Equity Shares of Rs. 10/- each)	1500.00	1500.00
Issued Share Capital: 1,24,69,956 Equity Shares of Rs. 10 each fully paid up (Previous Year 1,24,69,956 Equity Shares of Rs.10/- each)	1247.00	1247.00
Subscribed and Paid Share Capital: 1,24,69,956 Equity Shares of Rs. 10 each fully paid up (Previous Year 1,24,69,956 Equity Shares of Rs.10/- each)	1247.00	1247.00
	1247.00	1247.00

Note: The Company has only one class of equity shares at a par value of Rs. 10. All the equity shares carry equal rights and obligations including the right to receive dividend and also with respect to voiting rights.

Reconciliation of the equity shares outstanding at the beginning and at the end of the year				
	As at March 31, 2023		As at March 31, 2022	
	Numbers	Value	Numbers	Value
Equity Shares				
At the beginning of the year	12469956	1247.00	12469956	1247.00
Issued during the year	-	-	-	-
Outstanding at the and the year	12469956	1247.00	12469956	1247.00

Details of Shareholders holding more than 5 percent shares in the company				
Name of Shareholders	No. of Shares as at			
	31.03.23	% of Holding	31.03.22	% of Holding
Alok K Garg	3225920	25.87%	3225920	25.87%
Manisha Garg	2694820	21.61%	2694820	21.61%
Sangeetha S	694400	5.57%	694400	5.57%

Shares held by promoters at the end of the year					
Name of Promoter	31-Mar-2023		31-Mar-2022		% Change
	No. of shares	% Held	No. of shares	% Held	
R.C.Mittal	10000.00	0.08%	10000.00	0.08%	0.00%
Alok K Garg	3225920.00	25.87%	3225920.00	25.87%	0.00%
MANISHA GARG	2694820.00	21.60%	2694820.00	21.60%	0.00%
NIRMALA ANANTRAM MITAL	3172.00	0.03%	3172.00	0.03%	0.00%
TRAPTI INVESTMENTS LLP	307128.00	2.46%	307128.00	2.46%	0.00%
KUSUM MITTAL	10000.00	0.08%	10000.00	0.08%	0.00%
GITIKA AGRAWAL	400.00	0.00%	400.00	0.00%	0.00%

	Amount in Lacs.	
	As at 31st March 2023	As at 31st March 2022
Note : 12 Other Equity		
Capital Reserve		
Opening Balance	9.90	9.90
Less: Adjustment for Investment in Share Written Off	0.00	0.00
	9.90	9.90
Share Forfeiture A/c		
As per last balance sheet	27.55	27.55
General Reserve		
As per last balance sheet	304.57	304.57
Surplus		
Opening balance of Profit & Loss A/c	4314.21	4318.01
Add: Net profit for the current year	14.65	-3.80
Closing Balance	4328.86	4314.21
Other Comprehensive Income		
Opening balance of Other Comprehensive Income	225.57	189.88
Add: Other Comprehensive Income	-32.70	35.69
Closing Balance	192.87	225.57
	4863.75	4881.80

Explanation to the Note No. 12 Other Equity

Capital Reserve

The Capital Reserve has been created as per the requirement of earlier provisions of The Companies Act, 1956. Such reserve is not available for distribution to the shareholders.

General Reserve

The Company has transferred a portion of the net profit before declaring dividend to General Reserve pursuant to earlier provision of The Companies Act, 1956. As transfer to the general reserve is not mandatorily required under The Companies Act, 2013.

	As at 31st March 2023	As at 31st March 2022
Note : 13 Provisions		
Provision for Employee Benefit-Gratuity	0.00	0.00
	0.00	0.00

	As at 31st March 2023	As at 31st March 2022
Note : 14 Deferred Tax Liability		
On Depreciation (Difference as per Books & as per I.T. Act)	43.98	44.13
	43.98	44.13

	As at 31st March 2023	As at 31st March 2022
Note : 15 Trade Payable		
Total Outstanding dues to Micro & Small Enterprises	0.00	0.00
Total Outstanding dues of Creditors other than Micro & Small Enterprises	0.00	0.05
	0.00	0.05

As on 31st March 2023

Note : 15A Trade Payable Ageing Schedule

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					
(ii) Others	0				0
(iii) Disputed Dues- MSME					
(iv) Disputed Dues- Others					

As on 31st March 2022

Note : 15A Trade Payable Ageing Schedule

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					
(ii) Others	0.05				0.05
(iii) Disputed Dues- MSME					
(iv) Disputed Dues- Others					

	As at 31st March 2023	As at 31st March 2022
Note : 16 Other Current Liabilities		
(a) Revenue Received in Advance		
(b) Other Advances		
(c) Others		
Audit Fee Payable	0.27	0.27
Commission Payable	4.86	4.86
GST Payable	0.01	0.59
Salary Payable	1.56	1.77
Professional Tax	0.01	0.01
TDS on Consultancy	0.04	0.07
TDS on Contractor Payment	0.43	0.00
Outstanding Expenses	0.64	0.00
	7.81	7.57

Note :17 Current Tax Liability		
For Taxation	0.00	0.00
	0.00	0.00

NOTES TO PROFIT & LOSS STATEMENT

	Amount in Lacs.	
	For the Year Ended 31st March 2023	For the Year Ended 31st March 2022
Note : 18 Revenue from Operation		
Sale of product	0.00	0.00
Other Operating Income		
Misc. Income	0.27	0.00
Interest Income	4.78	0.00
Lease Rent	5.08	0.00
	10.14	0.00

Note :19 Other Incomes		
(a) Interest Income	0.00	5.42
(b) Dividend income	0.00	0.00
(c) Other Non-operating income		
Lease Rent	0.00	5.08
Capital gain / (Loss) on Mutual Fund	64.46	42.72
Profit on sale of Fixed Assets	0.00	4.74
Foreign Exchange Rate Difference	0.00	0.00
Misc. Income	0.00	2.77
	64.46	60.74

Note : 20 Cost of Materials Consumed		
A) Raw Material Consumed		
Opening Stock	0.00	0.00
Purchases	0.00	0.00
	0.00	0.00
Less : Closing Stock	0.00	0.00
Raw Material Consumed	0.00	0.00
B) Packing Material Consumed		
Opening Stock	0.00	0.47
Less: Goods removed	0.00	0.47
Purchases	0.00	0.00
	0.00	0.00
Less : Closing Stock	0.00	0.00
Packing Material Consumed	0.00	0.00
Grand total of Materials Consumed (A) + (B)	0.00	0.00

Note : 21 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade		
Closing Stock of :		
Finished Goods	0.00	0.00
Stock in Process	0.00	0.00
Waste	0.00	0.00
Total (A)	0.00	0.00
Opening Stock of :		
Finished Goods	0.00	0.00
Stock in Process	0.00	0.00
Waste	0.00	0.00
Total (B)	0.00	0.00
Increase/(Decrease) in Stock (A-B)	0.00	0.00

	Amount in Lacs.	
	For the Year Ended 31st March 2023	For the Year Ended 31st March 2022
Note : 22 Employees Remuneration & benefits		
Salary, Wages, Allowances & other Benefits	22.90	28.40
Directors Remuneration	0.00	0.00
Gratuity	0.00	16.73
Staff Welfare Exp.	0.36	0.00
	23.26	45.13

Note : 23 Finance Charges		
Interest	0.00	0.00
	0.00	0.00

Note : 24 Other Expenses		
Advertisement & Publicity	0.42	0.62
Audit Fee	0.30	0.30
Annual Listing Fees	3.94	3.90
Bank Charges	0.33	0.16
Consultancy Charges	2.67	2.48
Conveyance Expenses	1.05	0.15
Insurance Charges	1.31	0.04
Interest on vat/ex.duty/gst	0.00	0.95
Legal Expenses	0.00	0.10
Membership Fee & Subscription	0.28	0.54
Misc. Expenses	2.82	0.03
News Paper & Periodicals	0.03	0.00
Office & General Expenses	0.01	0.04
Power & Electricity Exp.	0.21	0.00
Postage, telegram	0.09	0.01
Printing & Stationary	0.15	0.15
Professional Tax for Company	0.03	0.03
Rent, Rates & Taxes	1.24	0.95
ROC Exp.	0.89	0.52
Repairs & Maintenance		
Other	0.00	0.11
Telephone & Mobile Exp.	0.09	0.00
Vehicle Running & Maintenance	0.44	1.19
Website Maintenance Charges	0.20	0.19
	16.53	12.46

Note 25 Segment Information

The Company has only one reportable segment i.e., Real Estate division as the Company has discontinued its Pharma division w.e.f. 21/11/2019.

Note 26 Deferred Tax

Information on deferred tax has been provided in accordance with Ind AS-12 Accounting for taxation on income, issued by the Institute of Chartered Accountants of India.

The deferred tax assets for the year is Rs.0.14 Lakhs has been recognised in the profit & Loss Account.

			Amount in Lacs.	
Note 27 Income/(Loss) from Discontinue Operation			For the Year Ended 31st March 2023	For the Year Ended 31st March 2022
I.	Revenue from Finished Stock Sold		0.00	0.00
II.	Other Income		3.19	24.43
III.	Total Income (I +II)		3.19	24.43
IV.	Expenses:		0.00	4.94
	Changes in inventories:			
	Closing Stock of :	2022-23	2021-22	
	Finished goods	0.00	0.00	
	Stock in Packing Material	0.00	0.00	
	Stock in Stores & Spares	0.00	0.00	
		0.00	0.00	
	Opening Stock of :			
	Finished goods	0.00	0.00	
	Stock in Packing Material	0.00	0.47	
	Stock in Stores & Spares	0.00	4.46	
		0.00	4.94	
	Increase/(Decrease) in Stock (A-B)	0.00	4.94	
	Depreciation and amortization expense		6.78	8.96
	Electricity & Water		0.48	0.43
	Freight Expenses		0.00	0.02
	Factory Expenses		0.31	0.29
	Buildings		6.68	6.08
V.	Total Expenses		14.25	20.71
	Net Profit/(Loss) From Discontinue Operation		-11.07	3.72

Note 28 Payment to Auditors		
Audit Fees	0.30	0.30
	0.30	0.30

Note 29 Related Party Disclosure

Information on Related party transactions as per Ind AS 24 on related party disclosure:

S.No	Related Party	Transactions		
1	Medgel Pvt. Ltd. Subsidiary Company (on arm length basis in the ordinary course of business)	Purchase Sale Guarantee Investment	0.00 0.29 0.00 4282.35	0.00 1.04 200.00 4282.35
2	Medicaps Charitable Trust	Lease Rent (Inclusive of GST) Sales of Misc. Items (Inclusive of GST)	6.00 0.00	6.00 0.00
3	Mr. Abhishek Jain (Company Secretary appointed w.e.f. 08/10/2021)	Remuneration	5.24	2.67
4	Mr. Hemant Sethi (Chief Financial Officer)	Remuneration	10.85	8.86
5	Ms. Ayushi Silot (Company Secretary resigned w.e.f. 07/10/2021)	Remuneration	0.00	1.55

Note 30 Contingent Liability

The company has provided a corporate guarantee in favour of its wholly owned Subsidiary, Medgel Private Limited towards a cash credit limit of Rs. 2 Crore availed from IDBI Bank Limited, Indore, Which has been withdrawn during the financial year.

Note 31 Earning Per Share

Earning per share, the numerator and denominator used to calculate Basic and Diluted Earning per shares:

		2022-23	2021-22
i)	Profit after tax used as the numerator	14.65	-3.80
ii)	Basic / Weighted Average number of Equity Shares used as the denominator	12469956	12469956
iii)	Nominal Value of Equity shares	10/-	10/-
iv)	Basic & Diluted Earning per Equity Share		
	For Continuing Operation	0.21	-0.06
	For Discontinued Operation	-0.09	0.03
	For Continuing and Discontinued Operation	0.12	-0.03

Note 32 Employee Benefits	2022-23	2021-22
a. Defined benefits plan		
I Change in obligation during the year		
1 Present value of Defined benefit obligation at beginning of year	0.00	13.48
2 Current Service Cost	0.00	0.00
3 Past Service Cost	0.00	0.00
4 Interest Cost	0.00	0.00
5 Actuarial (Gains) / Losses	0.00	0.00
6 Benefits Paid	0.00	-13.48
7 Present value of Defined benefit obligation at the end of the year	0.00	0.00
II Change in assets during the year ended March 31		
1 Plan assets at the beginning of the year	0.00	7.41
2 Settlements	0.00	0.00
3 Expected return on plan assets	0.00	0.00
4 Contribution by Employer	0.00	0.00
5 Actual benefits paid	0.00	-13.48
6 Deductions	0.00	6.07
7 Plan assets at the end of the year	0.00	0.00
III Net Assets / (Liability) recognized in the Balance Sheet at March 31		
1 Present value of Defined benefits Obligation as at March 31.	0.00	0.00
2 Fair value of plan assets as at March 31	0.00	0.00
3 Fund Status (Surplus / (Deficit))	0.00	0.00
4 Net Assets / (Liability) as at end of the year	0.00	0.00
IV Expenses recognised in the Statement of Profit & Loss for the year ended March 31		
1 Current Service Cost	0.00	0.00
2 Interest Cost	0.00	0.00
3 Expected return on plan assets	0.00	0.00
4 Past service cost	0.00	0.00
5 Net Actuarial (Gains) / Losses	0.00	0.00
6 Total Expenses (Net)	0.00	0.00
V The major categories of plan assets as a percentage of total plan	N.A.	N.A.
b. Contribution to provident fund and other funds stated under defined contribution plans is Rs. 0.00 Lacs (Previous year Rs. 0.00 Lacs).		

Note 33: The Company does not have outstanding for more than 30 days as on 31st March 2023 of S.S.I units of the respective parties.

Note 34: The previous year's figures have been regrouped/ restated wherever necessary to confirm with the current years classification.

Note 35: Ratio

Ratios	Numerator	Denominator	FY 2022-23	FY 2021-22	Change	Explanation
Current Ratio (in times)	Total Current Assets	Total Current Liabilities	194.66	197.73	-1.55%	N.A.
Debt-Equity Ratio (in times)	Long Term Borrowings+ Short Term Borrowings	Total Equity	-	-		N.A.
Debt-Service Coverage Ratio	Earnings for Debt service = Net profit after tax + Non- cash operating expenses + interest + other non cash adjustments+ Interest on debt debited in P&L	Debt service = Interest + Principal Repayment (Non-Current debts only)	-	-		N.A.
Return on Equity Ratio (in times)	Profit for the year less preference dividend (if any)	Average Total Equity	0.0024	-0.0012	292.86%	During the year the company earned a profit which resulted into better ROE.
Inventory Turnover Ratio (in times)	Revenue From Operations	Average Inventory	-	-		N.A.
Trade Receivable Turnover Ratio (in times)	Revenue From Operations	Average Trade Receivable	-	-		N.A.
Trade Payable Turnover Ratio (in times)	Revenue From Operations	Average Trade Payable	-	-		N.A.
Net Capital Turnover Ratio (in times)	Revenue From Operations	Working Capital (i.e. Total current assets less Total Current Liabilities)	-	-		N.A.
Net Profit Ratio (in %)	Profit for the year before exception items	Revenue From Operations				N.A.
Return On Capital Employed	Profit Before Tax And Finance Costs	Average capital Employed Capital Employed = Net Worth + Deferred Tax Liabilities	-	-		N.A.
Return on Investment	Income Generated from Investment Funds	Average invested Funds	0.072	0.087	-17.37%	N.A.

Note 36: Other Statutory Information-

- The Company has not borrowed any funds from banks and financial institutions for any specific purpose.
- All the immovable properties title deeds are held in the name of the company and Company is the sole owner of these immovable properties.
- The Company does not have any Benami property, and no proceeding has been initiated or is pending against the Company for holding any Benami property.
- The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- The Company does not have any transactions with companies struck off.
- The Company has charges which are yet to be registered with ROC beyond the statutory period the details of which are:

Details of Charges yet to be registered with ROC				
Charge ID	Charge Holder's Name	Date of Creation	Amount	Reason
90207250	Bank of Baroda	24/03/1992	3.00	The Company has filed the forms for satisfaction of charge in physical mode and the same are not traceable as the matter is very old. The Company has made several requests to the ROC for deletion of the charge ID; however, in absence of the adequate evidence same could not be processed. Due to that only these charges are still being reflected on MCA Portal.
90202622	Bank of Baroda	05/10/1990	10.00	
90204557	Bank of Baroda	24/07/1986	7.00	

- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- The Company has not issued any security for a specific purpose.
- The Company has not proposed or declare dividend during the year
- The Company has initiated the legal proceedings under section 138 of negotiable instruments act and u/s 420 of the Indian penal code, against Jay formulation Limited before First Class Civil Judge, District Court, Indore. The same has been initiated for recovery of sale proceedings.

INDEPENDENT AUDITORS' REPORT ON CONSOLIDATED FINANCIAL STATEMENTS

To,
The Members,
MEDICAPS LIMITED,
Pithampur (M.P.)

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Ind AS Consolidated Financial Statements of **Medicaps Limited** ("the Company") and its subsidiary **Medgel Private Limited** (the Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2023, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date and notes to the consolidated financial statement and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the Ind AS Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS Consolidated Financial Statements give the information required by the **Companies Act, 2013** (the "Act") in the manner so required and give a true and fair view in conformity with Indian Accounting Standards prescribed under section 133 of the Act read with the **Companies (Indian Accounting Standards) Rules, 2015**, as amended ("Ind AS") and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2023, the consolidated profit, consolidated total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Ind AS Consolidated Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Ind AS Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Ind AS Consolidated Financial Statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS Consolidated Financial Statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Ind AS Consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the Ind AS Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Information Other than the Ind AS Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Corporate Governance and Shareholder's Information, but does not include the Ind-AS Consolidated Financial Statements, Standalone Financial Statements and our auditor's report thereon.

Our opinion on the Ind AS Consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Ind AS Consolidated Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Ind AS Consolidated Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed we conclude that there is a material misstatement of this other information, we are required to communicate the matter to those charged with Governance. We have nothing to report in this regard.

Management's Responsibility for the Ind AS Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to preparation of these Ind AS Consolidated Financial Statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for maintenance of the adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Ind AS Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Ind AS Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Ind AS Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Ind AS Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Ind AS Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company and its subsidiary companies which are companies incorporated in India, has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Ind AS Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Ind AS Consolidated Financial Statements, including the disclosures, and whether the Ind AS Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Ind AS Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements, which have been audited by our auditors, such other auditors remains responsible for the direction, supervision and performance of the audits carried out by them. We are solely responsible for our audit opinions.

Materiality is the magnitude of misstatements in the Ind AS Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Ind AS Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

PLACE: INDORE

DATE: 23/05/2023

UDIN: 23429040BGXBDY3508

FOR: RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
FIRM REG. NO: 021606C

VENUS RAWKA
(PARTNER)
M. NO.: 429040

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Ind AS Consolidated Financial Statements.

b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Ind AS Consolidated Financial Statements have been kept so far as it appears from our examination of those books.

c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Ind AS Consolidated Financial Statements.

d) In our opinion, the aforesaid Ind AS Consolidated Financial Statements comply with the Ind AS specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended.

e) On the basis of the written representations received from the directors of the Company as on March 31, 2023 taken on record by the Board of Directors of the Company and its subsidiaries incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting and the operating effectiveness of such controls; refer to our separate Report in “Annexure A” which is based on the auditor’s reports of the Company and its subsidiary companies incorporated in India. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the internal financial control over financial reporting of those companies, for reasons stated therein.

g) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company and its subsidiary Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the **Companies (Audit and Auditors) Rules, 2014**, as amended in our opinion and to the best of our information and according to the explanations given to us :

i) The Ind AS Consolidated Financial Statements disclose impact of pending litigations on the consolidated financial position of the Group. The group has following pending litigations which are stated in the table below.

Name of the Statute	Nature of Dues	Forum where dispute is pending	Period to which the amount relates	Amount Involved	Amount Unpaid
Income Tax Act, 1961	Income Tax	CIT(A)	A.Y. 2017-18	Rs. 9,86,409/-	Rs. 7,88,128/-
Income Tax Act, 1961	Income Tax	ITAT	A.Y. 2018-19	Rs. 20,44,810/-	Rs. 20,44,810/-
Income Tax Act, 1961	Income Tax	CIT(A)	A.Y. 2014-15	Rs. 3,77,00,360/-	Rs. 3,77,00,360/-

ii. Provision has been made in the Ind AS Consolidated Financial Statements, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long term contracts including derivative

iii. The company was not required to transfer any amount to Investor Education and Protection Fund during the financial year.

iv.

a. The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entities, including foreign entities (“Intermediaries”), with the understanding whether recorded in writing or not that the intermediary shall whether directly or indirectly lend or invest in other persons or entities identified in any manner by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of ultimate beneficiaries.

b. The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the company from any person(s) or entities including foreign entities (“Funding Parties”) with the understanding that such company shall whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or provide guarantee, security or the like on behalf of the Ultimate beneficiaries.

c. Based on the audit procedures performed, we report that nothing has come to our notice that has caused us to believe that the representations given under sub-clause (i) and (ii) by the management contain any material mis-statement.

d. No dividend has been declared or paid by the Company during the year.

2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor’s Report) Order, 2020 (the “Order”/“CARO”) issued by the Central Government in terms of section 143(11) of the Act, to be included in

the Auditor's Report, according to the information and explanations given to us and based on the CARO report issued by us for the company and its subsidiaries included in the consolidated financial statements of the company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO Reports.

PLACE: INDORE
DATE: 23/05/2023
UDIN: 23429040BGXBDY3508

FOR: RAWKA & ASSOCIATES
 CHARTERED ACCOUNTANTS
 FIRM REG. NO: 021606C

VENUS RAWKA
 (PARTNER)
 M. NO.: 429040

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 1 (f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Medicaps Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the Ind AS Consolidated Financial Statements of the Company as of and for the year ended March 31, 2023, we have audited the internal financial controls over financial reporting of **Medicaps Limited** (hereinafter referred to as "Company") and its subsidiary companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company and its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the respective Companies considering the essential components of internal control stated in the **Guidance Note on Audit of Internal Financial Controls Over Financial Reporting** issued by the Institute of Chartered Accountants of India ("the ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India, based on our audit. We conducted our audit in accordance with the **Guidance Note on Audit of Internal Financial Controls Over Financial Reporting** (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing, prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the Company and its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal

financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

PLACE: INDORE

DATE: 23/05/2023

UDIN: 23429040BGXBDY3508

FOR: RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

FIRM REG. NO: 021606C

VENUS RAWKA

(PARTNER)

M. NO.: 429040

MEDI-CAPS LIMITED			
Consolidated Balance Sheet as at 31st March, 2023			
CIN: L70100MP1983PLC002231			
		Amount in Lacs	
Particulars	Note	As at 31st March 2023	As at 31st March 2022
Assets			
-1 Non-current assets			
(a) Property, Plant and Equipment	2	3076.73	3117.21
(b) Capital Work in Progress	2	0.00	24.34
(c) Goodwill	2	2814.15	2814.15
(d) Financial Assets			
i. Investments	3	648.73	371.76
ii. Other Financial Assets			
(e) Other non-current assets	4	38.58	38.69
Sub-Total - Non Current Assets		6578.19	6366.15
-2 Current assets			
(a) Inventories	5	706.90	1184.97
(b) Financial Assets			
i. Investments	6	2558.70	2695.65
ii. Trade receivables	7	846.44	1007.19
iii. Cash and cash equivalents	8	111.36	22.83
iv. Bank Balance other than (iii) above	9	0.00	952.66
(c) Other current assets	10	1797.05	805.60
Sub-Total - Current Assets		6020.45	6668.90
Total		12598.65	13035.05
II. EQUITY AND LIABILITIES			
-1 Equity			
(a) Equity Share Capital	11	1247.00	1247.00
(b) Other Equity	12	10610.12	10378.60
Equity attributable to owners of the Company			
Non Controlling interest			
Total - Equity		11857.12	11625.60
-2 Liabilities			
A Non-Current Liabilities			
(a) Provisions	13	180.87	45.34
(b) Deferred tax liabilities (Net)	14	43.98	44.13
Sub-Total - Non Current Liabilities		224.86	89.47
-3 Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		0.00	0.00
(ii) Trade payables			
(a) Total Outstanding dues of Micro enterprises and Small enterprises: and		0.00	0.00
(b) Total Outstanding dues of creditors other than Micro enterprises and Small enterprises	15	282.94	1168.03
(b) Other current liabilities	16	233.71	151.95
(c) Current Tax Liabilities (Net)	17	0.00	0.00
Sub-Total -Current Liabilities		516.66	1319.98
Total		12598.65	13035.05
The Notes referred to above are integral part of Financial Statement.			
Note on Accounts as Note '1 to 33'			
As per our report of even date,		For and on behalf of the board ,	
Rawka & Associates			
Chartered Accountants			
Firm Reg. No.:-021606C			
Venus rawka		Ramesh Chandra Mittal	
Partner		Chairman & Director	
Membership No. 429040		DIN :00035272	
Place : Indore			
Date: 23/05/2023		Hemant Sethi	
UDIN: 23429040BGXBDY3508		C.F.O.	
		Alok K. Garg	
		Managing Director	
		DIN :00274321	
		Abhishek Jain	
		Company Secretary	
		ACS: 36699	

MEDI-CAPS LIMITED				
Consolidated Profit and Loss statement for the year ended 31st March, 2023				
CIN: L70100MP1983PLC002231				
Amount in Lacs				
Particulars	Note	For the year ended 31st March 2023	For the year ended 31st March 2022	
I. Revenue from operations	18	4937.10	6987.11	
II. Other Income	19	160.32	191.42	
III. Total Income (I +II)		5097.42	7178.53	
IV. Expenses:				
Cost of materials consumed	20	2205.25	3004.63	
Purchase of stock in trade		0.00	0.00	
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	21	85.21	6.43	
Taxes on sale of goods		0.00	0.00	
Employee benefit expense	22	768.92	771.01	
Finance Cost	23	0.16	0.02	
Depreciation and amortization expense	2	174.32	181.32	
Other expenses	24	1355.28	2196.87	
Corporate Social Responsibility Expenses	25	16.20	12.50	
Total Expenses		4605.34	6172.77	
Profit before exceptional and extraordinary items and tax (III - IV)		492.08	1005.77	
VI. Exceptional Items		0.00	0.00	
VII. Profit before extraordinary items and tax (V - VI)		492.08	1005.77	
VIII. Extraordinary Items		0.00	0.00	
IX. Profit before tax (VII - VIII)		492.08	1005.77	
X. Tax expense:				
(1) Current tax		122.00	0.00	
(2) Earlier year (excess)/Short provision for tax written back		183.58	0.00	
(3) Deferred tax		-0.14	1.44	
XI. Profit/(Loss) for the period From Continuing Operation (IX - X)		186.64	1004.32	
XII. Profit/(Loss) From Discontinue Operation		-11.07	3.72	
XIII. Total Profit (Loss) For the Period		175.57	1008.05	
XIV. Profit or Loss Attributable to owners of Parents		175.57	1008.05	
XV. Profit or Loss Attributable to non-Controlling Interest		0.00	0.00	
XVI. Other Comprehensive Income				
(i) Items that will not be reclassified to Profit and Loss		55.95	146.32	
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss				
(iii) Items that will be reclassified to Profit or Loss				
(iv) Income Tax relating to items that will be reclassified to Profit or Loss				
Total Comprehensive Income for the period comprising Profit(Loss) and other				
XVII. comprehensive income for the period (XIV+XVI)		231.52	1154.37	
XVIII. Total Comprehensive Income Attributable to owners of Parents		231.52	1154.37	
XIX. Total Comprehensive Income Attributable to non-Controlling Interest		0.00	0.00	
XV. Earning per equity share:	29			
For Continuing Operation				
(1) Basic		1.50	8.05	
(2) Diluted		1.50	8.05	
For Discontinued Operation				
(1) Basic		-0.09	0.03	
(2) Diluted		-0.09	0.03	
For Continuing and Discontinued Operation				
(1) Basic		1.41	8.08	
(2) Diluted		1.41	8.08	
The Notes referred to above are integral part of Financial Statement.				
Note on Accounts as Note '1 to 33'				
As per our report of even date,		For and on behalf of the board ,		
Rawka & Associates				
Chartered Accountants				
Firm Reg. No.:021606C				
Venus Rawka		Ramesh Chandra Mittal		Alok K. Garg
Partner		Chairman & Director		Managing Director
Membership No. 429040		DIN :00035272		DIN :00274321
Place : Indore				
Date : 23/05/2023				
UDIN: 23429040BGXBDY3508		Hemant Sethi		Abhishek Jain
		C.F.O.		Company Secretary
		ACS: 36699		

MEDI CAPS LIMITED							
Consolidated Statement of Changes in Equity for the period ended 31.03.2023							
CIN: L70100MP1983PLC002231							
Amount in Lacs.							
A. Equity Share Capital							
(1) Current reporting Period							
Equity Share Capital Rs. 10 Each	Balance at the Beginning of the reporting period	Changes in equity share capital due to prior period errors	Restated balance at the beginning of the reporting period	Changes in equity share capital during the year	Balance at the end of the reporting period		
2022-23	1247.00	0	0	0	1247.00		
(2) Previous reporting Period							
Equity Share Capital Rs. 10 Each	Balance at the Beginning of the reporting period	Changes in equity share capital due to prior period errors	Restated balance at the beginning of the reporting period	Changes in equity share capital during the year	Balance at the end of the reporting period		
2021-22	1247.00	0	0	0	1247.00		
B. Other Equity							
(1) Current reporting Period 2022-23							
	Reserves and Surplus						
	General Reserves (specify nature)	Share Forfeiture account	Securities Premium	Capital Reserve	Retained Earnings	Other Items of Other Comprehensive Income	Total
Balance at the beginning of the reporting period 01.04.2022	304.57	27.55	3263.49	9.90	6243.59	529.50	10378.60
Changes in accounting policy or prior period errors	0.00	0.00		0.00	0.00		0.00
Restated balance at the beginning of the reporting period	304.57	27.55	3263.49	9.90	6243.59	529.50	10378.60
Dividends	0.00	0.00		0.00			0.00
Profit For the Year	0.00	0.00		0.00	175.57	55.95	231.52
Balance at the end of the reporting period 31.03.2023	304.57	27.55	3263.49	9.90	6419.16	585.45	10610.12
(2) Previous reporting Period 2021-22							
Balance at the beginning of the reporting period 01.04.2021	304.57	27.55	3263.49	9.90	5235.54	383.18	9224.24
Changes in accounting policy or prior period errors	0.00	0.00		0.00	0.00	0.00	0.00
Restated balance at the beginning of the reporting period	304.57	27.55	3263.49	9.90	5235.54	383.18	9224.24
Dividends	0.00	0.00		0.00	0.00		0.00
Profit For the Year	0.00	0.00		0.00	1008.05	146.32	1154.37
Balance at the end of the reporting period 31.03.2022	304.57	27.55	3263.49	9.90	6243.59	529.50	10378.60
As per our report of even date, Rawka & Associates Chartered Accountants Firm Reg. No.:-021606C				For and on behalf of the board ,			
Venus rawka Partner Membership No. 429040 Place : Indore Date: 23/05/2023 UDIN: 23429040BGXBDY3508				Ramesh Chandra Mittal Chairman & Director DIN :00035272		Alok K. Garg Managing Director DIN :00274321	
				Hemant Sethi C.F.O.		Abhishek Jain Company Secretary ACS: 36699	

MEDI CAPS LIMITED		
Consolidated Cash Flow Statement for the year ended 31st March, 2023		
CIN: L70100MP1983PLC002231		
Amount in Lacs.		
PARTICULARS	31st March 2023	31st March 2022
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	492.09	1005.77
Adjustment For:		
Depreciation	181.10	190.27
Dividend Income	-0.28	0.00
Other Comprehensive Income	55.95	146.32
Loss from discontinue Operation	-11.07	3.72
Operating Profit before Working Capital Change	717.79	1346.07
Ajustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	160.75	-368.53
(Increase)/ Decrease in Inventories	478.08	-514.37
(Increase)/ Decrease in Loans & Advances	-991.34	-158.44
Increase/(Decrease) in Current Liabilities & Provisions	-667.80	397.37
Cash Generated from Working Capital	-1020.31	-643.97
Cash generated from Operation	-302.52	702.10
Income Tax for the year	305.58	0.00
Net cash Flow from Operating Activity	-608.10	702.10
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	-140.02	-128.16
Purchase of Fixed Assets	-116.28	-279.35
Dividend Received	0.28	0.00
Net Cash used in Investing Activities	-256.02	-407.51
C. Cash Flow from Financial Activities		
Increase in Short term Bank Borrowings	0.00	0.00
Proceeds from Long Term Borrowings	0.00	0.00
Net Cash Used in Financial Activities	0.00	0.00
Net Increase in Cash and Cash Equivalents (A+B+C)	-864.13	294.60
Cash & Cash Equivalents at the		
Beginning of the year	975.49	680.90
Closing of the year	111.36	975.49
Increase in Cash and Cash Equivalents	-864.13	294.60

Note: This Cash flow statement is belongs to Continuing and Discontinued operation both

As per our report of even date annexed

Rawka & Associates

Chartered Accountants

Firm Reg. No.: -021606C

For and on behalf of Board

Venus rawka

Partner

Membership No. 429040

Place: Indore

Date: 23/05/2023

UDIN: 23429040BGXBDY3508

Ramesh Chandra Mittal

Chairman & Director

DIN:00035272

Alok K. Garg

Managing Director

DIN: 00274321

Hemant Sethi

C.F.O.

Abhishek Jain

Company Secretary

ACS: 36699

NOTE -1- BASIC ACCOUNTING POLICIES (CONSOLIDATED)

1. Corporate Information:

Medi-Caps Limited ('the Company') is a Public Limited Company incorporated in India under the Companies Act, 1956 in 1983 as Medi-Caps Pvt. Ltd. The Company has permanently discontinued its manufacturing activities on 21.11.2019 and now operates in Real Estate Sector while its wholly owned subsidiary, Medgel Private Limited operates as a pharmaceutical Company. The financial statements were authorised to be issued in accordance with a resolution of the directors on 23/05/2023. The Company's shares are listed for trading on BSE Limited.

2. Basis of preparation:

(i) Compliance with Ind AS

These financial statements have been prepared to comply in all material aspects with the Indian Accounting Standards (hereinafter referred to as the ('Ind AS')) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ('Act') read with the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act.

(ii) Historical Cost Convention

The financial statements have been prepared and presented under the historical cost convention on accrual basis of accounting, Indian Accounting Standards prescribed under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014, except where otherwise stated, the accounting principles have been consistently applied.

3. Rounding of amounts:

All amounts disclosed in the financial statement and notes have been rounded off to the nearest Lacs; except where otherwise indicated.

4. Current versus non-current classification:

The company presents its assets and liabilities in the balance sheet on current/non-current classification. An Asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realised within twelve months after the reporting period; or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is Current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other Liabilities are classified as non-current.

Deferred tax liabilities are classified under non-current Liabilities.

5. Use of Estimates and Assumptions:

The preparation of financial statements in accordance with Ind AS requires subjective and complex judgments to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses at the date of these financial statements.

Estimates and underlying assumptions are reviewed at each balance sheet date. Revisions to accounting estimates are recognised in the period in which the estimate is revised and future periods affected.

In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements are as below:

- Fair value of Financial Assets and Financial liabilities,
- The useful lives of, or expected pattern of consumption of the future economic benefits embodied in, depreciable assets,
- Valuation of Inventories and Inventory obsolescence,
- Provisions and Bad Debts.

6. Revenue Recognition:

Sale of Goods

Revenue from sale of goods is recognized when the significant risks and rewards of ownership of the goods are transferred to the buyer, usually on delivery of the goods and when all the following conditions are satisfied:

- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- The costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns and allowance, trade discounts and volume rebates and does not include Value added tax (VAT), Central Sales tax (CST) and any other taxes.

7. Property, Plant and Equipment:

Property, plant and equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses. The initial cost of an asset comprises of its purchase price or construction cost, any costs directly attributable to bringing the asset into the location and condition necessary for it to be capable of operating in the manner intended by management. The purchase price or construction cost is the aggregate amount, paid and the fair value of any other consideration given to acquire the asset.

When significant parts of plants and equipments are required to be replaced at intervals, the Company depreciates them separately based on their specific useful life. All other repair and maintenance costs are recognised in Statement of Profit or Loss as and when incurred.

The residual values and useful lives of property, plant and equipment are reviewed at each financial year end and changes, if any, are accounted prospectively

Depreciation on Property, Plant & Equipment is provided on straight line method. In accordance with requirements prescribed under Schedule II of the Companies Act, 2013, Company has assessed the estimated useful lives of its property, plant and equipment and has adopted the useful lives and residual value as prescribed in Schedule II. The estimated useful lives of assets are as follows:

ASSETS	USEFUL LIFE OF ASSET
Factory Building	30 years
Leasehold Land	30 years
Office Building	30 years
Plant & Machinery	20 years
Furniture & Fixtures	10 years
Vehicles	8 years

8. Inventories:

Inventories are valued at Lower of cost or net realizable value. Costs incurred in bringing each product to its present location and conditions are accounted for as follows:

Raw materials

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Finished goods and work-in-progress

Cost includes direct materials, labour and a proportion of manufacturing overheads based on the normal operating capacity.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

9. Trade Receivable:

Trade receivables are recognized at fair value, the outstanding balances of sundry debtors, advances etc. are verified by the management periodically and on the basis of such verification management determines whether the said outstanding balance are good, bad or doubtful and accordingly same are written off or provided for.

Receivables that are expected in one year or less, are classified as current assets, if not they are presented as non-current assets.

10. Cash Flow Statement:

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

For the purpose of presentation in the Statement of Cash Flows, cash and cash equivalents includes cash in hand and Balances with Banks.

11. Investments:

The investments are valued at fair market value are therefore reported as per relevant Ind-AS 113 and comprehensive Income consequent to that effect have been reported in Financial Statements.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value.

12. Cash and cash equivalents:

Cash and cash equivalent in the balance sheet comprise of cash in hand and at banks. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and bank balances, as defined above.

13. Share Capital:

Ordinary shares are classified as equity.

During the year there is no change in the subscribed share capital as is issued by the company.

14. Earnings per Share:

Basic earnings per share are calculated by dividing the profit attributable to owners of the Company by average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders is adjusted for after income tax effect of interest and other financing costs associated with dilutive potential equity shares and the number of shares that are outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

15. Provisions:

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

16. Deferred Tax:

Deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases, and unutilized business loss and depreciation carry-forwards and tax credits. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carry-forwards and unused tax credits could be utilized.

Deferred tax assets and liabilities are measured based on the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

17. Borrowings:

Borrowings are initially recognised at fair value, net of transaction costs incurred. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in statement of profit or loss over the period of the borrowings.

Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

18. Borrowings Cost:

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur.

The Company ceases capitalising borrowing costs when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete.

19. Trade payables:

These amounts represent liabilities for goods that have been acquired in the ordinary course of business from suppliers. Trade payables are presented as current liabilities unless payment is not due within 12 months after the reporting period.

20. Current Tax:

Tax on income for the current period is determined on the basis of estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments / appeals.

Where current tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

21. Employee Benefits:

(a) Gratuity:

The Employee's Gratuity Fund Scheme, which is defined benefit plan, is managed by Trust maintained with Life Insurance Corporation of India (LIC). The liability with respect to Gratuity is made as per the method stipulated in the payment of gratuity Act, 1972.

(b) Provident Fund

Provident fund is a defined contribution plan, in which both employees and the Company make monthly contributions at a specified percentage of the employee's salary (currently 12% of employees' salary). The contributions are made to the provident fund as specified under the Employees Provident Fund & Miscellaneous provisions Act, 1952.

22. Financial Instruments and Risk Review:

The Company's principal Financial Assets include investments, trade receivables, cash and cash equivalents, other bank balances and loan. The Company's financial liabilities comprise of borrowings and trade payables.

23. Fair Value Hierarchy:

The Fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of the following three levels:

Level 1- Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities,

Level 2- Inputs are other than quoted prices included within Level-1 that are observable for the assets or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3- Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on the assumptions that are neither supported by prices from observable current market transactions in the instrument nor are they based on available market data. The following table summarises carrying amounts of financial instruments by their categories and their values in fair value hierarchy for each year presented.

FOR 31ST MARCH, 2023

(Amount in lacs)

Particulars	FVTPL			FVTOCI	Amortized Cost	Total
	Level-1	Level-2	Level-3			
Financial Assets						
Investments	0	0	0	3207.43	0	3207.43
Trade Receivable`s	0	0	0		846.44	846.44
Cash & Cash Equivalents	0	0	0		111.36	111.36
Other Bank Balances	0	0	0		0	0
Loans	0	0	0		0	0
Derivative Assets	0	0	0		0	0
Other Financial Assets	0	0	0		0	0
Total	0	0	0	3207.43	957.8	4165.23
Financial Liabilities						
Borrowings	0	0	0		0	0
Trade Payables	0	0	0		282.94	282.94
Derivative Liabilities	0	0	0		0	0
Other Financial Liabilities	0	0	0		0	0
Total	0	0	0		282.94	282.94

FOR 31ST MARCH, 2022

(Amount in lacs)

Particulars	FVTPL			FVTOCI	Amortized Cost	Total
	Level-1	Level-2	Level-3			
Financial Assets						
Investments	0	0	0	3067.41	0	3067.41
Trade Receivable`s	0	0	0	0	1007.19	1007.19
Cash & Cash Equivalents	0	0	0	0	22.83	22.83
Other Bank Balances	0	0	0	0	0	0
Loans	0	0	0	0	0	0
Derivative Assets	0	0	0	0	0	0
Other Financial Assets	0	0	0	0	0	0
Total	0	0	0	3067.41	1030.02	4097.43
Financial Liabilities						
Borrowings	0	0	0		0	0
Trade Payables	0	0	0		1168.03	1168.03
Derivative Liabilities	0	0	0		0	0
Other Financial Liabilities	0	0	0		0	0
Total	0	0	0		1168.03	1168.03

24. Additional Information, as required under Schedule III to the Companies Act, 2013, of Enterprises Consolidated as Subsidiaries / Associates / Joint Ventures.

Name of the entity in the Group	Net Asset i.e. total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount	As % of consolidated other comprehensive income	Amount	As % of total comprehensive income	Amount
31st March 2023								
Parent								
Medi-Caps Limited	51.54%	6110.75	8.34%	14.65	(-58.44%)	-32.7	-7.79%	-18.05
Subsidiaries Indian								
Medgel Private Limited	48.46%	5746.38	91.66%	160.94	158.44%	88.65	107.79%	249.59
Total	100.00%	11857.14	100.00%	175.59	100.00%	55.95	100.00%	231.54
31st March 2022								
Parent								
Medi-Caps Limited	52.72%	6128.61	-0.38%	-3.8	24.39%	35.69	2.76%	31.89
Subsidiaries Indian								
Medgel Private Limited	47.28%	5496.99	100.38%	1011.85	75.61%	110.63	97.24%	1122.48
Total	100.00%	11625.6	100.00%	1008.05	100.00%	146.32	100.00%	1154.37



Note-02- Property, Plant and Equipment

S. No		GROSS BLOCK			DEPRECIATION/AMORTIZATION			(Amount in Lacs.)			
		As at 01.04.2022	Additions	Deductions	As at 31.03.2023	Up to 01.04.2022	For the Year	Deletions	Upto 31.03.2023	As at 31.03.2023	As at 31.03.2022
1	Free Hold Land	11.78	0.00	0.00	11.78	0.00	0.00	0.00	0.00	11.78	11.78
2	Leasehold Land	500.00	0.00	0.00	500.00	241.19	16.67	0.00	257.85	242.15	258.81
3	Factory Building	1240.67	55.17	0.00	1295.84	450.45	36.81	0.00	487.25	808.58	790.22
4	Office Equipment	11.49	2.58	0.00	14.07	6.07	0.73	0.00	6.80	7.27	5.42
5	Office Building	191.21	0.00	0.00	191.21	65.91	6.56	0.00	72.48	118.74	125.30
6	Plant & Machinery	3534.18	55.18	300.00	3289.36	1848.61	71.71	285.00	1635.32	1654.04	1685.57
7	Furniture & Fixtures	591.57	0.00	0.00	591.57	542.73	21.61	0.00	564.34	27.23	48.84
8	Vehicles	317.10	42.45	0.00	359.55	127.52	26.01	0.00	153.53	206.01	189.57
9	Computers	41.13	0.24	0.00	41.37	39.45	1.00	0.00	40.44	0.93	1.68
TOTAL - A		6439.13	155.62	300.00	6294.74	3321.92	181.10	285.00	3218.02	3076.73	3117.21

S. No		GROSS BLOCK			DEPRECIATION/AMORTIZATION			NET BLOCK			
		As at 01.04.2022	Additions	Deductions	As at 31.03.2023	Up to 01.04.2022	For the Year	Deletions	Upto 31.03.2023	As at 31.03.2023	As at 31.03.2022
1	Capital Work in Progress	24.34	0.00	24.34	0.00	0.00	0.00	0.00	0.00	0.00	24.34
TOTAL - B		24.34	0.00	24.34	0.00	0.00	0.00	0.00	0.00	0.00	24.34

S. No		GROSS BLOCK			DEPRECIATION/AMORTIZATION			NET BLOCK			
		As at 01.04.2022	Additions	Deductions	As at 31.03.2023	Up to 01.04.2022	For the Year	Deletions	Upto 31.03.2023	As at 31.03.2023	As at 31.03.2022
1	Goodwill	2814.15	0.00	0.00	2814.15	0.00	0.00	0.00	0.00	2814.15	2814.15
G. TOTAL (A+B)		2814.15	0.00	0.00	2814.15	0.00	0.00	0.00	0.00	2814.15	2814.15
PREVIOUS YEAR		4154.87	512.05	202.89	4464.04	1427.91	172.09	0.00	1600.00	2864.04	2726.96

Note: Goodwill is an Intangible asset and this being purchased goodwill with infinite life, hence no amortization charged in the books of account.

CWIP aging schedule For the year ended 31/03/2023

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Year	2-3 year	More than 3 year	
Projects in progress	0	0	0	0	0
Projects temporarily suspended	0	0	0	0	0

CWIP aging schedule For the year ended 31/03/2022

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Year	2-3 year	More than 3 year	
Projects in progress	0	24.34	0	0	24.34
Projects temporarily suspended	0	0	0	0	0

Amount in Lacs

Note : 3 Investments		As at 31st March 2023	As at 31st March 2022
a)	Investment in properties	107.93	107.93
b)	Investment in Equity instruments		
i)	Other Investment (Quoted)		
	100 (100) Equity Shares of Natural Capsules limited	0.39	0.46
		0.39	0.46
c)	Investment in Mutual Funds (Quoted)		
	Reliance Large Cap Fund -SIP	76.61	60.37
	HDFC Equity Fund -SIP	82.76	63.36
	SIP - ABSL Pure Value Fund	94.16	92.62
	Centrum Capital Ltd(Debenture)		0.00
	ICICI Prudential Flexicap Fund	16.71	0.00
	IDFC Midcap Fund	48.17	0.00
	White Oak Capital (Cash & Equity)	50.57	0.00
d)	Investment in Debentures (quoted)		
	Centrum Capital Ltd(Debenture)	108.58	0.00
e)	Other Investments		
	LIC Group Gratuity Fund Scheme	62.84	47.01
		540.40	263.36
		648.73	371.76
	Aggregate amount of quoted Investments	398.71	175.01
	Aggregate Market value of quoted Investments	477.95	216.82
	Aggregate amount of unquoted Investments	170.77	154.94
	Aggregate amount of impairment in value of Investment	0.00	0.00

Note : 4 Other Non Current Assets		
(Unsecured, considered good unless otherwise stated)		
Security Deposits	38.58	38.69
	38.58	38.69

Note : 5 Inventories		
Raw Materials	406.30	776.03
Finished Goods	293.67	378.88
Packing Material	6.92	30.06
	706.90	1184.97

Note : 6 Investment		
Investment in Mutual Funds (Quoted)		
Axis Focused 25 Fund	8.57	10.13
SIP - IDFC Equity Fund	121.17	124.80
SIP - Reliance Top 200 Equity Fund	139.27	130.73
HDFC Low Duration Fund	370.05	337.97
Birla Sun Life Mutual Fund	256.24	281.92
HDFC Low duration fund	504.32	481.03
Reliance Money Manager Fund- Growth	811.56	925.15
SBI MAGNUM LOW DURATION FUND	40.53	158.59
HDFC BANKING & PSU DEBT FUND	181.99	199.03
ICICI Lombard Gen Ins. Co Ltd	0.00	30.35
ICICI Prudential Flexicap Fund	0.00	15.94
Investment in Debentures		
Centrum Retail Services Ltd.(ltd)	125.00	0.00
	2558.70	2695.65
Aggregate amount of quoted Investments	1927.50	2207.96
Aggregate Market value of quoted Investments	2433.70	2695.65
Aggregate amount of unquoted Investments	125.00	0.00
Aggregate amount of impairment in value of Investment	0.00	0.00

Note : 7 Trade Receivables			As at 31st March 2023	As at 31st March 2022
(a) Trade Receivables considered good - Secured				
(b) Trade Receivables considered good - Unsecured		846.44		1007.19
(c) Trade Receivables which have significant increase in credit risk				
(d) Trade Receivables- Credit impaired				
		846.44		1007.19

As on 31st March 2023

Note : 7A Trade Receivables Ageing Schedule

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	months - 1 ye	1-2 years	2-3 years	More than 3 years	Total
(a) Trade Receivables considered good - Secured						
(b) Trade Receivables considered good - Unsecured	465.82	137.79	1.15	17.87	223.82	846.44
(c) Trade Receivables which have significant increase in credit risk						
(d) Trade Receivables- Credit impaired						

As on 31st March 2022

Note : 7A Trade Receivables Ageing Schedule

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	months - 1 ye	1-2 years	2-3 years	More than 3 years	Total
(a) Trade Receivables considered good - Secured						
(b) Trade Receivables considered good - Unsecured	751.18	2.17	18.04	157.46	78.34	1007.19
(c) Trade Receivables which have significant increase in credit risk						
(d) Trade Receivables- Credit impaired						

	Amount In Lacs	
	As at 31st March 2023	As at 31st March 2022
Note : 8 Cash & Cash Equivalents		
(a) Balances with banks		
In Current Accounts	8.11	12.99
In Cash Credit Account	102.70	9.56
(b) Cheques, drafts on hands		
(c) Cash on Hand	0.55	0.28
	111.36	22.83
Note : 9 Bank Balance		
Balance with Scheduled and Noted Banks :		
In Fixed Deposit Accounts	0.00	952.66
(a) Earmarked balances With bank	0.00	0.00
(b) Balances held as margin money or security against guarantees and other commitments	0.00	0.00
	0.00	952.66
Note : 10 Other Current Assets		
(i) Advances other than capital advances		
Advance to Suppliers & Others	248.16	146.38
(ii) Others (to be specified)		
Balances with Government Authorities	2.45	2.65
Advance Tax & TDS /TCS Receivable	305.37	364.09
MAT Credit Entitlement	257.68	264.47
Prepaid Expenses	15.68	14.01
Pre-Operative Exp	7.34	7.34
Deposit with Banks (FDR)	954.18	0.00
Other Loans & Advances	6.19	6.66
	1797.05	805.60

Note: The figures in Other Current Assets schedule have be regrouped during the year.

	Amount In Lacs	
	As at 31st March 2023	As at 31st March 2022
Note : 11 Equity Share Capital		
Authorised Share Capital :		
1,50,00,000 Equity Shares of Rs. 10/- each (Previous Year 1,50,00,000 Equity Shares of Rs. 10/- each)	1500.00	1500.00
Issued Share Capital		
1,24,69,956 Equity Shares of Rs. 10 each fully paid up (Previous Year 1,24,69,956 Equity Shares of Rs.10/- each)	1247.00	1247.00
Subscribed and Paid Share Capital:		
1,24,69,956 Equity Shares of Rs. 10 each fully paid up (Previous Year 1,24,69,956 Equity Shares of Rs.10/- each)	1247.00	1247.00
	1247.00	1247.00

Note: The Company has only one class of equity shares at a par value of Rs. 10. All the equity shares carry equal rights and obligations including the right to receive dividend and also with respect to voting rights.

Reconciliation of the equity shares outstanding at the beginning and at the end of the year				
	As at March 31, 2023		As at March 31, 2022	
	Numbers	Value	Numbers	Value
Equity Shares				
At the beginning of the year	124.7	1247.00	124.7	1247.00
Issued during the year	-	-	-	-
Outstanding at the and the year	124.7	1247.00	124.7	1247.00
Details of Shareholders holding more than 5 percent shares in the company				
Name of Shareholders	No. of Shares as at			
	31.03.23 % of Holding		31.03.22 % of Holding	
Alok K Garg	3225920	25.87%	3225920	25.87%
Manisha Garg	2694820	21.60%	2694820	21.60%
Sangeetha S	694400	5.57%	694400	5.57%

Shares held by promoters at the end of the year					
Name of Promoter	31-Mar-2023		31-Mar-2022		% Change
	No. of shares	% Held	No. of shares	% Held	
R.C.Mittal	10000	0.08%	10000	0.08%	0.00
Alok K Garg	3225930	25.87%	3225930	25.87%	0.00
MANISHA GARG	2694820	21.60%	2694820	21.60%	0.00
NIRMALA ANANTRAM MITAL	3172	0.03%	3172	0.03%	0.00
TRAPTI INVESTMENTS LLP	307128	2.46%	307128	2.46%	0.00
KUSUM MITTAL	10000	0.08%	10000	0.08%	0.00
GITIKA AGRAWAL	400	0.00%	400	0.00%	0.00

Note : 12 Other Equity	Amount in Lacs	
	As at 31st March 2023	As at 31st March 2022
Capital Reserve		
Opening Balance	9.90	9.90
Less: Adjustment for Investment in Share Written Off	0.00	0.00
	9.90	9.90
Share Forfeiture A/c		
As per last balance sheet	27.55	27.55
Securities Premium		
Opening Balance	3263.49	3263.49
Add: Security Premium on Share issued during the year	0.00	0.00
	3263.49	3263.49
General Reserve		
As per last balance sheet	304.57	304.57
Surplus		
Opening balance of Profit & Loss A/c	6243.59	5235.54
Add: Net profit for the current year	175.57	1008.05
Closing Balance	6419.16	6243.59
Other Comprehensive Income		
Opening balance of Other Comprehensive Income	529.50	383.18
Add: Other Comprehensive Income	55.95	146.32
Closing Balance	585.45	529.50
	10610.12	10378.60

Note : 13 Provisions	Amount in Lacs	
Provision for Gratuity	58.87	45.34
Provision for Income Tax	122.00	0.00
	180.87	45.34

Note : 14 Deferred Tax Liability (Net)	Amount in Lacs	
On Depreciation (Difference of as per Books & as per Income Tax Act)	43.98	44.13
	43.98	44.13

Note : 15 Trade Payable	Amount in Lacs	
Total Outstanding dues to Micro & Small Enterprises	0.00	0.00
Total Outstanding dues of Creditors other than Micro & Small Enterprises	282.94	1168.03
	282.94	1168.03

As on 31st March 2023

Note : 15A Trade Payable Ageing Schedule

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					
(ii) Others	269.13	0.00	13.81	0.00	282.94
(iii) Disputed Dues- MSME					
(iv) Disputed Dues- Others					

As on 31st March 2022

Note : 15A Trade Payable Ageing Schedule

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					
(ii) Others	1144.71	15.11	0.00	8.21	1168.03
(iii) Disputed Dues- MSME					
(iv) Disputed Dues- Others					

Note : 16 Other Current Liabilities	Amount in Lacs	
	As at 31st March 2023	As at 31st March 2022
(a) Revenue Received in Advance	131.72	48.38
(b) Other Advances		
(c) Others		
Audit Fee Payable	0.27	0.27
Bonus Payable	13.00	15.00
Commission Payable	4.86	4.86
CST & VAT Payable	0.00	0.00
ESI Payable	0.08	0.10
GST Payable	0.01	0.59
Outstanding Liabilities	33.29	32.91
Professional Tax	0.10	0.09
Provident Fund	2.67	2.64
TCS on Scrap Sales	0.01	0.00
Unpaid Salary & Wages (Provision)	36.55	35.90
TDS on Consultancy	0.63	0.53
TDS on Contractor Payment	2.04	3.23
TDS on Salary	7.78	7.41
TDS on Sales Commission	0.00	0.00
TDS ON INTEREST ON LEASE RENT	0.00	0.00
TDS on Purchase	0.06	0.05
TCS Payable	0.00	0.00
Security Deposit from Medicaps Business Park	0.00	0.00
Other	0.64	0.00
	233.71	151.95
Note :17 Current Tax Liabilities (Net)		
For Taxation	0.00	0.00
	0.00	0.00

NOTES TO PROFIT & LOSS STATEMENT

Note : 18 Revenue from Operation	Amount in Lacs	
	For the year ended 31st March 2023	For the year ended 31st March 2022
Sale of product	4857.75	6831.10
Other Operating Income		
Misc. Income	12.57	156.01
Interest Income	61.69	0.00
Lease Rent	5.08	0.00
	4937.10	6987.11
Note :19 Other Incomes		
(a)Interest income	0.00	52.99
(b)Dividend Income	0.28	0.00
(c)Other operating Income		
Lease Rent	0.00	5.08
Capital gain / (Loss) on Mutual Fund	71.27	42.72
Profit on sale of Fixed Assets	0.00	4.74
Foreign Exchange Fluctuation	88.77	85.89
	160.32	191.42
Note : 20 Cost of Materials Consumed		
A) Raw Material Consumed		
Opening Stock	776.03	267.72
Purchases	1665.31	3264.13
	2441.34	3531.85
Less : Closing Stock	406.30	776.03
Raw Material Consumed	2035.04	2755.83
B) Packing Material Consumed		
Opening Stock	30.06	13.11
Less: Goods Removed	0.00	0.47
Purchases	147.07	266.23
	177.14	278.86
Less : Closing Stock	6.92	30.06
Packing Material Consumed	170.21	248.80
Grand total of Materials Consumed (A) + (B)	2205.25	3004.63

Note : 21 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade		
Closing Stock of :		
Finished Goods	293.67	378.88
Stock in Process	0.00	0.00
Waste	0.00	0.00
Total (A)	293.67	378.88
Opening Stock of :		
Finished Goods	378.88	385.31
Stock in Process	0.00	0.00
Waste	0.00	0.00
Total (B)	378.88	385.31
Increase/(Decrease) in Stock (A-B)	-85.21	-6.43

	Amount in lacs	
	For the year ended 31st March 2023	For the year ended 31st March 2022
Note : 22 Employees Remuneration & benefits		
Salary, Wages, Allowances & other Benefits	514.73	490.99
Directors Remuneration	204.22	209.24
Gratuity	13.89	34.93
P.F. Contribution	33.56	34.12
Staff Welfare Expenses	2.52	1.74
	768.92	771.01

Note : 23 Finance Cost		
Interest on C.C. Limit	0.16	0.02
	0.16	0.02

Note : 24 Other Expenses		
Advertisement & Publicity	0.42	0.62
Audit Fee	3.30	3.30
Annual Listing Fees	3.94	3.90
Bank Charges	12.63	9.85
Certificate & Standard Exp.	19.27	13.07
Charity & Donations	0.10	5.11
Consultancy Charges	23.45	16.18
Conveyance Expenses	7.93	5.79
Development Charges to AKVN	3.31	3.31
Electricity & Water	9.16	6.70
Freight Expenses	505.30	1163.33
Factory Power & Fuel	216.22	328.63
Insurance Charges	16.45	11.68
Interest on vat/ex.duty/gst	0.00	0.95
Import / Export Expenses	0.00	12.34
Legal Expenses	1.50	1.67
Membership Fee & Subscription	18.83	0.07
Misc. Expenses	65.28	120.60
News Paper & Periodicals	0.03	
Office & General Expenses	0.01	0.04
Postage, telegram	0.74	0.76
Professional Tax for Company	0.03	0.03
Prior Period Item	3.74	0.00
Printing & Stationary	11.15	14.36
Rent, Rates & Taxes	3.45	3.16
ROC Exp.	1.17	0.52
Round Off.	0.00	0.00
Repairs & Maintenance		
Buildings	31.97	20.40
Machinery	47.25	85.78
Electricals	2.91	6.32
Other	3.06	2.67
Sales promotion Expenses	63.75	138.02
Security Charges	16.82	15.15
Stores & Spares Consumed	4.20	5.73
Telephone & Telex Charges	2.12	1.58
Tour & Travelling Expenses	82.29	28.96
QC Chemicals & Items	31.29	29.26
Vehicle Running & Maintenance	142.02	136.85
Website Maintenance Charges	0.20	0.19
	1355.28	2196.87

Note : 25 Corporate Social Responsibility	Amount in lacs	
	For the year ended 31st March 2023	For the year ended 31st March 2022
CSR Expense	16.2	12.5
a. Gross amount required to be spent by the Company during the year	15.89	12.34
b. Amount Spent during the year on the above	16.2	12.5
c. Shortfall at the end of the year	0	0
d. Total of previous year shortfall	0	0
e. Reason for shortfall	0	0
f. Excess amount spent during the year	0.31	0.16
g. Nature of CSR activities	Note Below (a)	Note Below (b)
h. Details of related party transactions	0	0
i. where a provision is made with respect to liability incurred-movement in the provision needs to be disclosed separately	0	0

Note:

(a) The Funds were provided to Shree Shraddha Education and Charitable Trust for the Implementation of Educational activities for the under privileged children.

(b) The Funds were provided to Anupam Udbhav Welfare society for the purpose of Health camps, awareness Programs and Plantation work.

Note 26: Segment Information

On consolidated basis the Company is having two segments. One is related with Real Estate division in Medi-Caps Limited and other one is related with Pharma division in its wholly owned subsidiary, Medgel Private Limited.

S.N o.	Segment Revenue	Amount in Lacs	
		31.03.2023 Audited	31.03.2022 Audited
1	Segment Revenue		
	Pharma Division	5022.82	7117.80
	Real Estate Division	74.60	60.74
	Other	0.00	0.00
	Net Sale/Income From Operations	5097.42	7178.53
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest		
	Pharma Division	466.67	1011.87
	Real Estate Division	25.58	-6.08
	Other	0.00	0.00
	Total	492.25	1005.79
	Interest Income	0.00	0.00
	Interest Expenses	0.16	0.02
	Other Unallocable Expenditure net off	0.00	0.00
	Unallocable Income	0.00	0.00
	Profit Before Tax	492.08	1005.77
	Current Tax	122.00	0.00
	Earlier year (excess)/Short provision for tax written back	183.58	0.00
	Deferred Tax	-0.14	1.44
	Profit After Tax	186.64	1004.32
3	Capital Employed		
	Segment Assets (A)		
	Pharma Division	12434.16	12861.34
	Real Estate Division	164.48	173.71
	Other	0.00	0.00
	Total (A)	12598.65	13035.05
	Segment Liabilities (B)		
	Pharma Division	741.51	1409.45
	Real Estate Division	0.00	0.00
	Other	0.00	0.00
	Total (B)	741.51	1409.45
4	Total Capital Employed (Segment Assets-Segment Liabilities)		
	Pharma Division	11692.65	11451.88
	Real Estate Division	164.48	173.71
	Other	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	11857.13	11625.59

Note 27: Deferred Tax

Information on deferred tax has been provided in accordance with Ind AS-12 Accounting for taxation on income, issued by the Institute of Chartered Accountants of India.

The deferred tax assets for the year is Rs. 0.14 Lakhs has been recognized in the profit & Loss Account.

	Amount in Lacs	
	For the year ended 31st March 2023	For the year ended 31st March 2022
Note 28 Payment to Auditors		
Audit Fees	2.80	2.80
In other Capacity		
Tax Audit Fee	0.20	0.20
Other	0.30	0.30
	3.30	3.30

Note 29 Related Party Disclosure

Information on Related party transactions as per Ind AS 24 on related party disclosure:

S.No	Related Party	Transactions	As at 31st March 2023	As at 31st March 2022
1	Mr. Alok K. Garg Managing Director	Remuneration	74.10	74.69
2	Mrs. Manisha Garg Whole time Director of Medgel Pvt. Ltd.	Remuneration	36.65	37.19
3	Akshit Garg Whole time Director of Medgel Pvt. Ltd.	Remuneration	36.65	37.97
4	Praveen Nalwaya Whole time Director of Medgel Pvt. Ltd.	Remuneration	56.82	59.39
5	Mr. Palash Garg Vice President	Remuneration	4.50	0.00
6	Mrs. Saloni Garg General Manager	Remuneration	18.30	0.00
7	Sandhya Nalwaya Manager	Remuneration	18.86	19.09
8	Medicaps Charitable Trust	Rent Sales of Misc. Items (Inclusive of GST)	6.00 0.00	6.00 0.00
9	Hemant Sethi (CFO)	Remuneration	10.85	8.86
10	Mr. Abhishek Jain (Company Secretary)	Remuneration	5.24	2.67
11	Nikita Sharma (Company Secretary Left w.e.f 18/01/2022)	Remuneration	0.00	1.50
12	Mr. Prakhar Dubey (Company Secretary)	Remuneration	2.52	0.00
13	Ayushi Silot (Company Secretary Left w.e.f. 07/10/2021)	Remuneration	0.00	1.82
14	Lokesh Parmar (CFO of Subsidiary Company)	Remuneration	7.27	7.04

Note 30 Earning Per Share

Earning per share, the numerator and denominator used to calculate Basic and Diluted Earning per shares:

	Amount in lacs	
Particulars	As at 31st March 2023	As at 31st March 2022
i) Profit after tax used as the numerator	175.57	1008.05
ii) Basic/Weighted Average number of Equity Shares used as the denominator	12469956	12469956
iii) Nominal Value of Equity shares	10/-	10/-
iv) Basic & Diluted Earning per Equity Share		
For Continue Operation	1.50	8.05
For Discontinue Operation	-0.09	0.03
For Continue and Discontinue Operation	1.41	8.08

Note 31 Employee Benefits			
a. Defined benefits plan			
I Change in obligation during the year			
1 Present value of Defined benefit obligation at beginning of year		45.34	40.91
2 Current Service Cost		13.89	18.20
3 Past Service Cost		0.00	0.00
4 Interest Cost		0.00	0.00
5 Actuarial (Gains) / Losses		0.00	0.00
6 Benefits Paid		-0.36	-13.77
7 Present value of Defined benefit obligation at the end of the year		58.87	45.34
II Change in assets during the year ended March 31			
1 Plan assets at the beginning of the year		47.01	35.46
2 Settlements		0.00	0.00
3 Expected return on plan assets		3.39	2.03
4 Contribution by Employer		13.89	18.20
5 Actual benefits paid		-0.36	-13.77
6 Deductions		-1.08	5.08
7 Plan assets at the end of the year		62.84	47.01
III Net Assets / (Liability) recognized in the Balance Sheet at March 31			
1 Present value of Defined benefits Obligation as at March 31.		58.87	45.34
2 Fair value of plan assets as at March 31		62.84	47.01
3 Fund Status (Surplus / (Deficit))		3.97	1.67
4 Net Assets / (Liability) as at end of the year		3.97	1.67
IV Expenses recognised in the Statement of Profit & Loss for the year ended March 31			
1 Current Service Cost		13.89	18.20
2 Interest Cost		0.00	0.00
3 Expected return on plan assets		-3.39	-2.03
4 Past service cost		0.00	0.00
5 Net Actuarial (Gains) / Losses		0.00	0.00
6 Total Expenses (Net)		10.50	16.17
V The major categories of plan assets as a percentage of total plan			
		N.A.	N.A.

Note 32: The Company does not have outstanding for more than 30 days as on 31st March 2022 of S.S.I units of the respective parties.

Note 33: The previous year's figures have been regrouped/ restated wherever necessary to confirm with the current years classification.

Note 34: Ratio

Ratios	Numerator	Denominator	FY 2022-23	FY 2021-22	Change	Explanation
Current Ratio (in times)	Total Current Assets	Total Current Liabilities	11.65	5.68	105.15%	Change is because of reduced current liabilities
Debt-Equity Ratio (in times)	Long Term Borrowings+ Short Term Borrowings	Total Equity	-	-	0.00%	N.A.
Debt-Service Coverage Ratio	Earnings for Debt service = Net profit after tax + Non- cash operating expenses + interest + other non cash adjustments+ Interest on debt debited in P&L	Debt service = Interest + Principal Repayment (Non-Current debts only)	-	-	0.00%	N.A.
Return on Equity Ratio (in times)	Profit for the year less preference dividend (if any)	Average Total Equity	0.01	1.20	-98.76%	During the year the company earned a profit which resulted into better ROE.
Inventory Turnover Ratio (in times)	Revenue From Operations	Average Inventory	5.22	11.79	-55.74%	The change is because of reduced average of inventory
Trade Receivable Turnover Ratio (in times)	Revenue From Operations	Average Trade Receivable	5.33	13.87	-61.61%	The change is because of reduced average of Trade Receivables.
Trade Payable Turnover Ratio (in times)	Revenue From Operations	Average Trade Payable	6.81	11.96	-43.12%	The change is because of reduced average of Trade Payables.
Net Capital Turnover Ratio (in times)	Revenue From Operations	Working Capital (i.e. Total current assets less Total Current Liabilities)	0.90	1.31	-31.33%	The change is because of reduced working capital during the year.
Net Profit Ratio (in %)	Profit for the year before exception items	Revenue From Operations	9.97%	14.39%	-30.76%	The Change is because of reduced profit during the year.
Return On Capital Employed	Profit Before Tax And Finance Costs	Average capital Employed Capital Employed = Net Worth + Deferred Tax Liabilities	0.041	0.086	-52.01%	The change is because of reduced average of network.
Return on Investment	Income Generated from Investment Funds	Average invested Funds	0.023	0.028	-18.45%	N.A.

Note 35: Other Statutory Information

1. The Funds borrowed by the Company from banks and financial institutions have been used for the specific purpose for which they were raised.
2. All the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) title deeds are held in the name of the Company and Company is the sole owner of these immovable properties.
3. The Company does not have any Benami property, and no proceeding has been initiated or is pending against the Company for holding any Benami property.
4. The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
5. The Company does not have any transactions with Companies struck off.
6. The Company have charges which are yet to be registered with ROC beyond the statutory period the detail of which are:

Details of Charges yet to be registered with ROC				
Charge ID	Charge Holder's Name	Date of Creation	Amount	Reason
90207250	Bank of Baroda	24/03/1992	3.00	Medi-Caps Limited has filed the forms for satisfaction of charge in physical mode and the same are not traceable as the matter is very old. The Company has made several requests to the ROC for deletion of the charge ID, however, in absence of the adequate evidence same could not be processed. Due to that only these charges are still being reflected on MCA Portal.
90202622	Bank of Baroda	05/10/1990	10.00	
90204557	Bank of Baroda	24/07/1986	7.00	

7. The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
8. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
9. The Company has not issued any such type of security for a specific purpose.
10. The Company has not proposed or declare dividend during the year.
11. The Company has initiated the legal proceedings under section 138 of negotiable instruments act and u/s 420 of the Indian penal code, against Jay formulation Limited before First Class Civil Judge, District Court, Indore. The same has been initiated for recovery of sale proceedings.